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Abstract 
The revolutionary discovery of penicillin in 1928 by Alexander Fleming held the promise of 
treatment and cure of all infectious diseases. Indeed, in the following decades the levels 
of bacterial infections largely declined with consequent large improvements for public 
health. However, nowadays we live in an era where bacterial resistance to antimicrobial 
agents is rapidly spreading throughout the world, putting at risk the success of treatments 
for infectious diseases, and thus placing them again as one of the world’s major threats to 
global public health. To fight this tendency, new antimicrobial drugs must be introduced 
into the clinic, especially drugs with different paradigms from those of conventional 
antibiotics, and keeping resistance avoidance as one of the main goals. Antimicrobial 
peptides (AMP) are being extensively studied as a new potential alternative to fight 
infectious diseases. These peptides are widespread in nature and are characterized by a 
wide range of activity against several pathogens. Their mode of action is thought to rely 
on membrane destabilization through a variety of mechanisms that lead to cell death, 
possibly acting also on internal targets and/or through immunomodulation. Due to the 
nature of the main AMP target, the cytoplasmic membrane, and to the possibility of acting 
on different targets and by different mechanisms, it is believed that induction of resistance 
is less likely to occur for AMP than for conventional antibiotics. 
The main goals of this thesis were to study the mechanisms of action of two families of 
AMP, cecropin A-melittin hybrids and lactoferrin peptides, and to assess the potential of 
lactoferricin peptides against Mycobacterium avium, an opportunistic intracellular 
pathogen. 
The interaction of a cecropin A-melittin hybrid, CA(1-7)M(2-9), with bacterial model 
membranes composed of phosphatidylethanolamine (PE) and phosphatidylglycerol (PG) 
was evaluated through a number of biophysical techniques, such as Small Angle X-ray 
Diffraction, Differential Scanning Calorimetry, Isothermal Titration Calorimetry, Circular 
Dichroism and microscopy techniques. Our findings showed that the peptide’s interaction 
takes place mainly at the surface (lipid heads level), without pore formation. Thus overall 
the results obtained indicate that CA(1-7)M(2-9) induces membrane condensation by 
disrupting the lipid vesicles and forming multilamellar structures in onion-like structures, 
with the peptide intercalated between the bilayers. We thus propose the “carpet model” as 
the best description of CA(1-7)M(2-9) mechanism of action with this bacterial model 
membranes, having membrane disruption as the final stage of its action. 
In the case of lactoferrin peptides, LFcin17-30, LFampin265-284 and LFchimera, their 
mechanism of action was studied by X-ray diffraction with fungal model membranes 
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composed of phosphatidylcholine (PC) and phosphatidylglycerol (PG). The obtained 
results showed that although the three peptides belong to the same family, they interact 
differently with membranes. LFcin17-30 has a small effect on membrane structure, 
inducing mainly lipid segregation; LFampin265-284 induces the formation of a micellar 
cubic phase (Pm3n) that would thus completely disrupt the membrane; and LFchimera 
leads to membrane destruction through the formation of bicontinuous cubic phases (Im3m 
and Pn3m). Remarkably, these results are in very good agreement with the ones 
previously obtained for the action of these peptides against Candida albicans. 
Lactoferricin, LFcin17-30, and variants obtained by specific amino acid substitutions were 
tested in vitro against Mycobacterium avium. Our results showed that all peptides were 
highly active against M. avium in broth culture, the most active peptides being the D 
enantiomer of LFcin17-30 (D-LFcin17-30) and the variant with all lysines substituted by 
arginines (LFcin17-30 all R). They all induced surface and ultra-structural changes upon 
contact with the mycobacteria, but no evident signs of membrane disruption were seen, 
leading us to propose that these lactoferricin peptides probably have an intracellular target 
within M. avium. Interestingly, when treating M. avium-infected macrophages, only D-
LFcin17-30 had a significant activity against this pathogen. The combined administration 
of lactoferricin peptides and the conventional antibiotic ethambutol significantly increased 
the activity of all peptides and that of the antibiotic alone. Nevertheless, it did not 
surpassed the effect of D-LFcin17-30 alone. Further investigations on the mechanism of 
action of this particular peptide revealed that it does not co-localize with M. avium when 
inside macrophages, probably exerting its activity through modulation of the macrophage 
antimicrobial defence mechanisms. 
With this work, we contributed to the elucidation of the mechanisms by which antimicrobial 
peptides interact with target membranes, showing a high heterogeneity of the 
mechanisms involved. We also highlighted the contribution of non-membrane disrupting 
mechanisms for the inhibitory effects of lactoferricin peptides. These lactoferricin peptides 
revealed potential as anti-mycobacterial agents in combination with the conventional 
antibiotic ethambutol and the D-enantiomer of LFcin17-30 as a highly active molecule 
against M. avium. 
The work described in this thesis may contribute to the future development of effective 
antimicrobial peptides for the treatment of mycobacterial as well as other infectious 
diseases. 
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Resumo 
A descoberta revolucionária da penicilina por Alexander Fleming em 1928 continha a 
promessa de tratar e curar todas as doenças infeciosas. Efetivamente, nas décadas que 
se seguiram, os níveis de infeções bacterianas diminuíram, levando a importantes 
melhorias na qualidade da saúde pública. No entanto, nos dias de hoje, a resistência das 
bactérias aos antibióticos está a espalhar-se rapidamente, sendo considerada uma das 
maiores ameaças mundiais para a saúde pública, colocando em risco o tratamento de 
infeções. Para combater este fenómeno, novos fármacos têm de ser introduzidos na 
clínica, de preferência com paradigmas diferentes dos antibióticos convencionais, em que 
a evasão à resistência bacteriana seja o principal objetivo. Neste âmbito, péptidos 
antimicrobianos (PAM) têm sido extensivamente estudados como uma nova alternativa 
para o combate de doenças infeciosas. Estes péptidos estão presentes na natureza e em 
quase todos os seres vivos, caraterizando-se por serem ativos contra uma vasta gama de 
agentes patogénicos. O mecanismo de ação dos PAM consiste na destabilização da 
membrana, por diferentes processos que conduzem à morte celular, podendo também 
atuar em alvos intracelulares e por imunomodulação. Devido à natureza do principal alvo 
destes péptidos, a membrana citoplasmática, e à possibilidade de atuarem em alvos 
diferentes por diferentes mecanismos, em princípio a indução de resistência é menos 
provável para os PAM do que para os antibióticos convencionais. 
O objetivo desta tese foi determinar o mecanismo de ação de duas famílias de PAM, 
nomeadamente híbridos da cecropina A-melitina e péptidos derivados da lactoferrina, e 
ainda avaliar o potencial de péptidos derivados da lactoferricina contra um patogénio 
intracelular e oportunista, o Mycobacterium avium.  
A interação de CA(1-7)M(2-9), um híbrido da cecropina A-melitina, com membranas 
modelo de bactérias, compostas por fosfatidiletanolamina (PE) e fosfatidilglicerol (PG), foi 
analisada através de várias técnicas biofísicas, como difração de raios-X, calorimetria 
diferencial de varrimento, calorimetria isotérmica de titulação, dicroísmo circular e 
técnicas de microscopia. Os resultados mostram que o péptido interage fortemente com a 
superfície da membrana, ao nível das cabeças lipídicas, sem mostrar evidência de 
formação de poros com estas membranas. Os resultados obtidos indicam que o 
CA(1-7)M(2-9) induz extensa condensação da membrana por disrupção das vesículas, 
formando uma estrutura multilamelar (tipo “cebola”) em que os péptidos se encontram 
intercalados entre as bicamadas. Propomos assim, que o modelo da carpete é o que 
melhor descreve o mecanismo de ação do CA(1-7)M(2-9) com este modelo de 
membranas bacterianas, com rutura vesicular como estado final. 
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O mecanismo de ação de péptidos derivados da lactoferrina, LFcin17-30, 
LFampin265-284 e LFchimera foi estudado por difração de raios-X com membranas 
modelo de membranas de fungos, compostas por fosfatidilcolina (PC) e PG. Os 
resultados mostram que apesar dos três péptidos pertencerem à mesma família, atuam 
por mecanismos diferentes. LFcin17-30 tem um efeito moderado nas membranas, 
induzindo apenas segregação lipídica; LFampin265-284 induz a formação de uma fase 
cúbica micelar (Pm3n) que irá levar à disrupção da membrana; LFchimera leva à 
destruição da membrana através da formação de fases cúbicas bicontínuas (Im3m e 
Pn3m). É de realçar o excelente acordo destes resultados com os obtidos anteriormente 
para o efeito destes péptidos contra Candida albicans.  
Lactoferricina, LFcin17-30, e suas variantes obtidas por substituições de aminoácidos 
específicos, foram testadas in vitro contra Mycobacterium avium. Os nossos resultados 
mostram que todos os péptidos são ativos contra M. avium a crescer em culturas líquidas, 
sendo que o enantiómero D da LFcin17-30 (D-LFcin17-30) e a variante com todas as 
lisinas substituídas por argininas (LFcin17-30 all R) foram os péptidos mais ativos. Todas 
as lactoferricinas estudadas induziram alterações na superfície e na ultra-estrutura das 
micobactérias, mas sem sinais evidentes de disrupção membranar, e por isso propomos 
que estes péptidos têm provavelmente um alvo intracelular. Curiosamente, quando 
usados contra M. avium a crescer dentro de macrófagos, apenas o D-LFcin17-30 teve 
uma atividade significativa contra este agente patogénico. A administração combinada 
das lactoferricinas com o antibiótico etambutol aumentou significativamente a atividade 
de todos os péptidos e do antibiótico sozinho, sem no entanto ultrapassar o efeito do D-
LFcin17-30 sozinho. Outras experiências com vista à clarificação do mecanismo de ação 
deste péptido revelaram que este não co-localiza com a micobactéria dentro dos 
macrófagos, estando provavelmente a exercer a sua atividade através da modulação dos 
mecanismos de defesa antimicrobianos dos macrófagos.  
Com os resultados obtidos neste trabalho, conseguimos contribuir para a elucidação dos 
mecanismos de ação pelos quais os PAM interagem com as membranas alvo, mostrando 
uma grande heterogeneidade nos mecanismos envolvidos. Destaca-se também a 
contribuição de mecanismos que não envolvem disrupção membranar para a atividade 
das lactoferricinas. Estes péptidos em particular revelaram ser potenciais agentes 
antimicobacterianos, em particular em combinação com o antibiótico etambutol. Entre os 
péptidos estudados é de realçar o enantiómero D da LFcin17-30, que se revelou 
altamente eficaz contra M. avium. 
O trabalho descrito nesta tese pode contribuir para o futuro desenvolvimento de péptidos 
antimicrobianos adequados ao tratamento de infeções por micobactérias, bem como por 
outros agentes.  
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Thesis Organization 
This thesis is organized into three parts, Introduction, Results and Final Remarks. 
 Part I comprises the introduction to the theme of the thesis, developing the more 
relevant topics, including also the objectives of the work. 
 Part II encompasses four chapters of results, presented in the form of original scientific 
articles. In all four chapters the author of this thesis made substantial contributions for 
the design, conception, analysis and data interpretation, particularly: 
 Chapters 5, 7 and 8 – All the presented data was obtained and analysed 
by the author of this thesis with the collaboration of the remaining authors; 
 Chapter 6 – Only the DSC and CD data were not obtained by the author. 
However their analysis and interpretation, as well as their integration into 
the discussion and overall conclusions were made by the author of this 
thesis with the collaboration of the remaining authors. 
 Part III contains the final remarks and future perspectives of the work. 
 
 
 
 
 
 
 
 
 
 
 
 
 
PART I. INTRODUCTION 
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CHAPTER 1. Antimicrobial Peptides 
We face at present an alarming situation regarding antibiotic resistance and the 
emergence of multidrug-resistant “super bugs”. The treatment of these infections is 
increasingly prone to failure and costly, strongly contributing to the terrible economic 
burden of global public health worldwide. Aggravating the problem, antimicrobial drug 
development is not keeping pace with the appearance of resistant pathogens. In the last 
40 years, only three new classes of antibiotics for human use where discovered, and one 
of them is limited to topical application (Fischbach and Walsh 2009, Bassetti et al. 2013). 
World Health Organization (WHO) reported in 2014 that antibiotic resistance is spreading 
rapidly throughout the world and putting at risk the treatment of common infections. For 
instance, the failure of the treatment for gonorrhoea using last resort drugs (third-
generation cephalosporins) has been reported in several countries and extensively drug-
resistant tuberculosis has been identified in 100 countries (WHO 2015a). Also, methicillin-
resistant Staphylococcus aureus (MRSA) are responsible for a high percentage of 
hospital-acquired infections that are spreading outside the hospital zones (Spellberg and 
Shlaes 2014, WHO 2015a). Within Europe, Portugal has one of the highest incidences of 
MRSA, as well as vancomycin-resistant Enterococcus faecium and multi-drug resistant 
Acinetobacter (DGS 2014). 
Considering all this, we must acknowledge that we are moving towards a post-antibiotic 
era, where new antimicrobial strategies must emerge. In this context, antimicrobial 
peptides (AMP) are a new potential alternative for fighting infectious diseases.  
Antimicrobial peptides are a large group of compounds that exhibit antimicrobial activity 
towards several pathogens. They are produced by almost all living organisms, as a 
primitive and conserved part of their immune defence system (Ganz and Lehrer 1999). 
These peptides are multifunctional and act in concert with other immune mechanisms 
providing a first line of defence against invading organisms, having evolved in nature to 
protect their hosts against diverse pathogens, such as bacteria, fungi, protozoa, and virus, 
as well as cancer cells (Zasloff 2002, Wiesner and Vilcinskas 2010). AMP production can 
be constitutive or induced as a response to inflammation, infection or injury, depending on 
the organism, cell type and peptide. They can also be expressed systemically, or they can 
be localized in specific sites more frequently exposed to pathogens, such as the skin or 
mucosa, or in some blood cell types, such as neutrophils, eosinophils and platelets 
(Yeung et al. 2011, Mansour et al. 2014). Although their mechanism of action is a matter 
of debate, AMP can exhibit a wide range of activities that include disrupting the pathogens 
membrane, acting on internal targets, immunomodulation, among others (see chapter 1.3), 
increasing their efficacy and capacity to evade potential resistance mechanisms (Nguyen 
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et al. 2011). Due to their multifunctional roles in both innate and adaptive immunity (see 
chapter 1.4), antimicrobial peptides can also be called host defence peptides (for an 
extensive review see (Mansour et al. 2014)).  
Since the discovery of AMP and their potential as antimicrobial drugs, intensive research 
has been made not only to discover new peptides and characterize them, but also to drive 
their clinical use. So far more than 2600 antimicrobial peptides have been described in 
The Antimicrobial Peptide Database – APD (http://aps.unmc.edu/AP/main.php). Their 
described activities are equally vast, including antibacterial, antiviral, antifungal, 
antiparasitic, anticancer, antiprotist, insecticidal, spermicidal, chemotactic, wound healing, 
antioxidant and protease inhibitors (Wang et al. 2009). 
 
1.1. Structural characteristics 
Antimicrobial peptides vary widely in many aspects, such as length, sequence, structure, 
activity and source. As a result of such diversity, there is no universal target or mechanism 
of action for this class of compounds. Even so, membranes are believed to be the main 
target for most peptides. AMP are classified as small peptides (<50 amino acids), the 
majority of which have a positive charge at neutral pH due to the presence of arginine and 
lysine residues, and about 50% of hydrophobic residues. Their cationic character allows 
them to interact more easily with negatively charged membranes, such as prokaryotic 
membranes, than with zwitterionic membranes, as is the case of animal cells (membrane 
selectivity will be discussed later in more detail, see chapter 1.2) (Teixeira et al. 2012). 
When in solution, AMP usually have a random structure; however, when in contact with 
membranes they adopt an amphipathic structure where hydrophobic and cationic residues 
will segregate into different faces. This separation is essential for their mechanism of 
action as the positively charged face will establish the first contact with the membrane 
through electrostatic interactions whereas the non-polar face will interact with the lipid acyl 
chains, allowing the peptide to insert into the membrane through hydrophobic and van der 
Walls interactions (Hancock and Chapple 1999, Teixeira et al. 2012). Although the 
structural characteristics just mentioned are known to be important, their correlation with 
antimicrobial activity is not simple. Usually the increase in the number of positive residues 
correlates with an increase in the antibacterial activity, but above a certain threshold, the 
higher cationicity will result in a higher haemolytic activity and consequent toxicity for the 
host, with no improvement in the antibacterial activity (Bessalle et al. 1992, Giangaspero 
et al. 2001, Jiang et al. 2008). The same occurs with the hydrophobicity. The increased 
number of hydrophobic residues, which leads to large hydrophobic surfaces, usually 
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contributes to higher toxicity towards host cells, with no improvement in the antimicrobial 
activity (Shin et al. 2001, Kondejewski et al. 2002, Jiang et al. 2008). The same could be 
described for the length, amino acid composition, and secondary structure. Therefore, in a 
diverse and wide group of compounds such as antimicrobial peptides, there are no 
universal characteristics that guarantee a good antimicrobial peptide with high and 
selective activity. 
Due to their diversity, classification of AMP is not trivial. Most authors classify them based 
on their secondary structure, but it could also be based on their origin.  
The most common classification based on the secondary structure divides AMP into three 
groups – alpha-helical peptides, beta-sheet peptides and extended peptides. Alpha-
helical peptides are the largest group, the most studied peptides being the cecropins 
from the cecropia moth, melittin from the bee venom toxin, magainins expressed in the 
skin and intestine of frogs and cathelicidins present in mammals (Teixeira et al. 2012). 
Beta-sheet peptides contain a defined number of beta-strands with few or no helical 
domains. This structure is usually stabilized by the presence of disulphide bonds, as in the 
case of lactoferricin obtained from lactoferrin and present in mammals, protegrin from pigs, 
and defensins, present in several vertebrates (Nguyen et al. 2011, Teixeira et al. 2012). 
The last group of AMP is the extended peptides. These peptides do not fold into regular 
secondary structures and are composed of a high number of certain amino acids, like 
histidine (histatins), tryptophan (indolicidins) and arginine and proline (PR-39) (Nguyen et 
al. 2011). 
 
1.2. Selective toxicity 
Independently of how AMP exert their activity, they will interact with the pathogen cellular 
membrane but also with the host membranes. This interaction must be as selective as 
possible to prevent toxic effects to the host cells. Melittin, from the bee venom, was one of 
the first described membrane-active peptides (Habermann 1972), but it is well known for 
its haemolytic properties, which prevented its clinical use. However, it remains until today 
one of the well described and characterized antimicrobial peptides. In the evaluation of the 
activity of AMP, the cytotoxicity of these peptides towards mammalian cells should always 
be addressed. There are many different cytotoxicity assays that can be performed, but 
their outcome strongly depends on many factors such as the origin and life storage of the 
mammalian cells, the peptide-to-cell ratio, the medium used, and therefore the results 
must be carefully analysed (van 't Hof et al. 2001). Based on the results of cytotoxicity 
assays together with the antimicrobial activity of AMP, the selectivity index, defined as the 
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ratio between cytotoxic activity and antimicrobial activity, can be determined, being a 
useful tool to predict the potential of a given AMP as a therapeutic agent.  
One of the major factors underlying AMP selectivity is the membrane lipid composition, 
which varies considerably between eukaryotic and prokaryotic cells (Teixeira et al. 2012). 
Cytoplasmic membranes of mammalian cells are mostly constituted by phospholipids and 
cholesterol. Phospholipids are asymmetrically distributed between the inner and the outer 
leaflet of the bilayer exposing predominately zwitterionic phosphatidylcholine (PC) and 
sphingomyelin to the extracellular side. On the other hand, bacterial cytoplasmic 
membranes do not have cholesterol and are mainly composed of zwitterionic 
phosphatidylethanolamine (PE) and negatively charged phosphatidylglycerol (PG) and 
cardiolipin, conferring an overall negative charge to the outer side of the cytoplasmic 
membrane (Lohner and Blondelle 2005, Lohner 2009, Teixeira et al. 2012). There are also 
differences in the membrane potential, which is less negative in eukaryotes (-15 mV) than 
in prokaryotes (-140 mV) (van 't Hof et al. 2001, Steinstraesser et al. 2011). Since one of 
the main principles of peptide activity is thought to be electrostatic interaction with 
membranes, the higher amount of negatively charged lipids (Teixeira et al. 2012), a higher 
negative electrical potential (van 't Hof et al. 2001, Steinstraesser et al. 2011) and the lack 
of sterols like cholesterol (Benachir et al. 1997, Raghuraman and Chattopadhyay 2004, 
Sood and Kinnunen 2008) turns bacterial membranes into a preferred target for AMP. 
Nonetheless, it should be noted that in the case of bacteria, before reaching the 
cytoplasmic membrane, the peptides have to overcome other barriers. In the case of 
Gram-positive bacteria, a thick peptidoglycan layer embedded with teichoic and 
lipoteichoic acids (which are negatively charged) is present around the cell. For Gram-
negative bacteria the cell wall consists of an outer lipid membrane layer, with a unique 
and highly asymmetrical composition (negatively charged lipopolysaccharides are located 
in the outer leaflet and phospholipids are confined to the inner leaflet) and a layer of 
peptidoglycan (much thinner than that of Gram-positive bacteria) between the inner and 
the outer membranes (Cabeen and Jacobs-Wagner 2005, Lohner and Blondelle 2005, 
Lohner 2009). Therefore in normal conditions the overall charge of a bacterial cell wall is 
negative, increasing the chances of interaction with AMP over mammalian cells. 
Antimicrobial peptides can also kill eukaryotic pathogens, such as fungi and protozoa. The 
specificity here also relies on charge, since these pathogens have a higher percentage of 
anionic phospholipids in the outer leaflet than mammalian cells (Wassef et al. 1985, Cintra 
et al. 1986, Seabra et al. 2004, Wanderley et al. 2006). The same happens for cancer 
cells. Although they are mammalian cells, their neoplastic transformation introduces 
significant changes in the cytoplasmic membrane, such as the exposure of 
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phosphatidylserine (negatively charged) that is usually confined to the inner leaflet, the 
higher expression of O-glycosylated mucins, sialic acids linked to glycoproteins and 
glycolipids, and heparin sulphates, all these leading to an overall negative charge, 
rendering them more susceptibility to AMP activity. Also, these cells have increased 
number of microvilli, which leads to increase in cell surface area exposed to AMP. In 
some cases, cancer cells also have lower levels of cholesterol increasing their fluidity and 
therefore their susceptibility to AMP’s action (Riedl et al. 2011, Teixeira et al. 2012, 
Gaspar et al. 2013). 
 
1.3. Mechanisms of action 
The mechanism of action of antimicrobial peptides is not fully understood but properties 
such as the secondary structure, overall charge and hydrophobicity, play important roles 
in their interaction with pathogen membranes. Other parameters also have to be 
considered, for instance, the membrane lipid composition, the peptide-to-lipid molar ratio, 
and environmental conditions like ionic strength and pH (Lohner and Blondelle 2005). Due 
to the high diversity of AMP and their properties there is no universal mechanism for their 
action. However, there are some proposed mechanisms providing possible ways to 
understand how the peptides exert their antimicrobial activity. Overall these mechanisms 
rely on the same steps: adsorption of AMP onto the membrane due to electrostatic 
interactions between the cationic peptides and the head groups of anionic phospholipids; 
conformational change upon membrane contact; attachment and insertion into the 
membrane as the concentration of peptide increases; membrane permeability that could 
lead to cell death or not; and finally, translocation to the cytoplasm and possible 
intracellular killing (Brogden 2005). 
According to the barrel-stave model (figure 1), peptides large enough (~ 22 amino acids) 
form transmembrane aqueous channels/pores by inserting into the hydrophobic core 
perpendicularly to the membrane plane where the hydrophobic region of the peptide is 
aligned with the acyl chains of the phospholipids while the hydrophilic peptide regions 
form the inner surface of the pore channel (figure 1). The continuous recruitment of 
peptides to the membrane increases the pore size leading to leakage of the cells contents, 
membrane depolarization and thereby cell death (Nguyen et al. 2011). The peptides 
arrangement in the membrane causes high repulsion due to their charges, and this can 
culminate in the disintegration of the pore. This model is only possible for peptides with 
not too high charge and high hydrophobic, and it is believed that the number of peptides 
acting by this mechanism is low. An example is alamethicin from the fungus Trichoderma 
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viridis, perforin, produced by cytotoxic T lymphocytes and NK cells, and complement 
component C9 (Wiesner and Vilcinskas 2010). 
The carpet model (figure 1) proposes that the membrane surface is covered by the 
peptides, parallel aligned to the bilayer surface, in a “carpet-like” manner, diminishing the 
fluidity of the membrane. When the concentration of the peptide reaches a threshold value, 
the integrity of the membrane is lost due to the disruption of the bilayer curvature, that can 
happen through transient toroidal pores or other peptide/lipid structures, leading 
eventually to membrane micellization and cell death (figure 1) (Teixeira et al. 2012). 
The formation of toroidal or wormhole pores (figure 1) can be seen as representing one 
of the possible final stages of the previous carpet model, where the formation of pores 
leads to disruption of the membranes. In fact, these two models have been unified in the 
so-called “Shai-Matzusaki-Huang” model that proposes that peptides bind parallel to 
the membrane with the apolar amino acids penetrating partly into the hydrophobic core, 
while the cationic residues interact with the head groups of anionic phospholipids, 
inducing membrane thinning and a high curvature strain. To release this strain the 
orientation of the peptides changes from parallel to perpendicular, causing bending of the 
membrane interface towards the hydrophobic interior, maintaining the contact between 
the peptides and the charged head groups from the phospholipids. These events lead to 
the formation of water-filled toroidal pores composed of the peptides and the lipid head 
groups (figure 1). Upon disintegration of the pores, some peptides can be translocated to 
the inner leaflet of the membranes reaching the cytoplasm or the membrane can be 
disrupted due to depolarization or micellization, resulting in cell death (Nicolas 2009, 
Rivas et al. 2009).  
Other mechanisms of action have recently been suggested that do not imply a 
membranolytic activity. These do not necessarily exclude each other, or even the models 
explained above. In the aggregate channel model, the peptides insert into the 
membrane and cluster into short-lived transmembrane aggregates which allows not only 
the peptides to cross the membrane, but also the leakage of ions and other molecules 
(Teixeira et al. 2012). Lipid segregation is the formation of lipid-peptide domains as a 
result of lateral segregation of anionic and zwitterionic lipids induced by the presence of 
the positively charged peptide (figure 1). This can cause small leakage of intracellular 
contents, depolarization due to a dissipation of the membrane potential, and also 
membrane destabilization due to changes in the curvature strain. These will affect the 
function of membrane proteins and biological processes, with harmful consequences for 
the cell (Nguyen et al. 2011, Teixeira et al. 2012). In the sinking raft model, the peptides 
induce a mass imbalance between the two leaflets due to preferential binding to some 
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lipid domains. As the curvature of the membrane increases, the peptides sink into the 
bilayer forming transient pores that allow not only the peptide translocation to the cytosol 
but also the leakage of intracellular metabolites (Teixeira et al. 2012). In the 
electroporation model, the interaction between peptide and membrane creates an 
electric potential difference in the membrane. When this difference reaches a certain 
threshold, pores can be formed by molecular electroporation, allowing the peptides to 
translocate (figure 1) (Nguyen et al. 2011, Teixeira et al. 2012). Another model predicts 
the formation of non-lamellar phase structures, such as hexagonal and cubic phases 
formed by membrane lipids (figures 1 and 6 – see chapter 2), which could induce 
membrane disruption or could affect the establishment of lipid domains in the cellular 
membrane. These domains are important for many biological processes such endocytosis 
(induced by lipid rafts) and for the activity of membrane proteins, thus disturbing them 
could culminate in the impairment of membrane function and eventually cell death (Luzzati 
1997, Lohner 2009, Haney et al. 2010, Teixeira et al. 2012). 
Whatever the mechanism is, peptide interaction with membranes can induce cell death by 
the dissipation of transmembrane electrochemical ion gradients, loss of metabolites, lipid 
asymmetry and eventually lysis of the cell (Wiesner and Vilcinskas 2010). However, an 
increasing amount of research has shown that membrane permeabilization alone may not 
be sufficient to cause cell death. Some AMP can be translocated to the cytoplasm, with or 
without permeabilizing the cytoplasmic membrane, and bind to DNA, RNA and proteins. 
This interaction can culminate in inhibition of several cellular processes such as cell wall 
synthesis, protein synthesis, enzymatic activity and even membrane septum formation, 
which would lead to cell death (Brogden 2005, Li et al. 2012). Buforin is an example of a 
non-lytic peptide that although having high antimicrobial activity this does not correlate 
with lysis of the bacterial membrane. Instead the peptide translocates efficiently to the 
cytoplasm, probably through the formation of short-lived toroidal pores, enabling this 
peptide to enter the cell and act on intracellular targets (Kobayashi et al. 2000, Kobayashi 
et al. 2004, Henriques et al. 2006). 
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Figure 1– Proposed mechanisms of action for AMP. Illustration of some of the proposed 
events/mechanisms occurring at the cytoplasmic membrane after an initial interaction of 
antimicrobial peptides with the membranes (adapted from: (Nguyen et al. 2011)). 
 
1.4. Host Defence Peptides 
More recently, antimicrobial peptides have been increasingly recognized for their 
multifunctional roles in innate and adaptive immunity, being this effect in some cases 
more significant than their direct antimicrobial activity. The combination of these different 
but complementary functions is essential for the efficient control of infections in the host 
organism. Thus, in response to an infection, antimicrobial peptides can promote bacterial 
clearance through direct killing but also through the establishment of immune cell circuits, 
leading some authors to re-name them “host defence peptides” (HDP) (Auvynet and 
Rosenstein 2009, Guaní-Guerra et al. 2010, Yeung et al. 2011). 
In humans, the two major classes of HDP are the defensins and the cathelicidins. These 
peptides can be found in neutrophils, monocytes, mast cells, epithelial cells, among others. 
They can be expressed constitutively, as beta-defensin 1 (HBD1) in keratinocytes, or 
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induced by an inflammatory stimulus like beta-defensin 2 (HBD2) that is present in 
epithelial cells, and is induced by lipopolysaccharide (LPS) and tumour necrosis factor 
alpha (TNF-alpha) (Arnett and Seveau 2011, Mansour et al. 2014). Their 
immunomodulatory activities are vast, including, recruitment of immune cells; inhibition of 
the production of pro-inflammatory cytokines such as TNF-alpha, IL-6 and IL-8, and at the 
same time enhancing anti-inflammatory cytokines (IL-10 and chemokines); induction of 
cellular differentiation and activation; modulation of adaptive immunity by recruiting T cells; 
regulation of several cellular processes such as autophagy, apoptosis and pyroptosis, and 
also the promotion of wound healing (Mansour et al. 2014). 
The importance of HDP for the health of the host was demonstrated by studies where 
their enhanced expression increased resistance to bacterial infections in mice (Bals et al. 
1999, Salzman et al. 2003). On the other hand, mice lacking endogenous cathelicidin 
(CRAMP) or beta-defensin were more susceptible to streptococcal infections being this 
effect reversed by administration of exogenous cathelicidin (Nizet et al. 2001, Fukumoto et 
al. 2005). Moreover, and as a consequence of the immunomodulatory activities, HDP are 
also involved in autoimmunity. Increased expression of these peptides is associated with 
different inflammatory conditions such as cystic fibrosis, psoriasis, and others (Guaní-
Guerra et al. 2010). On the other hand, lack or decreased amounts of HDP is related to 
increased susceptibility to infections in diseases such as morbus Kostmann (Putsep et al. 
2002). 
 
1.5. Resistance to AMP 
Induction of resistance is thought to be less likely for AMP when compared to 
conventional antibiotics. This is mostly due to the fast kinetics of the antimicrobial process, 
to the possibility of acting on multiple targets and to the fact that their main molecular 
target – the membrane- is highly conserved and essential for pathogen survival. Although 
in principle acquiring resistance to AMP is more difficult, it has been pointed that it might 
have more severe consequences if it led to cross-resistance to innate human antimicrobial 
peptides (host defence peptides) (Samuelsen et al. 2005, Hancock and Sahl 2006, 
Habets and Brockhurst 2012). Some studies have already pointed out the existence of 
resistance to AMP, while others suggest some possible mechanisms, based on the 
documented mechanisms of resistance to peptide antibiotics such as polymyxin B and 
daptomycin, which have a similar mechanism of action as AMP, acting on the cell 
membrane (Maria-Neto et al. 2015). 
12 
Since the basis of antimicrobial activity is an initial electrostatic interaction between the 
cationic peptides and the pathogen, the first resistance mechanisms which could be 
predicted would be a reduction of the negative charge at the pathogen surface. In fact, 
electrostatic repulsion of AMP can arise from several modifications of the bacterial surface, 
some of which were already documented, such as: the addition of the positively charged 
lysine to phosphatidylglycerol (lysyl-PG) by staphylococci and clostridia, the incorporation 
of aminoarabinose and ethanolamine on the lipid A of LPS in some Gram-negative 
bacteria, or L-rhamnosylation and esterification of teichoic acids by D-alanine in Gram 
positives (Bauer and Shafer 2015, Carvalho et al. 2015, Joo and Otto 2015, LaRock and 
Nizet 2015, Maria-Neto et al. 2015, Nuri et al. 2015).  
It has also been described that bacteria can induce the production of secreted or cell-
surface proteins that irreversibly bind or cleave AMP and glycopolymeric matrices that 
trap the peptides preventing their access to the bacterial cytoplasmic membrane. 
Additionally, some of the efflux pumps involved in antibiotic expulsion have been shown to 
be able to export AMP (Bauer and Shafer 2015, Joo and Otto 2015, LaRock and Nizet 
2015, Matamouros and Miller 2015). Increased resistance can also be achieved by 
changing membrane fluidity by modification of fatty acid acylation pattern of lipid A of LPS 
(Koprivnjak and Peschel 2011, Bauer and Shafer 2015, LaRock and Nizet 2015, Nuri et al. 
2015). Another form of bacterial resistance is the formation of biofilms, since, usually, the 
susceptibility to AMP of bacterial biofilm is lower than that of bacteria in the planktonic 
state (Nuri et al. 2015). 
It has been recently described that bacteria can sense the presence of AMP and activate 
resistance mechanisms, through either two-components or three-components sensor-
transducer response systems (Joo and Otto 2015, Matamouros and Miller 2015). The 
activation of these sensor systems will result in the changes on the above mentioned 
surface charge and rigidity, cell wall and membrane thickness or membrane fluidity (Nuri 
et al. 2015). It is thought that these systems evolved to guarantee that such alterations, 
which often come with a high energy burden or loss of fitness to the bacteria are activated 
only when needed. 
 
1.6. AMP in the clinic: Will it be possible? 
Since the discovery of the potential of antimicrobial peptides as new therapies to fight 
infectious diseases, there has been a tremendous effort to try to get these peptides into 
the clinic. Cationic peptides such as polymyxin B and gramicidin S have been used for a 
long time in the clinic as topical agents, and the lantibiotic nisin, produced by fermentation 
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using Lactococcus lactis is used as an antimicrobial food additive (Hancock and Sahl 
2006).  
Several AMP are in different stages of clinical trials for a variety of applications such as 
diabetic foot ulcers, prevention of catheter-related infections, acne therapy, among others. 
However, their success has been limited. There are some AMP that have reached the last 
stages of clinical trials but, so far, none has been approved (Steinstraesser et al. 2011, 
Seo et al. 2012). As drug candidates, AMP present some disadvantages due to their 
peptidic nature, including reduced activity in the presence of salts and divalent cations, 
susceptibility to pH changes, proteases and other plasma components’ activity, resulting 
in low metabolic stability and bioavailability, and reduced in vivo half-lives (Rotem and Mor 
2009). The route of administration is also a problem. If administered orally, they most 
probably would be degraded upon encounter with the enzymes from the digestive tract, 
and if injected, besides the susceptibility to the proteases in the blood, they could trigger 
immune responses that neutralize the active component or induce allergic reactions. 
Other safety considerations raise many concerns. They can cross-react with receptors for 
neuropeptides and peptide hormones, and the rapid degradation of AMP could lead to 
unwanted levels of amino acids for which some patients are sensitive, such as glutamate 
(Chinese restaurant syndrome) and phenylalanine (phenylketonuria) (van 't Hof et al. 
2001). The high cost of production associated with peptide synthesis is another major 
drawback in the clinical application of these peptides.  
All the above factors contribute to the current limitations of the use of AMP as topical 
drugs for the treatment of skin and wound infections (Wiesner and Vilcinskas 2010). 
Different approaches have been adopted to try to overcome these problems. Several 
classes of modified antimicrobial peptides have appeared, including AMP mimetics, hybrid 
AMP, AMP congeners, stabilized AMP, AMP conjugates and immobilized AMP (Brogden 
and Brogden 2011). All these compounds derive from natural AMP as the result of 
modifications to the peptide composition, or are molecules that imitate their structure and 
function. Some of the strategies employed consist of i) the use of D-amino acids (rather 
than L-amino acids) which are resistant to proteases but have higher costs when 
compared with L-amino acids; ii) the use of nonpeptidic backbones (peptidomimetics); iii) 
conjugation with a specific antibody or receptor, and micelles or liposomes, for improved 
stability and “targeted” delivery; iv) pro-drug molecules, among others (Hancock and Sahl 
2006, Brogden and Brogden 2011). 
In the work described in this thesis, two classes of AMP – cecropin A-melittin hybrids and 
lactoferrin peptides – were studied for their mechanisms of action and the potential of 
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modifications that can result in improved clinical potential. These two classes of peptides 
will thus be described here in more detail. 
 
1.7. Cecropin A-melittin peptides 
Cecropin A, with 37 amino acids, was the first antimicrobial peptide from an insect to be 
reported (Steiner et al. 1981). It is active against Gram-negative and Gram-positive 
bacteria (Steiner et al. 1981, Andreu et al. 1983, Boman and Hultmark 1987, Andreu et al. 
1992), forms an amphipathic α-helix when in contact with lipid membranes (Steiner 1982, 
Silvestro and Axelsen 2000) and acts by forming voltage-dependent channels that 
collapse the ionic gradients (Diaz-Achirica et al. 1994). 
Melittin, from the bee venom toxin, has a variety of toxic properties namely a high 
haemolytic activity (Mackler and Kreil 1977). This peptide adopts a α-helical conformation 
aggregating into tetramers (Vogel 1981, Lafleur et al. 1991), and is used as a model of a 
cytolytic peptide to monitor lipid–protein interactions using a variety of biophysical 
techniques (Raghuraman and Chattopadhyay 2007). 
These two peptides, cecropin A and melittin, are composed of hydrophilic and 
hydrophobic domains separated by a flexible hinge region, adopting α-helix – hinge – α-
helix conformation. The hydrophobic region of cecropin A is localized on its C-terminal 
whereas in melittin it is localized on the N-terminal (Merrifield et al. 1982, Holak et al. 1988, 
Fink et al. 1989, Raghuraman and Chattopadhyay 2007). In an attempt to obtain 
antimicrobial peptides with strong bactericidal activity and low haemolytic properties, 
Boman, et al. in 1989 synthesized for the first time cecropin A-melittin hybrids, and they 
found that these hybrids had better antimicrobial properties than the parental compounds 
(Boman et al. 1989). In particular, a hybrid formed by the first 8 amino acids of the cationic 
region of cecropin A and the first 18 amino acids of the hydrophobic and non-haemolytic 
region of melittin (CA(1-8)M(1-18)) exhibited a wider spectrum of antimicrobial activity and 
improved potency in comparison to cecropin A, without the cytotoxic effects of melittin 
(Wade et al. 1990). In the continuation of this work, Andreu et al. in 1992 synthesized 
shorter hybrids that retained significant activity when compared to the larger versions of 
the hybrid, especially CA(1-7)M(2-9) (Andreu et al. 1992).  
The mechanism of action of these hybrids is thought to be membrane disruption due to 
the formation of toroidal pores and/or disintegration of the membrane due to a detergent-
like action (Andreu et al. 1992, Diaz-Achirica et al. 1994, Juvvadi et al. 1996, Diaz-
Achirica et al. 1998, Abrunhosa et al. 2005, Sato and Feix 2006, Pistolesi et al. 2007, 
Bastos et al. 2008, Ferre et al. 2009, Milani et al. 2009, Teixeira et al. 2010). Supporting 
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this is the fact that the antimicrobial activity of the hybrid peptides composed of all D-
amino acids was equivalent to that of the hybrids with L-amino acids. This strongly 
indicates that the peptides do not act by interacting with chiral receptors in the lysis and 
killing of the pathogens, but instead follow a non-specific membranolytic way of action 
(Wade et al. 1990, Merrifield et al. 1995, Diaz-Achirica et al. 1998, Arias et al. 2006). 
Cecropin A-melittin hybrids are active against several different Gram-positive and Gram-
negative bacteria, and protozoan in vitro (Andreu et al. 1992, Piers et al. 1994, Chicharro 
et al. 2001, Rodriguez-Hernandez et al. 2006, Fernandez-Reyes et al. 2010), can 
synergize with antibiotics for the control of MRSA infections (Giacometti et al. 2004, 
Mataraci and Dosler 2012), and have proven efficacy on in vivo model of dog 
leishmaniasis (Alberola et al. 2004) and in an experimental pseudomonas keratitis model 
in rabbits (Nos-Barbera et al. 1997). Interestingly, they strongly interact with LPS 
protecting from induced lethal endotoxic shock in vivo (Gough et al. 1996). These hybrids 
can also be involved in the regulation of the host defence. Arias et al. (Arias et al. 2006) 
showed that CA(1-8)M(1-18) was capable of activating murine macrophages by inducing 
the expression of NOS2 due to unspecific but limited membrane permeation. More 
recently, Salomone et al., constructed a chimeric peptide between a cecropin A-melittin 
derivative and an arginine-rich Tat peptide, from the HIV-1 Tat protein, successfully 
obtaining a cell-penetrating peptide that can be used as a tool for gene-delivery 
applications (Salomone et al. 2012, Salomone et al. 2013). 
 
1.8. Lactoferrin peptides 
Lactoferrin (LF) is a mammalian iron-binding glycoprotein of 80 kDa that belongs to the 
transferrin family (Brock 2002). Contrary to transferrin, that appears primarily in the 
bloodstream delivering iron to the cells, lactoferrin is mostly found in exocrine secretions, 
like milk, tear fluid and seminal plasma, and in neutrophil granules playing an important 
role in maternal and innate immunity (Wiesner and Vilcinskas 2010). This is a 
multifunctional protein that has antibacterial, antiviral, antifungal and antiparasitic activities 
and can protect against cancer development and metastasis owing to its 
immunomodulatory potential (Brock 2002, Wiesner and Vilcinskas 2010). The antibacterial 
activity of lactoferrin was first thought to be due only to the sequestration of iron, an 
essential nutrient, from bacteria (Jenssen and Hancock 2009). Now, it is known that allied 
to that, the existence of particular domains, such as the highly cationic N1 terminal 
domain, where lactoferricin and lactoferrampin can be found, are crucial for the 
antimicrobial activities of lactoferrin (Tomita et al. 1991). 
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Lactoferricin is obtained by pepsin digestion of lactoferrin (Tomita et al. 1991, Bellamy et 
al. 1992b, Kuwata et al. 1998) and has been extensively studied (Wakabayashi et al. 2003, 
Gifford et al. 2005). The bovine peptide is constituted by 25 amino acids, corresponding to 
the amino acids 17-41 in the native protein (bovine lactoferrin), forming a looped structure 
with a disulphide bond between two cysteine residues (Bellamy et al. 1992a). The 
antimicrobial spectrum of activity of lactoferricin ranges from several Gram-negative to 
Gram-positive bacteria (Bellamy et al. 1992a, Bellamy et al. 1992b), fungi (Bellamy et al. 
1994), protozoan and viruses (Gifford et al. 2005). Lactoferricin has been shown to have 
antitumor effects, like inhibition of tumour metastasis, suppression of tumour-induced 
angiogenesis and significant reduction of solid tumour (fibrosarcomas, melanomas, colon 
carcinomas) size in mice, without affecting erythrocytes or fibroblasts (Yoo et al. 1997b, 
Eliassen et al. 2002). This peptide can also have immunomodulatory properties, playing a 
role in the innate and adaptive immune system, including the induction of apoptosis in 
several cancer cell lines without harming normal mammalian cells (Yoo et al. 1997a, 
Mader et al. 2005, Furlong et al. 2006, Mader et al. 2007, Furlong et al. 2010, Pan et al. 
2013), and the inhibition of septic shock by binding to endotoxins (Yamauchi et al. 1993).  
Groenink, et al. in 1999 synthesized shorter peptides with sequences homologous to the 
N-terminal domain of bovine and human lactoferricin, and found that among the peptides 
tested, bovine lactoferricin containing amino acids 17-30 (LFcin17-30) had the highest 
number of positively charged residues and the highest antimicrobial activity against both 
Gram-positive and Gram-negative bacteria (Groenink et al. 1999). Recent studies showed 
that this peptide is active against different pathogens such as Escherichia coli, 
Staphylococcus aureus, Candida albicans, Leishmania, among others (van der Kraan et 
al. 2005b, Flores-Villasenor et al. 2010, Lopez-Soto et al. 2010, Silva et al. 2012), and can 
potentiate the effect of classical antimicrobial drugs aiming the use of low doses and 
therefore low toxicity (Leon-Sicairos et al. 2006, Sanchez-Gomez et al. 2011). 
Another peptide in the N1 domain of bovine lactoferrin was identified by the group of Jan 
G. Bolscher, namely lactoferrampin containing the amino acids 268-284 
(LFampin268-284). This peptide exhibited antimicrobial activity against a broad range of 
pathogens, especially against Candida albicans and several bacteria (van der Kraan et al. 
2004). Systematic studies, using the initial sequence of lactoferrampin to obtain other 
peptides by truncation and or extension, have shown that lactoferrampin 265-284 
(LFampin265-284) was the shortest and most active peptide, in particular against 
Candida albicans (van der Kraan et al. 2005a, van der Kraan et al. 2005b). The three 
extra amino acids (Aspartic acid-Leucine-Isoleucine) did not confer any additional positive 
charge (one of the most important characteristics of AMP) since the first is negatively 
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charged and the other two are uncharged. Instead, this N-terminal sequence endowed 
lactoferrampin with a high tendency to adopt a more stable amphipathic α-helix, 
enhancing in this way its microbicidal activity (van der Kraan et al. 2005a, van der Kraan 
et al. 2006, Haney et al. 2007, Adao et al. 2011, Haney et al. 2012a). 
Lactoferricin and lactoferrampin are spatially close in lactoferrin (figure 2), making it 
plausible that they cooperate in many of the beneficial properties of this protein. To test if 
these peptides would form a functional unit, a chimeric peptide (LFchimera) containing 
LFcin17-30 and LFampin265-284 was synthesized by Jan G. Bolscher (Bolscher et al. 
2009b). To try to mimic the spatial topology of these two peptides in lactoferrin, 
LFcin17-30 and LFampin265-284 are coupled by their C-terminals to the α- and ε-amino 
groups, respectively, of an additional lysine, leaving the two N-terminals as free ends 
(figure 2) (Haney et al. 2012b). LFchimera displays a strong activity against a wide 
variety of pathogens such as Escherichia coli, Pseudomonas aeruginosa, Vibrio 
parahaemolyticus, Staphylococcus aureus, Entamoeba histolytica, Candida albicans, 
Leishmania pifanoi, Burkholderia and Streptococcus pneumonia, which is maintained 
under different physiological conditions (including high ionic strength and rich growth 
medium) (Bolscher et al. 2009b, Leon-Sicairos et al. 2009, Flores-Villasenor et al. 2010, 
Lopez-Soto et al. 2010, Bolscher et al. 2012, Flores-Villasenor et al. 2012a, Silva et al. 
2012, Kanthawong et al. 2014, Leon-Sicairos et al. 2014). Additionally, it was recently 
found that LFchimera can protect mice against a lethal infection with enterohemorrhagic E. 
coli (Flores-Villasenor et al. 2012b). 
 
Figure 2 – Lactoferrin peptides. A) Ribbon diagram of bovine lactoferrin with LFcin17-30 (yellow) 
and LFampin265-284 (red). B) Designed of LFchimera composed by LFcin17-30 and LFampin265-
284 coupled by an additional lysine (K) (adapted from: (Bolscher et al. 2009b)). 
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CHAPTER 2. Antimicrobial peptides and model membranes 
The mechanism of action of AMP is complex and not entirely understood. Due to the high 
diversity of AMP it is now recognized that there is no universal mechanism for their action. 
Further, they can act in multiple ways, making it challenging to unravel all the molecular 
events resulting from their action. However, experimental data obtained so far clearly 
indicates that biological membranes are the main target of AMP. The use of liposomes, 
aimed at mimicking the biological membrane, allows the study of the activity of AMP in a 
highly controlled way, allowing easy modulation of lipid composition, and the informative 
use of numerous biophysical techniques. Studies on liposomes have been crucial to 
understand AMP modes of action and help a more rational design of AMP. In the work 
described in this thesis, lipid model membranes were used to study their interaction with 
AMP using several biophysical techniques, which are briefly presented below. 
 
2.1. Lipid model membranes as a tool to study AMP activity 
Biological membranes are mainly composed of a lipid matrix that anchors all other 
components, like proteins, glycoproteins and glycolipids that perform crucial functions in 
the life of the cell. Phospholipids, the building blocks of the cellular membranes, are 
amphiphilic molecules composed of a hydrophilic head group and a hydrophobic tail that 
consist of hydrocarbon chains. The lipid composition varies among different organisms 
and even among cell types of the same organism. The phospholipid distribution between 
the inner and outer leaflets of the lipid bilayer is asymmetrical, and some lipids are more 
common in one leaflet (Pozo Navas et al. 2005). The view of lipid molecules as only a 
scaffold for proteins is rapidly changing towards dynamic and active molecules, involved 
in various biological processes that are crucial to the life of the cell. In this context, the 
physical properties of membranes (such as fluidity and shape) are also increasingly 
recognized as fundamental for the proper functioning of the cell (Luzzati 1997, Haney et al. 
2010).  
Lipid organization upon contact with water is highly variable, depending on their intrinsic 
properties, on the composition of the medium (pH, ionic strength, additives, etc.), as well 
as on temperature and water content. The use of X-ray diffraction and other biophysical 
techniques reveals that lipids can assume different conformations or phases when in 
contact with water. For several lipids, systematic studies of phase transitions in relation to 
temperature and water content were performed, generating complex phase diagrams 
(figure 3). 
19 
 
 
Figure 3 – Temperature-composition phase diagram of monoolein. The phases formed by the 
lipid monoolein depend on temperature and hydration as illustrated in this phase diagram (adapted 
from: (Qiu and Caffrey 2000)). 
 
The tendency to form a certain phase, e.g. lamellar, hexagonal, cubic, depends among 
other factors on the geometric shape of the phospholipid molecule (Haney et al. 2010). 
Lipids where the hydrocarbon chain and the head group have similar cross-sectional 
areas will have a cylindrical shape (e.g. phosphatidylcholine and phosphatidylserine), and 
will tend to assume a planar bilayer structure, i.e. lamellar structure (figure 4A). When the 
head group area is smaller than the hydrocarbon chain, the structure is well represented 
by an inverted truncated cone (e.g. phosphatidylethanolamine) (figure 4B). When part of a 
membrane, these will favour a negative curvature and inverted hexagonal (HII) phases. 
Finally, lipids with the head group area larger than the hydrocarbon chain will appear as a 
cone (e.g. lysophosphatidylcholine), forming preferentially structures like normal 
hexagonal (HI) phase or micelles with a positive curvature (figure 4C) (Haney et al. 2010). 
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Figure 4 – Relation between the geometric shape of the phospholipid molecule and the 
structure favoured. A) Cylindrical shape phospholipids tend to assume lamellar structure. B) 
Inverted truncated cone shaped phospholipids favour a negative curvature of the membrane and 
can form inverted micelles or inverted hexagonal phases (HII). C) Cone shaped phospholipids 
favour a positive curvature of the membrane forming normal hexagonal phases (HI) or micelles 
(adapted from (Haney et al. 2010)). 
 
The functional structure of a biological membrane is a planar lipid bilayer in a lamellar 
phase (figure 5 and 6). Lamellar phases still include significant variations in their 
properties, depending on the lipids present and on the environment. The most common 
phases are  
 the liquid crystalline or fluid lamellar phase (Lα) where the hydrocarbon chains are 
in a “melted”, fluid state (figure 5) allowing easy lateral lipid movement and even flip-
flop, fundamental conditions for membrane reorganization upon external stimulus;  
 the gel lamellar phase (Lβ) in which the hydrocarbon chains are extended and much 
more rigid (figure 5) (Haney et al. 2010), occurs at lower temperatures that the ones 
where the liquid crystalline phase is stable. 
 Other gel lamellar phases such as tilted (Lβ’), interdigitated (LβI) and rippled (Pβ’) 
phase have been described for some lipids (Seddon and Templer 1995).  
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Figure 5 – Lamellar phases. Schematic representation of the structure and orientation of the 
phospholipids’ hydrocarbon chains in two lamellar phases, gel (Lβ) and fluid (Lα) (adapted from: 
(Tresset 2009)). 
 
The typical lipid state in biological membranes is the liquid crystalline or fluid lamellar 
phase. Although usually the maintenance of a stable bilayer is essential for normal 
membrane function, it is well known that in some cases membranes containing high 
amounts of non-lamellar phase-forming lipids (e.g. phosphatidylethanolamine) have the 
ability to form more complex 3D morphologies, adopting non-lamellar structures such as 
hexagonal and cubic phases (figure 6), that are believed to play important roles in some 
biological processes (Luzzati 1997, Lohner 2009). Hexagonal phases (figure 4 and 6) are 
formed by phospholipids cylinders oriented in a hexagonal lattice. In the case of the 
normal hexagonal phase (HI), the hydrocarbon chains represent the centre of the cylinder 
(figures 4C and 6B), whereas in the inverted hexagonal phase (HII) the head groups are 
oriented towards the core of the cylinder that is filled with water (figures 4B and 6C). The 
HII is implied for instance, in membrane fusion processes, whereas few lipids adopt HI 
(Tresset 2009, Haney et al. 2010). Cubic phases are part of a large family of phases that 
are complex and diverse, and can be divided essentially into two classes, bicontinuous 
and micellar phases (Luzzati et al. 1997). The bicontinuous phases consist of a single 
bilayer folded into a three-dimensional cubic network separating two disjointed water 
compartments with continuous regions of both polar (hydrophilic head groups) and non-
polar (hydrocarbon chains) structures (Ia3d, Pn3m, Im3m) (figure 6 D, E and F). The 
micellar phases are impervious to water-soluble components, and their structure is made 
of disjointed micelles with different sizes for a more efficient packing on a cubic lattice (e.g. 
Fd3m, Pm3n) (figure 6G) (Luzzati et al. 1997, Tresset 2009). Cubic phases are abundant 
in the biological world being present in the plasma membrane of archaebacteria, in the 
endoplasmic reticulum and in the mitochondria of mammalian cells. These phases are 
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also involved in biological processes such as membrane fusion and fat digestion (Luzzati 
1997, Tresset 2009). 
 
Figure 6 – Lamellar and non-lamellar phases. Schematic representation of lamellar phase (A), 
normal hexagonal phase (HI) (B), inverted hexagonal phase (HII) (C), bicontinuous cubic phases, 
Ia3d (D), Pn3m (E) and Im3m (F), and a micellar cubic phase, Fd3m (G) (adapted from (Seddon 
and Templer 1995, Tresset 2009, Haney et al. 2010)). 
 
When studying the interaction of antimicrobial peptides with membranes, it is crucial to 
understand if AMP are capable of altering the phospholipid phase behaviour and, if so, to 
correlate these changes in lipid polymorphism with models for the biological effects of 
AMP. Model membranes are particularly useful for that aim, as their properties can be 
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easily modulated, by varying phospholipid compositions, and easily analysed by using 
different techniques (e.g. calorimetry, X-ray diffraction, neutron scattering, fluorescence 
spectroscopy). They are very simplified models of complex structures enabling the 
discrimination of the different effects in the global mechanism of action. They can provide 
information that enables the understanding of the changes in polymorphism induced by 
AMP (e.g. the induction or disappearance of a certain phase), and how AMP affect the 
overall structure and stability of the membrane. In this way the mechanism of action of 
AMP can be clarified, and the conclusions may lead to a fine-tuning of new peptides to 
obtain better therapeutic agents.  
The phospholipid compositions most widely used to mimic the erythrocytes membranes 
for the study of AMP are zwitterionic membranes of phosphatidylcholine (PC), with or 
without cholesterol. The combination of PC and phosphatidylglycerol (PG) or 
phosphatidylethanolamine (PE) and PG are used to mimic the cytoplasmic membrane of 
pathogens, which usually have a global negative charge. For bacterial membranes, it is 
more common to use model membranes of PE and PE/PG mixtures, as these are the 
more common phospholipids in bacteria, whereas for mimicking fungus, membranes 
mainly composed of PC and PG are used (Teixeira et al. 2012). Few studies have 
addressed the importance of the hydrocarbon chain in the AMP/membrane interaction. In 
some cases, there has been some evidence that AMP may not only be sensitive to the 
head group type but also to the overall lipid composition of the membrane (Sevcsik et al. 
2007, Sevcsik et al. 2008). Therefore, efforts are now being made to include variations in 
this parameter in model membrane studies. More elaborate models could also be used by 
the introduction of sphingomyelin and sterols when mimicking eukaryotic membranes and 
cardiolipin for prokaryotic ones, or even by using membrane extracts obtained from 
bacteria. However, data analysis from these systems is much more complex. It should be 
stressed that the main paradigm of model studies is to “keep it simple”, to enable 
significant discriminative analysis of interaction effects. For that reason, most of the 
studies use model membranes composed of only one lipid or binary lipid mixtures. 
 
2.2. Biophysical techniques to study AMP activity 
2.2.1. Circular Dichroism 
Circular Dichroism (CD) is a spectroscopic technique used to study the orientation and 
secondary structure of a peptide when in contact with membranes. Structures such as α-
helix, β-sheet, β-turn, random and others, have positive and/ or negative peaks giving rise 
to unique profiles enabling their identification and discrimination (Brahms and Brahms 
24 
1980). As mentioned before (chapter 1.1), AMP in solution are usually characterized by a 
random coil structure, but upon contact with lipid membranes they tend to adopt a defined 
secondary structure. These conformational changes depend not only on the nature of the 
peptide, but also on the membranous environment, affecting parameters such as 
attachment and insertion in the membrane and, therefore, AMP activity (Abrunhosa et al. 
2005, Adao et al. 2011). 
 
2.2.2. Differential Scanning Calorimetry 
As mentioned before, lipids adopt different phases according to their characteristics and 
the environment where they are inserted. Changes in temperature (among other factors) 
can lead to a temperature-induced transition between these phases, referred as 
thermotropic mesomorphism (Seddon and Templer 1995). Differential Scanning 
Calorimetry (DSC) is a non-destroying technique that allows the determination of the heat 
involved in a thermotropic transition in solids, liquids and suspensions as well as the 
temperature at which transitions occur (Cooper et al. 2001). In a DSC experiment, the 
sample is heated at a constant rate, and as the sample undergoes temperature-induced 
phase transitions, it will release or absorb heat, which is measured throughout the 
experiment and recorded as a function of temperature. DSC studies allow the 
determination of the transition temperature (Tm), the transition enthalpy (ΔH) and 
cooperativity of a certain thermotropic phase transition (Cooper et al. 2001). DSC allows 
the study of the effects of peptides on liposomes by comparing the calorimetric profiles 
obtained for the pure lipid system with those of the peptide/lipid mixtures at various 
peptide-to-lipid molar ratios (P:L), and thus the evaluation of the influence of the peptide 
on the thermotropic transitions (e.g. the gel to liquid-crystalline transition) of different 
membranes (Lohner and Prenner 1999, Haney et al. 2010). This technique is a good 
screening tool to obtain information about the peptide’s activity and specificity (Lohner and 
Prenner 1999, Abrunhosa et al. 2005, Bolscher et al. 2009a, Teixeira et al. 2010, Adao et 
al. 2011) before going into experiments with cells.  
 
2.2.3. Isothermal Titration Calorimetry 
Isothermal Titration Calorimetry (ITC) measures the heat resulting from the interaction of 
two biomolecules (titrant and titrated) at a given temperature, allowing the determination 
of the thermodynamic parameters that characterize the interaction (O'Brien et al. 2001). 
The titration of a ligand (e.g. antimicrobial peptide) to a macromolecular assembly (e.g. 
lipid membrane) results in a heat change (heat will either be absorbed or released) that 
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will be monitored throughout the experiment, enabling the quantitative characterization of 
the energetics of the interaction. Depending on the type and the conditions of the 
experiment, thermodynamic parameters such as equilibrium constant (K), interaction 
stoichiometry (N) and enthalpy (ΔH) can be retrieved. From those, the remaining 
thermodynamic parameters, Gibbs energy (ΔG) and entropy (ΔS) can be easily calculated, 
providing a complete thermodynamic characterization of the interaction at one 
temperature (O'Brien et al. 2001). When experiments are performed at different 
temperatures, the change in heat capacity (ΔCp) can be calculated and is a fundamental 
parameter when the hydrophobic effect is involved (O'Brien et al. 2001). The overall 
analysis of the ITC profile, the thermodynamic parameters and the physical-chemical 
properties of the compounds allow the understanding of the characteristics of the 
interaction process. Since all chemical reactions involve changes in enthalpy, this 
information is very important in many applications, such as pharmaceutical development 
of new drugs, vehicles for drug delivery, food industry, surfactant/polymers applications, 
among others. 
To analyse ITC data, a model for the interaction is always needed. In the case of 
macromolecule/ligand interaction (e.g. protein-protein interaction), a ligand-binding 
model is appropriate, with a defined stoichiometry. The analysis will then provide the 
association constant (Ka) the enthalpy change (ΔH) and the stoichiometry (N) (O'Brien et 
al. 2001). When membranes are involved, the most appropriate model is the partition 
model, as long as the membrane is not destroyed upon partition. In the case of partition, 
the ligand is distributed between the aqueous and the membrane phase, in a 
concentration ratio that depends on its affinity for the two phases. We can thus obtain the 
partition constant (Kp) and the enthalpy (ΔH) of the process (Wieprecht et al. 1999, Seelig 
2004). If the ligand and/or the membrane are charged, the obtained partition constant is 
an apparent one, and the electrostatic effect have to be dealt with to obtain the intrinsic 
partition constant (Heiko 2004).  
Although other methods (e.g. fluorescence spectroscopy, zeta potential, Electron 
paramagnetic resonance – EPR) can provide the partition constant, the advantage of ITC 
is that it can measure directly the interaction enthalpy, and provide complete 
thermodynamic information from one ITC run (Seelig 1997).  
In the case of AMP and membrane interaction, the information provided by ITC 
characterizes the AMP affinity for different membranes (Kp value) (Abraham et al. 2005) 
as well as its energetics – association, helix formation, the importance of charge effects, 
among others (Seelig 2004). In many cases, information on the mechanism of action can 
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also be derived from proper interpretation of ITC results (Wieprecht et al. 2000, Abraham 
et al. 2005, Bastos et al. 2008).  
 
2.2.4. X-ray Diffraction 
X-ray diffraction is a powerful tool to characterize the structure of lipid mesophases and 
polymorphic changes in the lipid bilayer. Lipid dispersions in water form structures with 
long-range periodic order that can be analysed by X-ray techniques, in particular by 
diffraction methods, as these periodic structures will diffract the X-rays in a particular 
pattern depending on the existent phase and the respective space group. If an ordered 
mesophase is present (e.g. lamellar, hexagonal and cubic phases), sharp Bragg peaks 
will appear in the low-angle region of the diffraction pattern. These Bragg reflections have 
reciprocal spacing in characteristic ratios for each phase allowing their identification 
(Seddon and Templer 1995). Typically, depending on the lipid and temperature, 
liposomes form lamellar or hexagonal phases. However, the presence of an antimicrobial 
peptide can induce structural changes, by altering the lattice parameter, changing the 
transition temperature and or leading to the disappearance or appearance of phases. 
Understanding the type of polymorphic structure that is present in a peptide-lipid mixture 
can lead to a deeper knowledge of the mechanism of action of the peptide (Hickel et al. 
2008, Haney et al. 2010, Bastos et al. 2011, Pabst et al. 2012). 
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CHAPTER 3. Mycobacterium 
Tuberculosis (TB) remains one of the leading causes of human death worldwide (Nathan 
2014, WHO 2015b). Although the mortality associated with TB has decreased, in 2014 
WHO reported that 1.5 million people died from this infection (WHO 2015b). The 
incidence of multidrug and extensively drug-resistant TB (MDR-TB and XDR-TB) has 
been increasing worldwide, with more than 100 countries reporting cases of XDR-TB 
(Falzon et al. 2015, WHO 2015b).  
The genus Mycobacterium includes not only Mycobacterium tuberculosis but other 
pathogenic species such as M. leprae and M. ulcerans, as well as a multitude of non-
pathogenic species usually referred to as nontuberculous mycobacteria (NTM). More than 
150 species of NTM are known, being ubiquitous in the environment, present in water, 
soil, dust and plants (Tortoli 2006, Falkinham 2015). The consequences of mycobacterial 
infection depend on the virulence of the infecting Mycobacterium and the resistance of the 
host. In humans, the outcome can range from relatively mild and transient symptoms to a 
widely disseminated disease (Pieters 2001, Tortoli 2009). NTM can be the cause of 
several types of infections, such as pulmonary (one of the most common), cutis and soft 
tissue, bone and joint, and lymphonodal infections (Tortoli 2009). Disseminated disease 
occurs in immunocompromised patients, especially in HIV-infected patients, but also in 
patients with cancer, organ or stem cell transplant, with genetic immunodeficiencies, and 
patients undertaking therapies for immune-mediated inflammatory diseases (Tortoli 2009, 
Henkle and Winthrop 2015). The prevalence of NTM infections has been increasing 
worldwide, followed by a decrease in TB (Cassidy et al. 2009, Brode et al. 2014), and thus 
stressing the importance of these NTM and the infections caused by them. 
 
3.1. Mycobacterial cell wall 
Mycobacteria are irregular rods, aerobic, and unable to form spores (Prescott et al. 2002). 
Mycobacterium species are characterized by an extremely complex and highly 
impermeable cell wall, composed of three main components, the mycolic acids, a highly 
branched arabinogalactan (AG) polysaccharide and a cross-linked network of 
peptidoglycan, being called the mAGP complex (figure 7) (Jankute et al. 2015). The 
covalent linkage between these three layers results in a hydrophobic envelope of 
extremely low fluidity and high impermeability. Also intercalated between the mycolic 
acids, there is an outer layer containing various free lipids such as phenolic glycolipids 
and sulpholipids, among others. The outmost layer of the cell wall that some authors refer 
to as capsule, is mainly composed of polysaccharides and proteins (Abdallah et al. 2007, 
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Guenin-Mace et al. 2009, Jankute et al. 2015). This unique cell wall is critical for the 
capacity of mycobacterial pathogens to survive inside the host and to resist chemotherapy 
(Guenin-Mace et al. 2009). The presence of mycolic acids and other lipids outside the 
peptidoglycan layer also makes mycobacteria acid-fast. This means these bacteria are not 
stained by the Gram method but retain the primary stain fuchsin, when subject to the 
Ziehl-Neelsen method (Prescott et al. 2002). 
 
 
Figure 7 – Mycobacterial cell wall. Schematic representation of one of the current views of the 
mycobacterial cell wall (adapted from: (Abdallah et al. 2007)). 
 
Mycobacterium plasma membrane, which is protected by the cell wall, is an asymmetric 
bilayer essentially composed of lipids and proteins, as any biological membrane. The 
phospholipid composition is very similar to all the other bacterial membranes containing 
essentially phosphatidylethanolamine, phosphatidylglycerol, diphosphatidylglycerol, and 
phosphatidylinositol mannosides, these last three conferring the membranes an overall 
negative charge (Guenin-Mace et al. 2009).  
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3.2. Mycobacterium avium 
Mycobacterium avium complex (MAC), compromising M. avium and M. intracellulare, is 
the most common cause of NTM infections in immunocompromised hosts. Disseminated 
MAC was one of the first opportunistic infections detected in AIDS patients remaining until 
today a substantial cause of morbidity and mortality among these patients (Tortoli 2009). 
Infection of AIDS patients by M. avium occurs in advanced stages of the disease when the 
levels of CD4+ T cells are very low. M. avium can also infect patients with other 
debilitating diseases, especially restrictive and obstructive pulmonary diseases, that 
compromise the immune system, such as chronic obstructive pulmonary disease, 
emphysema, chronic bronchitis and children with lymphadenitis (Appelberg 2006b).  
M. avium, similar to other mycobacteria, is a facultative intracellular pathogen residing 
mainly inside macrophages. The outcome of M. avium infections, along with other 
mycobacteria, directly depends on the virulence of the infecting mycobacteria and the 
resistance of the host. After being phagocytized by macrophages, the mycobacteria reside 
inside the phagosomes of the host cells inhibiting the phagosome-lysosome fusion, and, 
therefore, the formation of the phagolysosome (Appelberg 2006b, de Chastellier 2009). 
The phagolysosome, designed to protect the host against invading pathogens, is 
characterized by an acidic environment containing proteolytic enzymes that degrade the 
content of the vacuole (Pieters 2001). By inhibiting the phagosome-lysosome fusion, 
mycobacteria escape from harmful environments (e.g. acidic pH), but at the same time 
maintain the interaction with endosomes, allowing the access to nutrients, and ensuring 
their survival and proliferation inside the host (Appelberg 2006b, Appelberg 2006a). 
The mechanism by which macrophages can inhibit the mycobacterial growth and the 
mechanisms used by mycobacteria to resist and live inside macrophages are only partially 
understood. M. avium can grow exponentially inside non-activated macrophages, this 
growth being more restrictive if the macrophages are activated with cytokines such as 
IFN-γ and TNF-alpha (Appelberg and Orme 1993, Appelberg et al. 1994, Appelberg 
2006c). This activation can unblock the maturation of the phagosome which can culminate 
in the inhibition of the mycobacterial growth (Schaible et al. 1998, Via et al. 1998). 
Nutriprive mechanisms, restricting the access to nutrients, such as iron, may contribute to 
the elimination of the pathogen (Gomes et al. 1999b, Gomes and Appelberg 2002, Pais 
and Appelberg 2004, Appelberg 2006a, Appelberg 2006c, Silva-Gomes et al. 2013). This 
restriction of nutrients can come in many ways, including alterations in vesicular trafficking 
and phagosome-lysosome fusion (Pais and Appelberg 2004, Appelberg 2006a, Appelberg 
2006c). The impact of phagosome maturation on M. avium viability is, however, not clear. 
For instance, co-infection of macrophages with M. avium and Coxiella burnetii resulted in 
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phagosome-lysosome fusion and, therefore, a decrease in the pH of the bacteria-
containing organelle, which did not decrease the viability of M. avium, contrary to what 
occurred with M. tuberculosis (Gomes et al. 1999c). In other report, the induction of 
phagosome maturation by fatty acids inhibited the growth of both M. tuberculosis and M. 
avium (Anes et al. 2003).  
Killing of M. avium by macrophages is independent of the respiratory burst or the 
production of nitric oxide (NO) (Gomes et al. 1999b, Gomes and Appelberg 2002, 
Appelberg 2006c), as opposed to M. tuberculosis and other pathogenic mycobacteria 
(Chan et al. 1995, MacMicking et al. 1997, Cooper et al. 2000). 
Apoptosis has been described as a way to eliminate the pathogen by sacrificing the host 
cell (Gao and Kwaik 2000). Macrophages may undergo apoptosis after infection with M. 
avium (Gan et al. 1995, Fratazzi et al. 1997) which does not impact the viability of the 
mycobacteria, instead they use it as a way to spread the infection (Early et al. 2011). 
Autophagy is another catabolic process used by the cell as a mechanism of internal 
quality control, removing proteins, cytosolic components or damaged organelles, and it 
has emerged as a host antimicrobial defence mechanism capable of degrading 
intracellular pathogens (Deretic and Levine 2009). Autophagy induction via vitamin D3 
inhibits M. tuberculosis growth (Gutierrez et al. 2004, Yuk et al. 2009, Selvaraj et al. 
2015). In the case of M. avium, there are a few evidences of diminished ability to survive 
in autophagic vacuoles (de Chastellier and Thilo 2006, Early et al. 2011). 
Understanding the mechanism by which the mycobacteria circumvent the host immune 
response, and the antimicrobial mechanisms of the macrophage responsible for 
controlling the microbial growth can open the way for the identification of novel targets and 
the development of new antimycobacterial drugs. 
 
3.3. Treatment 
Infections by mycobacteria are difficult to treat. Currently, the available treatments are 
poorly active, costly, toxic and require long periods of time that most often are not 
correctly followed by the patients, ultimately leading to increased levels of resistance. The 
primary treatment of all pathogenic mycobacteria consists of a combination of different 
antibiotics taken for several months. In the case of tuberculosis, the treatment varies 
according to the susceptibility of the isolated strain to the available drugs. The standard 
recommendations consist on a four antibiotic regime with isoniazid, rifampicin, 
pyrazinamide and ethambutol taken for 6 months. In the case of more resistant strains, 
fluoroquinolone or second-line injectable drugs, such as amikacin, kanamycin and 
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capreomycin are administrated (Koul et al. 2011). All these drugs are ineffective against 
extensively-drug resistant TB (XDR-TB), which has been increasing worldwide with 
reports in more than 100 countries (WHO 2015b).  
In the case of NTM, the treatments were not designed for these infections but instead 
have been extrapolated from the TB experience. Macrolides, such as clarithromycin and 
azithromycin, are central for the treatment of NTM infections, together with other 
antimycobacterial drugs such as ethambutol, rifampin or rifabutin, taken for months to 
several years (Egelund et al. 2015, Philley and Griffith 2015). In the case of disseminated 
MAC, the administration of effective antiretroviral therapy in immunocompromised patients 
reduces the number of people at risk of developing the disease by elevating the number of 
CD4+ T cells (Horsburgh et al. 2001, Henkle and Winthrop 2015). 
To achieve a better global control of mycobacterial infections, new antimycobacterial 
drugs should be developed to achieve shorten treatment duration, reduced daily pill 
burden and dose frequency, treatment of multidrug-resistant strains, and also the 
possibility of co-administration with anti-HIV drugs (Koul et al. 2011). 
Intensive efforts have been made towards the discovery and application of alternative 
therapies, using for instance adjunctive immunomodulators such as picolinic acid (Pais 
and Appelberg 2000, Pais and Appelberg 2004, Cai et al. 2006), or iron chelators 
(Fernandes et al. 2010, Moniz et al. 2013, Moniz et al. 2015). These last compounds are 
of great interest as M. avium growth inside macrophages is directly proportional to the 
amount of iron available. Furthermore, AIDS patients have increased iron deposition in 
different tissues, favouring the growth of M. avium. The use of iron chelators, depriving the 
mycobacteria of an essential nutrient for their survival, is thus a promising road for the 
treatment of this disease (Gomes et al. 1999a, Gomes et al. 2001, Fernandes et al. 2010, 
Moniz et al. 2013, Moniz et al. 2015). 
 
3.4. Mycobacteria as a target of AMP 
Antimicrobial peptides have been described as displaying antimycobacterial activity, both 
through direct killing or immunomodulation (Shin and Jo 2011, Teng et al. 2015).  
Cathelicidin peptide, LL-37, can kill M. tuberculosis both in vitro and in vivo, and its 
expression is increased in macrophages during mycobacterial infection (Rivas-Santiago et 
al. 2008, Sonawane et al. 2011, Rivas-Santiago et al. 2013, Santos et al. 2014). Also, it 
has been described that LL-37 can play a role in the induction and maturation of 
autophagy, activated by vitamin D3 in human monocytes, inhibiting the intracellular 
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mycobacterial growth (Liu et al. 2007, Yuk et al. 2009). Other effects of LL-37 have been 
pointed out, such as chemoattraction, regulation of apoptosis, induction of cytokines, 
among others, that altogether contribute to a better mycobacterial clearance (Shin and Jo 
2011, Santos et al. 2014). 
Defensins, such as human neutrophil peptide (HNP) and human β-defensin 2 (HBD-2), 
have also shown activity against M. tuberculosis and M. avium, in vitro and in vivo (Ogata 
et al. 1992, Sharma et al. 2000, Kisich et al. 2001, Sharma et al. 2001, Mendez-Samperio 
2008, Rivas-Santiago et al. 2011). The combination of defensins with anti-tuberculosis 
drugs, like isoniazid and rifampicin, resulted in a significant reduction of intracellular 
mycobacteria, allowing the reduction of the drugs dosage and the duration of treatment 
(Kalita et al. 2004). Similar to cathelicidins, defensins are also involved in the innate 
immune defence against mycobacteria, including the regulation of inflammation, activation 
of NFκB and chemotactic effects (Shin and Jo 2011). 
Hepcidin, besides playing an important role in iron metabolism (Ganz 2006), has been 
shown to have its expression increased in macrophages infected with mycobacteria, and 
to have a direct antimycobacterial activity against M. tuberculosis (Sow et al. 2007). 
Several synthetic peptides have displayed antimycobacterial activity in vitro and also 
synergism with conventional drugs (Jena et al. 2011, Jiang et al. 2011, Ramon-Garcia et 
al. 2013, Khara et al. 2014). 
The increasing number of reports describing the antimycobacterial activity of different 
AMP highlights the potential of these peptides to be used as new drugs for fighting 
mycobacterial infections. 
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CHAPTER 4. Objectives of this thesis 
Antimicrobial peptides comprise a vast array of compounds, which are promising potential 
alternatives to treat infectious diseases. With increasing levels of resistance and therefore, 
failure of the existing drugs, there is a demand for new and more effective antimicrobial 
compounds. Antimicrobial peptides are part of the innate immune defence mechanisms of 
almost all living organisms and they can act in multiple ways against pathogens avoiding 
resistance more easily than conventional drugs. The general goals of this work were to 
assess the activity of several peptides against Mycobacterium avium and to investigate 
the mechanisms of action of different peptides using lipid model membranes. 
In order to achieve these general goals, several tasks were performed, with more focused 
objectives, which are detailed below: 
 To characterize the interaction of a cecropin A-melittin hybrid peptide (CA(1-7)M(2-9)) 
with lipid model membranes using Circular Dichroism, Differential Scanning 
Calorimetry, Isothermal Titration Calorimetry, X-ray diffraction and microscopy 
techniques (chapter 5).  
 To characterize the interaction of three peptides derived from lactoferrin (lactoferricin 
(LFcin17-30), lactoferrampin (LFampin265-284) and LFchimera) with model 
membranes by Circular Dichroism, Differential Scanning Calorimetry and X-ray 
diffraction. To correlate the observed effects with the previously reported structural 
changes of Candida albicans upon treatment with these peptides (chapter 6). 
 To evaluate the activity of lactoferricin (LFcin17-30), against Mycobacterium avium 
growing in broth culture. To identify the most relevant structural characteristics of the 
peptide for antimicrobial activity, using variants obtained by specific amino acid 
substitutions. To investigate the mechanism of action of these peptides, using scanning 
and transmission electron microscopy (chapter 7). 
 To evaluate the effect of lactoferricin (LFcin17-30) peptide and its variants against 
Mycobacterium avium growing inside macrophages, its natural host cells. To elucidate 
the mechanisms by which the peptides impact on the intramacrophagic growth of M. 
avium. To investigate the possibility of a synergistic effect of the peptides with 
conventional antibiotics (chapter 8). 
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Abstract 
The interaction of a cecropin A-melittin hybrid antimicrobial peptide, CA(1-7)M(2-9), with 
known antimicrobial action, was studied with bacterial model membranes of POPE/POPG 
3:1 to contribute to an understanding of its mechanism of action. Several biophysical 
techniques were used to assess the structural and thermodynamics of the interaction. 
CA(1-7)M(2-9) disrupts the vesicles inducing membrane condensation, forming an onion-
like structure of multilamellar held together by the intercalated peptides. DSC also 
indicated that the peptide induces extensive aggregation and stabilizes the gel lamellar 
phase suggesting a strong interaction with the membrane at the lipid heads level. Finally, 
ITC has shown that the energetics of the peptide/lipid interaction depend strongly on 
temperature, being endothermic in the gel lamellar phase and exothermic in the liquid 
crystalline phase. Further, the association ratio indicates that CA(1-7)M(2-9) only interacts 
with the outer leaflet, supporting the idea of a surface interaction with the membrane that 
leads to membrane condensation and not pore formation. Our results also indicate the 
existence of threshold value after which the behaviour changes. We thus propose that this 
peptide exerts its antimicrobial action through a carpet model where after a threshold 
concentration (related to membrane neutralization) there is membrane disruption and 
disintegration. 
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Introduction 
Antimicrobial resistance is increasing rapidly, being one of the world’s major health 
problem. Unfortunately, this is not being accompanied by the discovery of truly new drugs, 
but only 2nd and 3rd generation antibiotics (Fischbach and Walsh 2009, Bassetti et al. 
2013). Nevertheless, intensive research exists aiming at the development of alternatives 
to the existing drugs. Among others, antimicrobial peptides (AMP) have being extensively 
studied, as a new antibiotic paradigm. These diverse group of compounds are widespread 
in nature being part of the innate immune system of almost all living organisms (Yeung et 
al. 2011). They are active against several pathogens, such as virus, protozoa, bacteria 
and fungi, acting primarily on the pathogen’s membrane, but possibly having also 
intracellular targets (e.g. proteins, nucleic acids) and/or through immunomodulation 
(Nguyen et al. 2011, Mansour et al. 2014). This capacity of attacking in different fronts 
enables them to evade resistance more easily than conventional drugs (Nguyen et al. 
2011). Several strategies have been employed to optimize the antimicrobial properties of 
these compounds with the main goal of decreasing their cytotoxicity towards host cells 
while maintaining or increasing their activity against pathogens. Further, attain a high 
selectivity index with AMP with the smallest possible number of amino acids (Haney and 
Hancock 2013).  
One strategy that has been successfully used is hybridization, where parts of different 
peptides are combined into one molecule in order to optimize their individual 
characteristics (Brogden and Brogden 2011). Cecropin A-melittin hybrid peptides are one 
of the best examples of successful hybridization in the AMP field, and were first 
synthesized by Boman, et al. in 1989 (Boman et al. 1989). They are composed of the 
cationic region of cecropin A and the hydrophobic and non-haemolytic region of melittin. 
These hybrids have better antimicrobial properties than the parental compounds, with an 
improvement in the activity of cecropin A towards pathogens, together with a significant 
decrease in the haemolytic properties of melittin (Boman et al. 1989, Wade et al. 1990, 
Andreu et al. 1992). Their activity has been extensively studied, both on model 
membranes and pathogens, and their mechanism of action is thought to rely on 
membrane disruption due to the formation of toroidal pores and/or detergent-like action 
(Andreu et al. 1992, Diaz-Achirica et al. 1994, Juvvadi et al. 1996, Diaz-Achirica et al. 
1998, Abrunhosa et al. 2005, Sato and Feix 2006, Pistolesi et al. 2007, Bastos et al. 2008, 
Ferre et al. 2009, Milani et al. 2009, Teixeira et al. 2010). 
We have previously studied the interaction of CA(1-7)M(2-9) (or CAM), with model 
membranes of different compositions (Abrunhosa et al. 2005, Bastos et al. 2008, Teixeira 
et al. 2010). Following these works, we have now characterized the interaction of CAM 
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with model membranes of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine and 1-
palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1’-rac-glycerol) (POPE/POPG 3:1) using a 
variety of biophysical methods, in an attempt to ascertain its mechanism of action. The 
effect of the peptide was assessed by Small Angle X-ray Diffraction (SAXD), Differential 
Scanning Calorimetry (DSC), Isothermal Titration Calorimetry (ITC), Circular Dichroism 
(CD) and microscopy techniques.  
Our results show that CAM interacts strongly with this negatively charged model 
membrane system, mainly through electrostatic interactions. We suggest that the peptide 
binds to the membrane until a threshold peptide/lipid ratio, after which it disrupts the 
vesicles inducing membrane condensation into a multilamellar system with the peptide 
intercalated within the lamellae, in an onion-like structure.  
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Material and Methods 
Peptides 
CA(1–7)M(2–9) or CAM (KWKLFKKIGAVLKVL-NH2) was synthesized, purified, and 
characterized as described recently (Fernandez-Reyes et al. 2010). Peptide stock 
solutions were prepared in Phosphate Buffered Saline (PBS, 9.3 mM, 150 mM NaCl, pH 
7.4) or HEPES buffer (HEPES 10 mM, 150 mM NaCl, pH=7.0) and stored at -20ºC until 
use. 
 
Preparation of Liposomes 
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE) and 1-palmitoyl-2-oleoyl-
sn-glycero-3-phospho-(1'-rac-glycerol) (POPG) (Avanti Polar Lipids, Alabama, USA) in a 
proportion 3:1, were dissolved in chloroform/methanol (3:1) and transferred to a round 
bottom flask, where a film was obtained by drying the solvent under a slow nitrogen 
stream. The film was thereafter kept under vacuum overnight to remove all traces of 
organic solvents. After drying, the lipid film was first warmed for 30 minutes at ca. 10 °C 
above the temperature of the gel-to-liquid crystalline phase transition (Tm) in a 
thermostated water bath, and afterwards hydrated with buffer, either HEPES (10 mM 
HEPES, 150 mM NaCl, pH 7.4) or PBS (9.3 mM, 150 mM NaCl, pH 7.4), kept at the same 
temperature. The oligolamellar vesicles (OLVs) were obtained by alternating gentle vortex 
with short periods in the thermostated water bath at ~35 °C. After this the OLVs were 
frozen in liquid nitrogen and thawed in the water bath at 35 °C, process being repeated 5 
times.  
Large unilamellar vesicles (LUVs) were obtained from the OLVs by extrusion in a 10 mL 
stainless steel extruder (Lipex Biomembranes, Vancouver, BC, Canada), inserted in a 
thermostated cell with a re-circulating water bath, at 35 °C. The samples were passed 
several times through polycarbonate filters (Nucleopore, Pleasanton, CA, USA) of 
decreasing pore size (600, 200 and 100 nm; 5, 10 and 10 times, respectively), under inert 
(N2) atmosphere. The diameter of the vesicles were determined by Dynamic Light 
Scattering and found to be 101  8 nm. 
After preparation the lipid samples were kept overnight in the refrigerator at 4 °C before 
being used. The phospholipid concentration was determined by the phosphomolibdate 
method (McClare 1971). 
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Small Angle X-ray Diffraction 
Peptide solution in the same buffer used for preparing the liposomes was added to 
POPE/POPG 3:1 OLVs at different peptide-to-lipid (P:L) molar ratios, and the mixtures 
were incubated for 30 min at 35 °C. The samples were then centrifuged at 13 000 rpm in a 
microcentrifuge at least for 15 min, and transferred into glass capillaries (Spezialglas 
Markröhrchen 1.5 mm capillaries, Glass Technik & Konstruktion – Müller & Müller OHG, 
Germany). In the transfer, care was taken to always have a significant amount of 
supernatant in the capillaries, to guarantee that all samples were studied at high water 
contents. The capillaries were sealed by flame, and stored at 4 °C, at least 3 days before 
use. 
Small Angle X-ray diffraction (SAXD) experiments were performed at the synchrotron soft 
condensed matter beamline A2 in HASYLAB at Deutsches Elektronen Synchrotron 
(DESY), Hamburg, Germany, using a monochromatic radiation of λ=0.15 nm wavelength. 
Diffractograms were taken at selected temperatures, where the sample was equilibrated 
for 5 min before exposure to radiation, or by performing up and down temperature scans 
at a scan rate 1 °C/min, where diffractograms were recorded for 10 s every minute. The 
heating and cooling of the sample was regulated by a thermocouple connected to the 
temperature controller JUMO IMAGO 500 (JUMO GmbH & Co. KG, Fulda, Germany). The 
evacuated double-focusing camera was equipped with a linear position sensitive detector 
for WAXD and a 2D MarCCD detector or a linear position sensitive detector for SAXD. 
The raw data were normalized against the incident beam intensity. The SAXD patterns 
were calibrated using Ag behenate (Huang et al. 1993) or rat tail collagen (Roveri et al. 
1980). Each Bragg diffraction peak was fitted by Lorentzians above a linear background 
by use of the Origin software program, to determine the position of maxima. The lamellar 
repeat distance (d) was determined as the inverse of the slope obtained from plotting sn 
(Å-1) vs. n (n = 1, 2 …, order of the diffraction peak), with the straight line passing through 
the origin (0,0). The uncertainty assigned to the parameter is the standard error of the 
slope, as obtained from the regression. 
The domain size (L) can be estimated by fitting the shape of the lamellar Bragg peaks with 
the Caillé structure factor for stacks of membranes including finite size effects (Safinya et 
al. 1986, Silva et al. 2014). We find that a suitable approximation for L can also be 
obtained by fitting the Bragg peaks with a Lorentzian function, where L ≈ 1/FWHM (note 
that the lamellar peak’s full width at half maximum (FWHM) is defined in terms of 
momentum transfer s=2sin(θ)/λ, where s=q/2π). This method provides a good estimation 
of the domain size for broad peaks, but when the peaks become very narrow, the 
resolution of the instrument (which is not accounted here) will originate a systematic error, 
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with the calculated L being shifted to lower values. This systematic error does not affect 
our analysis, since we are interested in looking at the observed trends as a function of 
peptide content in the sample, not in obtaining accurate values. Once L is determined, the 
number of layers (nL) per complexed particle can be easily obtained through the 
expression nL = L/d where d is the lamellar repeat distance.  
 
Differential Scanning Calorimetry 
Differential scanning calorimetry (DSC) was performed in a MicroCal VP-DSC 
microcalorimeter from Malvern (Worcestershire, UK). Blank experiments with HEPES 
buffer in both cells were performed overnight prior to sample loading, for subsequent 
blank correction. Samples were run against HEPES buffer in the reference cell, 
performing several successive heating and cooling scans for each sample, at a scanning 
rate of 60 °C/hour, over the temperature range 10 – 35 °C (OLVs) and 4– 35 °C (LUVs). 
The results provided here refer to the third heating scan, as we have observed that small 
differences always exit between the first and following scans, but in present case not after 
the third scan. The sample mixtures were prepared immediately before the DSC run, by 
adding the desired amount of peptide stock solution (in HEPES buffer) to the LUVs 
suspension. Samples with peptide-to-lipid molar ratios (P:L) from 1:50 to 1:10 were used. 
The solutions were previously degassed for 15 min. All procedures regarding sample 
preparation and handling (lag time at low temperature, time between mixtures, and start of 
the experiment) were kept constant in all experiments, to ensure that all samples had the 
same thermal history. In all cases, the reported DSC curves are only corrected for the 
respective blank experiment. In the case of pure liposome suspensions, Tm and the ΔtransH 
were calculated by integration of the heat capacity versus temperature curve (Cp versus T), 
using a linear baseline to calculate the integral areas under the curves. In the case of 
peptide/lipid mixtures we only provide values for Tm (temperature of maximum Cp in Cp vs. 
T curves), as the shape of the curve shows that no correct ΔtransH assignment can be 
made (see results).  
 
Isothermal Titration Calorimetry 
Isothermal Titration Calorimetry (ITC) measurements were performed in a MicroCal VP-
ITC microcalorimeter from Malvern (Worcestershire, UK). Lipid-into-peptide titrations were 
performed by injecting 3-4 μL aliquots of POPE/POPG 3:1 LUVs (15 or 30 mM) into the 
calorimeter cell (V cell = 1.4323 mL) containing the peptide at concentrations between 10 
and 25 µM. Titrations were performed at 5, 17 and 30 °C, injection speed 0.5 µLs-1, 
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stirring speed 459 rpm, and reference power 15 µcals-1. For the experiments at 5 °C the 
room temperature was thermostated at ~15 °C, to guarantee that the lipid was in the gel 
phase throughout. The time between injections varied according to the used temperature. 
At 5 °C, very long times were needed to allow proper return to the baseline. A first 
injection of 1 µL was always performed to account for diffusion from/into the syringe tip 
during the equilibration period. Samples were run against HEPES buffer in the reference 
cell. All solutions were previously degassed for 15 min prior to calorimeter loading. 
Titration experiments where aliquots of peptide solution of concentration 250 µM were 
titrated into liposome suspension contained in the cell (concentration 30 mM) were also 
performed, in an attempt to see whether a constant enthalpy was obtained for the 
peptide/liposome interaction, at extremely low P:L ratios.  
Dilution experiments of LUVs suspensions into buffer, under the same experimental 
conditions were performed, to assess dilution effects, and compared with the values 
observed for the final peaks of each lipid into peptide titration run. Similar values were 
found, and thus the data treatment software used dealt with the dilution effects during data 
treatment. 
ITC data analysis for the experiments in the fluid phase (30 °C) was made by use of two 
approaches. First, the raw data was imported to the NITPIC software (Keller et al. 2012) 
where the curves were treated and the peak areas calculated. Thereafter the obtained 
datasets were analyzed in terms of a surface partition model taking into account 
Coulombic interactions between free peptide molecules in the aqueous phase and the 
membrane, according to Gouy-Chapman theory (Vargas et al. 2013). For this, nonlinear 
least-squares fitting was performed in a Microsoft EXCEL spreadsheet (Microsoft, 
Redmond,WA) kindly provided by Sandro Keller (Vargas et al. 2013) using the PREMIUM 
SOLVER PLATFORM add-in (Frontline Systems, Incline Village, NV). Alternatively, the 
raw data was imported to the AFFINImeter software and analysed there using an 
independent sites model (https://www.affinimeter.com/). 
 
Circular Dichroism 
Circular Dichroism (CD) experiments were carried out in a Jasco J-815 spectropolarimeter 
(JASCO Corporation, Tokyo) equipped with a rectangular cell, path length of 1 mm. Scans 
were performed between 190 – 250 nm, with a scan speed of 100 nm/min, DIT 1 second, 
data pitch 0.1 nm and bandwidth 1.0 nm. The measurements were performed in PBS (9.3 
mM, 150 mM NaF, pH 7.4). Spectra of pure liposome preparations (LUVs) were 
performed at the concentrations used in liposome/peptide mixtures, as blank experiments 
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to be subtracted from the liposome/peptide spectra. The peptide solution and liposome 
suspension (LUVs) were mixed just prior to each measurement, incubated at 35 °C for 30 
min and measurements were performed thereafter at the same temperature. Each 
spectrum was the average of twelve accumulations. After blank correction, the observed 
ellipticity was converted to a mean residue molar ellipticity (θ) (degcm2 dmol1), based on 
the total amount of peptide in the mixture, considering all amino acids. 
 
Confocal Microscopy 
OLVs of POPE/POPG 3:1 were prepared as stated above with the addition of 0.3% Texas 
Red®-1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine (Texas Red®-DHPE) 
(Molecular Probes). Mixtures of peptide solution and liposome suspension (OLVs) were 
prepared at different peptide-to-lipid (P:L) molar ratios, and were incubated for 30 min at 
35 °C. A 15 μL drop of each sample, including the liposomes suspension without peptide, 
were placed in microscope slides and observed and photographed in a Laser Scanning 
Confocal Microscope Leica SP2 AOBS SE (Leica Microsystems, Germany). 
 
Electron Microscopy 
Negative staining electron microscopy was performed in samples of LUVs of 
POPE/POPG 3:1 and in mixtures of CAM with POPE/POPG 3:1 at different peptide-to-
lipid (P:L) ratios and temperatures. Briefly, a 5 μL drop of each sample was placed on 
copper grids and allowed to stand for some minutes and thereafter the excess liquid was 
dried off with filter paper. Then a 5 μL drop of uranil acetate was added and incubated for 
few seconds, after which the excess was again removed with filter paper. For images of 
the gel phase, all these procedures were made at 4 °C to insure that the samples were in 
the gel phase before fixation. The samples were after observed and photographed in a 
Jeol JEM-1400 transmission electron microscope (TEM). 
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Results and Discussion 
Small Angle X-ray Diffraction 
Small Angle X-ray Diffraction (SAXD) experiments were performed to characterize the 
structure(s) present in liposome/peptide mixtures, and compare them with the ones shown 
by POPE/POPG 3:1 liposomes, to ascertain the changes in lipid structure induced by 
CAM.  
In figure 1, representative X-ray diffraction patterns of the OLVs and OLV-peptide systems 
are shown for two temperatures, 10 (figure 1A) and 30 °C (figure 1B), corresponding to 
the gel (Lβ) and liquid crystalline (Lα) phases. The pure POPE/POPG 3:1 OLVs below the 
gel-to-liquid crystalline phase transition (Tm) shows a lamellar pattern with an average 
spacing of 118 Å (figure 1A). The shape of the peaks is broad, as expected for OLVs, and 
the first lamellar peak is less intense than the second due to the proximity of a minimum in 
the membrane form factor to the first peak (Pozo Navas et al. 2005). The correlations 
between the layers in the OLVs are lost above the Tm, in Lα phase, as the membranes 
become unbound, and the lamellar peaks are replaced by diffuse scattering from the 
membrane form factor and perhaps by very weak correlations between the membranes. 
This observation agrees with the findings previously reported by Pozo Navas et al. for this 
system at different POPE/POPG ratios (Pozo Navas et al. 2005). 
When the OLV dispersions are mixed with the CAM peptide, a fine white precipitate 
spontaneously forms, suggesting massive aggregation and condensation of the lipid 
bilayers induced by the peptide. The occurrence of this precipitate suggests the formation 
of large aggregates, as opposed to a scenario where the membranes would be dissolved 
to small structures like bicelles or micellar aggregates. The formation of such large 
membrane aggregates mediated by oppositely charged multivalent species (here, the 
peptide) is commonly observed for instance in the condensation of cationic liposomes by 
oppositely charged polyelectrolytes like DNA (Rädler et al. 1997, Koltover et al. 1998, 
Bouxsein et al. 2011) or even short-interference RNA (Bouxsein et al. 2007, Leal et al. 
2010). 
At 30 °C, above Tm, the mixed OLV-CAM systems in the Lα phase show a typical lamellar 
pattern (figure 1B) with a lamellar spacing ca. 50.6-53.8 Å that decreases with increase in 
peptide content. This spacing is much smaller than the average lamellar spacing observed 
for POPE/POPG 3:1 OLVs in the Lβ phase, below Tm (118 Å), and also significantly 
smaller than the pure POPE lamellar spacing of ca. 62 Å for the same temperature range. 
This suggests that the CAM peptides are being intercalated within the interlamellar 
spacing, condensing the lamellar bilayers in a mechanism much similar to that one found 
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for condensation of cationic liposome-DNA (CL-DNA) systems (Rädler et al. 1997, 
Koltover et al. 1998, Bouxsein et al. 2011) in which a lamellar phase with DNA chains 
sandwiched between lipid bilayers is observed. However, in contrast to the CL-DNAs, a 
peak resulting from in-plane correlations between the peptides is not observed here above 
the transition temperature. This might be due to the small size of the peptides and 
correlates well with the difficulty in observing correlations between short non-sticky DNA 
pieces of 10 base pairs sandwiched between cationic membranes (Bouxsein et al. 2011). 
The width of the lamellar peaks in the mixed systems is much narrower than in the pure 
OLVs (figure 1), indicating that the presence of the peptides in the membranes makes 
them more tightly bound. Further, it decreases continuously as the peptide content in the 
system increases (i.e. as P:L increases) (figure 1), indicating an increase in the number of 
lamellar layers, condensed by the action of the positively charged peptides. This ordering 
effect can be clearly seen in values obtained for the number of layers (nL) present (figure 2 
and table S1). For the pure lipid system nL is very small (~5 in Lβ and~1 in Lα, figure 2 and 
table S1), in agreement with the literature (Pozo Navas et al. 2005). In the presence of the 
peptide, the nL values increase as the peptide content increases, up to ~100 in both Lβ 
and Lα for P:L=1:7 (figure 2 and table S1). 
On cooling and reaching the Tm, new Bragg peaks appear for OLV-CAM system, still with 
an apparent lamellar pattern, but now the lowest Bragg peak (figure 1A, asterisk) indicates 
a spacing of ~110 Å, as if the structure suddenly doubled the lamellar spacing in the gel 
phase as compared to the liquid crystalline spacing (dLα ~52Å). Curiously, the diffraction 
patterns of the mixed OLV-CAM systems and the pure POPE/POPG OLVs in the Lβ phase 
are similar. The first Bragg peak (figure 1A, asterisk) is less intense than the second, and 
also the spacing from the first peak is similar in both systems (ca. 110 and 118 Å, 
respectively). It could be tempting to relate both behaviors, and claim that the lamellar 
phase found expands from ~52 to ~110 Å at temperatures below Tm. However, a deeper 
consideration of the physics at stake makes such a lamellar system with a spacing of 
~110 Å unlikely. Both systems (with and without the peptide) should have extremely 
different bilayer-bilayer interactions, especially as regarding electrostatic interactions, 
since the peptide should neutralize most of the anionic charge from POPG. It is unlikely 
for the peptide-neutralized bilayers to keep such a large interlamellar spacing, especially 
with a large domain size that extends to dozens of bilayers. Indeed one possibility would 
be that the peptides would be expelled from the bilayers below Tm, so that the big lamellar 
aggregates expand to the size found for the pure OLVs, but that scenario also seems 
unrealistic, especially because the behavior is fully reversible in up-down-up-down 
temperature cycles. This makes it difficult to conceive a picture where the peptides would 
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leave and return systematically to the bilayers, inducing a bilayer expansion-condensation 
cycle induced by the temperature. Hence, the similarities between the scattering patterns 
in the systems with and without peptide are probably just a coincidence.  
The hypothesis/model we find more realistic to justify the emergence of the new Bragg 
peaks below Tm (figure 1A, asterisk), is that of a scenario where on cooling, and by 
influence of the peptide, adjacent lipid membranes become distinct from each other 
(perhaps due to subtle changes in the lateral organization induced by the peptides). 
Therefore, the simple lamellar lattice (d) is replaced by a centered rectangular lattice, with 
the lattice parameter br (perpendicular to the lamellae) being now twice the lamellar repeat 
distance d, owing to the fact that adjacent bilayers are not completely similar (see model 
in figure 3). Therefore the values for the lamellar repeat distance are similar, being 
somewhat larger in the Lβ phase (d ~65 Å) than in the Lα phase (~52 Å), as expected due 
to the more rigid hydrocarbon chains in the Lβ phase. Despite adjacent bilayers not being 
completely similar, they still resemble each other to some extent, which would justify that 
the reflections with odd n value partially cancel by symmetry, leading to the observed 
smaller intensities of these peaks as compared to those with even n value. This is clearly 
seen in the first and second peaks in the Lβ phase. Another interesting fact, is the 
appearance of a small extra peak at ~0.1 Å-1 (sometimes a shoulder) close to the second 
Bragg peak, for the highest P:L ratios (1:10 and 1:7), and temperatures below Tm (figure 
1A, arrows). Temperature cycles up and down between 10 and 80 °C and in independent 
samples with new peptide-lipid batches show that this behavior is completely 
reproducible, with this peak always appearing below Tm, in the Lβ phase. Within the model 
described above, this peak could be related with the lattice parameter ar (in the plane of 
the lamellae, figure 3). 
This model seems physically more sound than implying the condensation-expansion of 
lamellae as the temperature is cycled below and above Tm, since it relies only on subtle 
changes in the bilayers, which change the lamellar 1D lattice into a 2D centered 
rectangular lattice. The subtle changes in the bilayers should be promoted by action of the 
peptide and stiffening of the alkyl chains below Tm. Such stiffening modulated by the 
peptides would be in perfect agreement with the reproducibility in the behavior as the 
temperature is cycled, since it only requires minor rearrangements in the lattice, without 
peptides having to be expelled from the lamellae. The ordering of the lamellae into a 
centered rectangular lattice could occur by a number of mechanisms, such as, for 
instance, induction of periodic grooves in the lamellae to better accommodate the peptide, 
as sketched in figure 3. 
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Differential Scanning Calorimetry 
The effect of CAM on the thermotropic lipid transition was evaluated on both POPE/POPG 
3:1 OLVs and LUVs, for varying P:L ratios. The peptide has a very strong effect on the 
lipid system, whether we use OLVs or LUVs (Figure 4 A and B, respectively). The lipid 
transition for the pure POPE/POPG 3:1 presents in both cases a profile that indicates non-
ideal mixing between the two lipids (non-symmetric transition with low cooperativity), 
which have widely different transition temperatures, 24.7 °C for POPE and -5.3 °C for 
POPG (Pozo Navas et al. 2005). Indeed the transition is more cooperative in the case of 
OLVs when comparing to LUVs, due to higher number of layers. We obtained a Tm of 21.2 
°C in the case of POPE/POPG 3:1 OLVs and 20.5 °C for LUVs (table 1). The OLVs value 
is in agreement with the values reported by Pozo Navas et al. (22.7 ºC for xPOPG=0.18 and 
20.6 ºC for xPOPG=0.30) (Pozo Navas et al. 2005), and the LUVs value is in very good 
agreement with the one reported by Teixeira et al., 20.4 °C (Teixeira et al. 2010). As 
regarding the transition enthalpy, we obtained ΔtransH of 21 kJmol-1 for OLVs and 24 
kJmol-1 for LUVs, in fair agreement with Pozo Navas et al. value for OLVs (24.2 kJmol-1 for 
xPOPG=0.18 and 25.5 kJmol-1 for xPOPG=0.30) (Pozo Navas et al. 2005) and in good 
agreement with Teixeira et al. value for LUVs, 22 kJmol-1 (Teixeira et al. 2010).  
When peptide is added to both OLVs and LUVs the Tm increases (table 1), indicating that 
the peptide stabilizes the gel phase, moving the transition to higher temperatures. 
Previously we have studied this system at lower P:L ratios (1:80), where the increase in 
Tm was already apparent (Teixeira et al. 2010), together with an increase in enthalpy (33.5 
kJmol-1), consistent with a stabilization of the Lβ phase. This type of stabilizing effect has 
been reported by Schwieger et al. for the binding of poly(L-lysine) to DPPG membranes 
(Schwieger and Blume 2007). The initial stabilizing effect at low peptide concentrations 
must be the result of a more structured and compact lipid chain packing due to the 
electrostatic interaction of the peptide with polar lipid head groups, before significant 
segregation takes place.  
Analysing now the curve’s profile, in the case of OLVs, for the lowest P:L ratio (1:25), we 
can see in figure 4A that the peak height decreases and there is a significant drop in the 
baseline after the transition. These facts suggest that precipitation is taking place at this 
P:L ratio. The shoulder on the right is maintained, although shifted to higher temperatures, 
as occurs also with the main transition peak. As more peptide is present (P:L of 1:15 and 
1:10) the transition shape changes significantly, becoming much less sharp. Further, very 
broad peaks appear on the low temperature side (~12 °C) (figure 4A) suggesting a 
progressive destabilization of the membrane organization. 
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In the case of LUVs (figure 4B) a drop in baseline after the transition is also observed for 
P:L ratios of 1:50 and 1:25, being even more significant than for OLVs. For the lowest P:L 
(1:50), the shape of the curve is significantly changed, showing higher cooperativity in the 
main peak and a higher temperature, together with a new peak appearing at 15.5 °C and 
a shoulder at 25.1 °C. We did observe a similar effect in the previous study, where at P:L 
of 1:40 two peaks still appeared (Teixeira et al. 2010). This indicates that at the lowest P:L 
ratios we have a peptide-mediated domain segregation. The first peak at low temperature 
can be assigned to a peptide-rich, POPG-enriched domain, and the second one, at a 
higher temperature, to a peptide-poor, POPE-enriched domain, consistent with the main 
transition temperatures of the pure lipids. As we increase the peptide content (P:L=1:25) 
the lower temperature peak becomes broader and moves to even lower temperatures 
(~12 °C), whereas the shoulder on the right of the main peak is maintained. At 1:15, the 
highest peptide-to-lipid ratio tested with LUVs, a dramatic effect similar to the one 
described above for the highest P:L ratios with OLVs was observed, in terms of curve 
shape and peaks position, and also found in the results previously reported (Teixeira et al. 
2010). Therefore, in both cases (OLVs and LUVs) there appears to be a threshold 
concentration, after which the system behaviour changes. The existence of a threshold 
concentration has been reported for this peptide with different lipid systems. Bastos et al. 
suggest the value of 1:25 for the interaction with DMPC/DMPG 3:1 membranes, based on 
ITC results (Bastos et al. 2008), the same value being suggested by Pistolesi et al. for 
POPE/POPG/CL (70:25:5) (Pistolesi et al. 2007). 
 
Circular Dichroism 
The secondary structure of CAM was examined by Circular Dichroism (CD) in PBS buffer 
(9.3 mM PBS + 150 mM NaF) and in the presence of POPE/POPG 3:1 (figure 5). 
Measurements at different peptide concentrations in buffer showed that the peptide 
structure is not affected by concentration (results not shown). For the peptide in the 
presence of the membrane, the results at different P:L ratios were similar. In buffer the 
peptide is predominantly random (minimum at 198 nm), whereas in the presence of 
POPE/POPG 3:1 a α-helix structure is adopted, with well-defined minima around 208 and 
222 nm (figure 5). The fraction of α-helix was calculated (Ladokhin and White 1999) to be 
0.33, i.e., only ~5 amino acids are involved in the helix.  
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Isothermal Titration Calorimetry 
The experiments at 30 °C (lipid in Lα phase) show a simple profile with an endothermic 
effect that drops to zero after a relatively small number of injections (Figures 6A and 7A). 
Even at the low peptide concentration used (10 or 15 µM) the steep binding isotherms 
reflect the large membrane affinity of the peptide, as found in similar systems (Scheidt et 
al. 2015). Attempts to use lower peptide concentration did not produce isotherms that 
could be analysed, due to the very small number of observed peaks.  
The results were fitted first to a partition model with correction for electrostatic effects 
according to Gouy-Chapman theory (Seelig 2004, Vargas et al. 2013, Scheidt et al. 2015). 
In this model, the non-Coulombic interactions of a charged peptide with a lipid membrane 
are described as a partition equilibrium of the peptide between the interfacial aqueous 
phase (i.e., the aqueous phase adjacent to the membrane surface), and the lipid bilayer 
phase. This analysis provides values of the intrinsic partition constant, Kp, the molar 
transfer enthalpy from the aqueous phase to the bilayer phase, ΔH, and the effective 
charge of the peptide, zeff, which determines the strength of Coulombic interactions 
between the peptide and the membrane.  
The results obtained from the fitting of independent experiments at 30 °C when the 
peptide concentration in the cell was 15 µM and the lipid concentration in the syringe 30 
mM (figure 8) lead to the values Kp = (3.2x105 2x105) M-1, ΔH = (27 5) kJmol-1 and zeff = 
4.70.4. The overall quality of the fitting was acceptable (figure 8). The partition constant 
thus obtained agrees with the one previously determined by Time Resolved Fluorescence 
Spectroscopy (Teixeira et al. 2010), 5.1x105 (when transformed to M-1 by use of the lipid 
molar volume). The zeff value found for the effective charge is somewhat smaller than the 
nominal charge (+6). 
As the curves at 30 °C show a steep binding isotherm (figure 7A) we also did the fitting to 
a binding model, “independent binding sites model” (figure 9). As the positively charged 
peptide has a very strong interaction to the negatively charged bilayer, it is reasonable to 
also try this approach, and it has been used in recent publications (Arouri et al. 2013). In 
fact, the two constants (Kp and Kapp) can be related, as has been previously shown 
(Bastos et al. 2004, Melo et al. 2011), and in limiting cases they are similar. The model 
used provides the microscopy binding constants Kapp (i.e., per site), the enthalpy change 
ΔH, and the number of sites N. Thus, the total enthalpy observed can be calculated by 
multiplying the obtained ΔH by the number of “sites”. In this treatment we analysed two 
sets of data where the peptide concentration in the cell was 15 µM and the titrating lipid 
suspension was either 15 or 30 mM (see figure 9 for an example). The values retrieved 
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agree between the two sets of data, leading to average values Kapp = (1.8x105 0.7x105) 
M-1, ΔH = (1.11  0.02) kJmol-1 (per site) and number of sites N = 35  4 (thus the total 
enthalpy observed is 39  5 kJmol-1). The N values can provide us information on the 
extent of interaction between the lipids and the peptide (Arouri et al. 2013). This last 
number indicates that we have ~35 lipids per peptide. Since the interaction of the peptide 
with the membranes is mostly electrostatically driven, and assuming that the peptide can 
escape the vesicle aggregates and redistribute upon new lipid addition, if we base our 
reasoning on the peptide effective charge referred above (4.7) a stoichiometry of 9 could 
be expected if the peptide would only bind to the outer leaflet, or ~5 if it could interact with 
both leaflets (based on POPG content), or 36 and 20, if based only total lipid content. The 
value retrieved for N (354) would thus indicate that the peptide interacts only with the 
outer layer. This is in line with the assumption taken in the partition model calculations 
where it was assumed that the peptide would only interact with the outer leaflet (γ=0.5). 
Therefore, within the confines of the difference between the models, we find the 
agreement satisfactory.  
It is interesting to point that whereas similar results were obtained when the lipid 
concentration was varied between 15 and 30 mM as above in the case of the independent 
binding sites model, in the case of the partition treatment more significant variations were 
found. For this model, when the lipid concentration was kept at 15 mM but the peptide 
concentration was lower (10 µM) a good fit was obtained but leading to a Kp value that 
was higher (2.0x106 M-1) and ΔH (16 kJmol-1) and zeff (3.5) smaller than the values 
obtained for the higher peptide concentration. At odds, when keeping the peptide 
concentration at 15 µM but decreasing the lipid concentration to 15 mM the Kp value 
decreased to 4.5 x104 M-1 but the values for the enthalpy and zeff did not change 
significantly (28 kJmol-1 and 4.9, respectively). Further, when performing the reverse 
titration – peptide of concentration 250 µM titrated into 30 mM liposome suspension, the 
first injections had a slow increase in value up to the 5th one, with an average ΔH value of 
5.6  0.4 kJmol-1, and were constant thereafter at an average value of 12.40.9 kJmol-1. 
Thus not only were the values varying up to the 5th injection but also the constant enthalpy 
value retrieved is close to the one obtained for the lower peptide concentration (10 µM, 
not included in the calculation of the values presented here) but less than half the value 
retrieved for the other peptide concentrations used in the value reported above. These 
changes in thermodynamic parameters for different experimental conditions indicate that a 
simple partition model might not be the best choice for the present peptide/lipid system. In 
fact, in view of the results obtained in the SAXD experiments, and the interpretation we 
provided above of a condensation of the lamella by the peptide, the association model 
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tested might better describe the present system. Further, the indication extracted from the 
N value, suggesting interaction only with the outer layer, taken together with the SAXD 
results leads to the suggestion that the peptide associates with the lipids inducing vesicles 
destruction, forming lamellar structures with the peptide “sandwiched” between bilayers. 
As regarding the experiments at 5 °C, where the lipid is in the gel phase, a very different 
behavior was obtained (figures 6C and 7C). The interaction was exothermic throughout. In 
the first part of the curve we can see a steep increase in ΔH values (in absolute value) up 
to a P:L ratio of 1:46, followed by a plateau region between 1:46 and 1:87, and thereafter 
the enthalpy values decrease at a slower pace towards zero. The initial increase in 
negative values shows that the peptide/lipid interaction is exothermic in the gel phase, 
reflecting probably the extensive aggregation of the liposomes (or lipid bilayers) by the 
peptide. The fact that the interaction was endothermic at higher and exothermic at lower 
temperatures indicates that this is not a simple process and that delicate balances among 
the various interactions (electrostatic, hydrophobic, partial dehydration of the lipid heads 
upon peptide binding, among others) exist that are moderated by temperature. It is 
interesting to observe that at all studied temperatures a similar P:L ratio of ~1:44 is found 
where a change in behavior occurs (figure 7). At 30 °C (figure 7A), it is the locus where 
the enthalpy becomes ~zero (only lipid dilution), i.e., the end of the complexation process. 
At 17 °C (figure 7B), after this point the enthalpy becomes increasingly less negative, 
approaching the lipid dilution, indication also the end of the interaction process. Finally at 
5 °C (figure 7C), it is the onset of a plateau region, observed between P:L ratios of 1:46 
and 1:87. This P:L value must thus be a threshold that we propose reflects lipid saturation 
by the peptide. In terms of observed enthalpy, the existence of the plateau must reflect a 
range where phenomena of opposite enthalpy signs occur. Considering the interpretation 
of the interaction given above (see SAXD results) that the peptide disrupts the membrane 
forming bilayers stacks intercalated by the peptide, we propose that at this ratio 
(P:L=1:44) no more free peptide is available to interact with the lipids. Therefore, upon 
further injection of liposome suspension, the peptide can only redistribute among previous 
and new lipid layers. This implies disruption of the peptide lipid interaction (endothermic 
effect at this temperature), followed by association to new lipid layers (exothermic). Finally 
after P:L=1:87 the observed enthalpies only slowly tend to zero.  
Finally at the intermediate temperatures, 17 °C (figure 7B) the ITC curve start at 
endothermic values, cross zero at P:L=1:35 and became increasingly negative up to P:L 
ratio of 1:44 after which it decreases (in absolute value) towards zero (figure 7B). At this 
temperature we have a mixture of gel and liquid crystalline phases, as shown by the DSC 
results (figure 4B). In the initial region of excess peptide, we interpret the positive values 
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as reflecting both the interaction with the Lα phase (endothermic) and the peptide-induced 
gel-to-liquid crystalline phase transition (endothermic) due to excess peptide, as for the 
same P:L ratios the observed enthalpy values are more positive than those encountered 
at 30 °C. After P:L=1:35 the negative values reflect the interaction with the Lβ phase up to 
saturation at P:L=1:44. After the critical P:L ratio of 1:44, there is large excess lipid and 
the values decrease towards zero. 
Finally we would like to point that the critical P:L ratio where a minimum in the enthalpy 
profiles occurs for all studied temperatures (around 1:44) is similar to the one found by 
Bhargava and Feix in a EPR study of the interaction of this peptide with POPE/POPG 
80:20 (Bhargava and Feix 2004). 
 
Fluorescence microscopy 
In order to further investigate the mechanism of action of CAM on POPE/POPG 3:1 
membranes, and to shed some light onto the structures formed, we have performed 
fluorescence microscopy using OLVs of POPE/POPG 3:1 labelled with Texas Red®-
DHPE. Three different samples were visualized, the pure lipid mixture and two 
peptide/lipid mixtures at P:L of 1:25 and 1:10 (figure 10). The pure lipid mixture shows, as 
expected, oligolamellar vesicles of different sizes, well dispersed in the support (figure 
10A). The mixtures present a completely different structure, with very large aggregates for 
both P:L ratios (figure 10 B, C, D and E). This is in line with the hypothesis of the peptide 
inducing extensive aggregation of the lipid system. Although in both cases an extensive 
aggregation is apparent, at the higher P:L ratio significantly larger aggregates are 
observed (figure 10 C and E), whereas a bridged network between smaller structures 
appears at P:L=1:25 (figure 10 B and D).  
 
Electron Microscopy 
The use of negative staining electron microscopy can provide some further insight on the 
structural characteristics of mixtures of CAM and LUVs of POPE/POPG 3:1. The system 
was studied at a temperature below Tm and for different P:L ratios (1:25 and 1:10). Some 
tests were also performed above Tm with poor results (data not shown). In the case of 
pure lipid mixture individual round vesicles are observed, revealing the presence of 
liposomes (figure 11A). When peptide is added, condensation occurs, with large 
aggregates being formed by multilamellar or disrupted vesicles (figure 11 B, C and D), in 
agreement with the observations by fluorescence microscopy (figure 10). The aggregates 
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are larger in the sample with higher peptide content at 1:10 as compared to 1:25 (figure 
11 C and B, respectively), also in line with the observations by fluorescence microscopy 
(figure 10). In the enlargement presented in figure 11D we can easily see the different 
layers, in an “onion like” structure. 
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Conclusions 
The system CAM/POPE/POPG (3:1) was studied using a number of different techniques, 
to unravel the mode of interaction of this peptide with the model membrane system, in an 
attempt to understand its antimicrobial mechanism of action.  
The results obtained are consistent, and lead us to propose that CAM interacts strongly 
with the negatively charged membrane system, destroying the liposomes and leading to a 
lamellar stack of multilayers with peptide intercalated between them, in an onion-like 
structure. This is clearly shown by the SAXD results, where the increase in the number of 
layers upon peptide addition supports this suggestion. Further, the model we proposed to 
interpret the SAXD patterns reconciles the observed reversibility upon up and down 
temperature scans and the distances retrieved for the Lβ and Lα phases. This behavior is 
similar to the condensation observed in CL-DNA systems, widely described in the 
literature (Rädler et al. 1997, Koltover et al. 1998, Bouxsein et al. 2011). Further, the 
fluorescence and electron microscopy results show the large difference between the pure 
lipid and the combined peptide/lipid system, in structures compatible to the proposed 
aggregation/condensation. We should add that preliminary NMR results showed that 
POPE/POPG 3:1 presents a vesicle structure, but in the presence of the peptide the peak 
symmetry is lost, with a shoulder appearing on the left indicating the presence of a 
lamellar structure (unpublished results).  
Pistolesi et al. (Pistolesi et al. 2007) suggest that an initial interaction at low 
concentrations of membrane-bound peptide, occurs primarily near the membrane surface, 
with the peptide aligned parallel to the plane of the bilayer. With peptide insertion near the 
hydrophobic-hydrophilic interface, an expansion of the outer leaflet of the bilayer occurs, 
with continued accumulation of bound peptide, leading to membrane thinning as a prelude 
to pore formation or detergent-like disintegration of the bilayer. This would agree with our 
findings, suggesting that the end result is bilayer disintegration. It should also be pointed 
that a study by Ladokhin and White (Ladokhin and White 2001) showed that whereas 
melittin (a related peptide, as CAM is a cecropin A-melittin hybrid) induces release 
through pores of about 25 Å diameter in zwitterionic membranes (Ladokhin et al. 1997), 
release from POPG vesicles was found to be non-selective, i.e., ‘detergent-like' (Ladokhin 
and White 2001). 
The DSC experiments also showed that extensive aggregation takes place, in agreement 
with SAXD and microscopy findings. This precluded a quantitative analysis of the results 
obtained for peptide/lipid mixtures. Nevertheless, they indicate that at low P:L ratios the 
peptide stabilizes the Lβ phase, a result that can arise from a strong, surface interaction. 
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When the peptide content is increased, extensive aggregation occurs, particularly after 
P:L=1:25.  
Finally the ITC results showed that the enthalpy of interaction is endothermic in the Lα 
phase and exothermic in the Lβ phase. Further, at temperatures of coexistence of both 
phases, at high P:L ratios the peptide interacts initially with the Lα phase and induces gel-
to-liquid crystalline phase transition. In all cases a threshold P:L ratio of 1:44 was found, 
that we interpret as a saturation concentration. Moreover, the N value found from the 
treatment of the results in the Lα phase (~35 lipids per peptide) can provide information on 
the extent of interaction between the lipids and the peptide (Arouri et al. 2013). This value 
agrees with the one expected, considering the calculated effective charge (4.8), if we 
consider that the peptide only interacts with the outer lipid leaflet. This result is again in 
line with the peptide interaction at the level of the heads, inducing membrane 
condensation after a threshold value (related to charge neutralization) and not to pore 
formation. It should be noted that pore formation induced by CAM has been reported in 
other systems (Juvvadi et al. 1996, Sato and Feix 2006, Milani et al. 2009), however, our 
results are not compatible with such mechanism.  
Thus, the overall results presented here strongly suggest that the mechanism of action of 
CAM can be described by the “carpet model” where the cationic peptide adsorbs to the 
partially negatively charged membrane, folding into α-helix and covering the membrane 
until a threshold concentration, inducing thereafter bilayer disruption with significant 
condensation into a multilamellar system. Since the system studied in this work is a good 
model of the bacterial membrane, where PE and PG are the most abundant phospholipids 
(Teixeira et al. 2012), the mechanism proposed here would lead to bacterial membrane 
destruction, loss of membrane potential and inner contents, ultimately leading to cell death. 
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Tables 
Table 1 – Values of Tm for the gel-to-liquid crystalline phase transition of pure 
POPE/POPG 3:1 and mixtures with CAM at different P:L ratios as obtained from DSC. 
P:L 
Tma / °C 
OLVs LUVs 
0 21.2 20.5 
1:50 - 21.1 
1:25 22.0 20.6 
1:15 23.2 22.1 
1:10 23.0 - 
a The estimated uncertainty in Tm is ± 0.1 °C (same liposomes preparation, used for the 
full P:L series) and ± 0.3 °C (within samples). 
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Figures 
 
Figure 1 – SAX diffractograms of gel (Lβ) (A) and liquid crystalline (Lα) (B) phases, for 
POPE, POPE/POPG 3:1 and CAM/POPE/POPG mixtures at different P:L ratios: 1:25, 
1:15, 1:10 and 1:7, as marked in the figure. A) 10 °C; B) 30 °C. 
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Figure 2 – Evolution of the number of domains (nL) with increase in peptide content for 
mixtures of CAM and POPE/POPG 3:1 at different P:L molar ratios. Black symbols: 10 °C; 
grey symbols: 30 °C. Each symbol corresponds to a SAXD diffractogram, and the 
horizontal bar the average value for each group. 
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Figure 3 – Schematic representation of the proposed structural model, highlighting the 
condensed/complexed lamellar structure above Tm in the Lα phase (right) and its more 
ordered counterpart below Tm the Lβ phase (left). The peptide cross-section is depicted 
with the hydrophobic domains in black and cationic domains in red. The figure suggests 
that the hydrophobic domains can interact more favorably with the PE head groups (small 
and zwitterionic, here colored in white) while the cationic domains interact favorably with 
the PG anionic head groups (colored green) of the next membrane, with both effects 
leading to the condensation of the membranes. Below Tm the stiffening of the alkyl chains, 
the small structural changes induced by the peptide and the possible more regular 
arrangement of the peptides, make neighboring bilayers distinct within a unit cell (note 
that the grooves in the neighboring lamellae are out-of-phase). Thus the unit cell can no 
longer be ascribed to a simple 1D lamellar lattice, requiring a 2D centered rectangular cell 
with the lattice parameter perpendicular to the planes (br) that becomes twice the lamellar 
repeat distance (d), and with the lattice parameter ar in the plane of the lamellae. Because 
despite the slight differences between neighboring membranes, a large part of the 
structure is still similar, the odd-reflections are partially cancelled by symmetry and the 
therefore, the corresponding Bragg peaks have a smaller intensity than the even 
reflections.  
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Figure 4 – DSC curves for POPE/POPG 3:1 and its mixture with CAM at different P:L 
molar ratios. A) OLVs of POPE/POPG 3:1 (solid black); P:L=1:25 (grey); P:L=1:15 
(dashed grey); P:L=1:10 (dotted grey). B) LUVs of POPE/POPG 3:1 (solid black); 
P:L=1:50 (light grey); P:L=1:25 (grey); P:L=1:15 (dashed grey). The lipid concentration 
was 3 mM in all experiments. 
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Figure 5 – CD spectra of CAM in buffer (25 µM) (grey) and in a mixture with POPE/POPG 
3:1 (3 mM), at P:L=1:50 (black).  
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Figure 6 – ITC raw data for titration of CAM in buffer (15 µM) with POPE/POPG 3:1 (30 
mM) at A) 30, B) 17 and C) 5 °C. The raw data was imported to the AFFINImeter software 
(www.affinimeter.com) and processed therein. 
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Figure 7 – Integrated peaks as a function of lipid-to-peptide ratio for titration of CAM in 
buffer (15 µM) with POPE/POPG 3:1 (30 mM) at A) 30, B) 17 and C) 5 °C. The baseline 
correction and integration were performed using the AFFINImeter software 
(www.affinimeter.com). 
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Figure 8 – Titration of CAM (15 µM) with POPE/POPG 3:1 (30 mM) at 30 °C. The 
integrated reactions heats normalized to the molar amount of injected lipid, Qi, were 
obtained with the NITPIC software and are plotted as a function of lipid concentration in 
the cell. The data was analysed by use of a partition model taking into account Coulombic 
effects according to the Gouy-Chapman theory (Vargas et al. 2013). Experimental points 
are represented by circles and fitted values by the line. 
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Figure 9 – Titration of CAM (15 µM) with POPE/POPG 3:1 (30 mM) at 30 °C. The 
integrated reactions heats normalized to the molar amount of injected lipid, Qi, were 
obtained with the AFFINImeter software, and are plotted as a function of lipid-to-peptide 
ratio in the cell. The data was analysed using an “independent sites model” (AFFINImeter, 
www.affinimeter.com). Experimental points are represented by circles and fitted values by 
the line. 
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Figure 10 – Fluorescence confocal microscopy of POPE/POPG 3:1 (OLVs) containing 
0.3% of Texas Red®-DHPE and its mixture with CAM at different P:L ratios. Upper panel: 
A) POPE/POPG 3:1; B) P:L=1:25; C) P:L=1:10. Lower panel: same mixtures as in the 
upper panel but at higher magnification: D) P:L=1:25; E) P:L=1:10. Scale bar: 15 µm. 
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Figure 11 – Negative staining electron microscopy of POPE/POPG 3:1 (LUVs) and its 
mixture with CAM at different P:L ratios. Samples were incubated below Tm, in the gel 
state. A) POPE/POPG 3:1; B) P:L=1:25; C) P:L=1:10; D) higher magnification of C. Scale 
bar: 250 nm. 
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Supplementary Information 
Table 1 – Number of layers calculated for CAM + POPE/POPG 3:1 mixtures at different 
peptide-to-lipid (P:L) molar ratio at 10 and 30 °C. 
T / °C P:L a FWHM b d / Å 
Domain size 
L 
Number of 
layers 
nL 
10 
0 
1.96E-03 111.4 510 5 
1.83E-03 117.2 546 5 
1:25 
1.85E-03 55.5 541 10 
1.23E-03 54 813 15 
1.18E-03 50.35 847 17 
8.16E-04 55.5 1225 22 
1.51E-03 55.5 662 12 
1:15 
7.66E-04 54.45 1305 24 
4.50E-04 55.25 2222 40 
1.06E-03 53.15 943 18 
4.05E-04 55.45 2469 45 
1:10 
3.56E-04 54.45 2809 52 
3.10E-04 54.9 3226 59 
1:7 
2.76E-04 54 3623 67 
2.20E-04 54 4545 84 
2.35E-04 54.45 4255 78 
1.96E-04 55.25 5102 92 
1.85E-04 55.25 5405 98 
1.91E-04 55.3 5236 95 
30 
0 
7.84E-03 102 128 1 
1.26E-02 106.3 79 1 
1:25 
4.15E-04 53 2410 45 
4.54E-04 52.6 2203 42 
4.04E-04 54 2475 46 
4.33E-04 53.9 2309 43 
4.69E-04 54.1 2132 39 
1:15 
3.35E-04 51 2985 59 
3.20E-04 51.5 3125 61 
3.23E-04 51.4 3096 60 
2.99E-04 51.2 3344 65 
2.72E-04 51.4 3676 72 
1:10 2.89E-04 50.7 3460 68 
1:7 
1.96E-04 50.3 5102 101 
2.00E-04 50.3 5000 99 
1.78E-04 50.7 5618 111 
1.59E-04 50.7 6289 124 
1.62E-04 50.8 6173 122 
1.56E-04 50.8 6410 126 
a P:L – Peptide-to-lipid molar ratio 
b FWHM – full width of the peak at half maximum 
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We continue to face a reemergence of infectious diseases, mainly
due to the increasing resistance of the pathogens to current therapies
and the lack of new and more effective antimicrobial drugs. One po-
tential and interesting alternative to conventional antibiotics is the
use of antimicrobial peptides (AMPs). Natural AMPs are present in
almost all living organisms as a primary defense mechanism against
invading pathogens, with remarkably different structures and bioac-
tivity proﬁles [1]., circular dichroism; DMPC,
phatidylglycerol; DSC, differen-
cles; LC50, lethal concentration
rrampin 265–284; LFchimera,
17–30; LUVs, large unilamellar
d molar ratio; PC, phosphatidyl-
ylglycerol; SAXD, small angle
ímica CIQ(UP), Department of
rsity of Porto, Rua do Campo
1; fax: +351 220402659.
rights reserved.AMPs are considered membrane-active agents leading to cell
death by acting on the phospholipid membrane [2]. Within this
broad umbrella, it is recognized today that they do not act through
a universal mechanism. Different mechanisms have been proposed,
consistent with experimental results, providing possible ways for
the peptides to disrupt the membrane, leading to cell death. All rely
on the same main factor for initial action — adsorption of AMPs onto
the membrane due to electrostatic interactions between the cationic
peptides and the headgroups of anionic phospholipids. Thereafter,
accumulation and positional change eventually lead to the formation
of pores, membrane permeabilization or membrane micellization
[1,3–7]. In some cases internal targets have also been described
[5,8–11].
Independently of the details of themechanism of action the interac-
tion must be as selective as possible regarding the distinction between
mammalian cells (higher eukaryotes) and pathogen cells, such as bacte-
ria (prokaryotic cells) or lower eukaryotes as fungi and protozoan.
Cytoplasmic membranes of mammalian cells expose predominantly
zwitterionic phosphatidylcholine (PC) and sphingomyelin to the extra-
cellular side [1]. On the other hand, cytoplasmic bacterial membranes
are mainly composed of zwitterionic phosphatidylethanolamine (PE)
and negatively charged phosphatidylglycerol (PG) conferring an overall
1330 T. Silva et al. / Biochimica et Biophysica Acta 1828 (2013) 1329–1339negative charge to the membrane [1,12]. Lower eukaryotes, such as
fungi and protozoa also have PC, but they have higher amounts of ex-
posed anionic phospholipids, like phosphatidylserine, thanmammalian
cells [1,13,14]. Indeed it is this differential composition that justiﬁes the
unifying electrostatic character of the initial interaction, as well as the
ability of the AMPs to act preferentially against pathogens.
Biophysical studies can provide important information on the de-
tails of AMPs interaction with the membranes and thus help to unrav-
el their mechanism of action, by providing insight into the effects of
the peptides on the membrane structure and information on peptide
location. Different techniques have been employed, such as calorime-
try, spectroscopy, X-ray diffraction and others [3,12,15–28].
X-ray diffraction studies can give quantitative information on the
effects of AMPs on membrane structure, namely if they are capable
of altering the phospholipid structure and organization, as well as
phase behavior. This information thus allows correlation of these pos-
sible changes in lipid polymorphism with models for the mechanism
of action of AMPs [12,22,23,28]. Growing evidence shows that lipid
cubic phases are ubiquitous in the biological world as they have
been detected in the plasma membrane of archaebacteria, as well as
in the endoplasmic reticulum and mitochondria of mammalian cells.
These phases are also involved in biological processes such as mem-
brane fusion, fat digestion and in the reorganization of cell membrane
composition [1,29–32]. In the AMP research area, some reports
started to appear in the literature indicating the ability of AMPs to in-
duce cubic phases. So far most studies have revealed the existence of
bicontinuous (single or double) cubic phases [12,19,24–28,33–35]
and a recent one reported a micellar cubic phase [36].
Previously, Bolscher et al. [37,38] have obtained freeze-fracture
results on the action of peptides of the lactoferrin family against Can-
dida albicans, showing that the peptides have a quite different effect
on the membrane of this pathogen. In the present work we studied
the action of these peptides on model membranes of DMPC/DMPG
(3:1), considered to be a good model system for C. albicans, by a vari-
ety of biophysical techniques. We found that lactoferricin 17–30
(LFcin17-30) induces phase segregation and is the peptide with low-
est membrane activity, lactoferrampin 265–284 (LFampin265-284)
induces a micellar cubic phase (Pm3n) [36], which to the best of
our knowledge is the ﬁrst experimental evidence of such phase in
the context of antimicrobial peptide/membrane interaction. Finally
LFchimera, a hybrid peptide between the ﬁrst two [16], induces two
cubic phases of Pn3m and Im3m symmetry. These results parallel
their effect on C. albicans as derived from freeze-fracture electron mi-
croscopy, indicating a remarkable agreement between simple model
systems and living organisms.
2. Materials and methods
2.1. Peptide synthesis, puriﬁcation and characterization
LFcin17-30, LFampin265-284 and LFchimera were synthesized by
solid phase peptide synthesis using Fmoc-protected amino acids
(Orpegen Pharma GmbH, Heidelberg, Germany) in a Syro II synthe-
sizer (Biotage, Uppsala Sweden) as described previously [16]. The
chimerical peptide comprises a single C-terminal amidated lysine
substituted at the α- and ε-amino groups with the two peptides via
the C-terminal site and leaving two N-termini as free ends. Peptides
were puriﬁed to a purity of at least 95% by semipreparative RP-HPLC
(Jasco Corporation Tokyo, Japan) on a Vydac C18-column (218MS510;
Vydac, Hesperia, CA, USA) and the authenticity of the peptides was con-
ﬁrmed byMALDI-TOFmass spectrometry on aMicroﬂex LRFmass spec-
trometer equipped with an additional gridless reﬂectron (Bruker
Daltonik, Bremen, Germany) as described previously [39]. In Table 1
we provide basic information of the peptides, together with their LC50
and their ultrastructural effects against C. albicans, as obtained previ-
ously by Bolscher et al. [37,38].2.2. Preparation of liposomes
1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC)was dissolved
in chloroform, and its mixture with 1,2-dimyristoyl-sn-glycero-3-
[phospho-rac-(1-glycerol)] (DMPG) at amolar ratio of 3:1was dissolved
in chloroform/methanol (3:1 (v/v)). Both lipids were from Avanti Polar
Lipids, Alabama, USA. A ﬁlm was prepared thereafter in round bottom
ﬂasks by drying the sample under a stream of nitrogen, and was kept
under vacuum for 3 h to remove all traces of organic solvents. After dry-
ing, the lipid ﬁlm was ﬁrst warmed for 30 min at ca. 10 °C above the
temperature of the gel-to-liquid crystalline phase transition (Tm) in a
thermostated water bath, and afterwards hydrated with buffer, either
HEPES (10 mM HEPES, 100 mM NaCl, pH 7.4) or PBS (9.3 mM,
154 mMNaCl, pH 7.2), kept at the same temperature. Themultilamellar
vesicles (MLVs) were obtained by alternating gentle vortex with short
periods in the thermostated water bath at ~35 °C. After this the MLVs
were frozen in liquid nitrogen and thawed in a water bath at 35 °C,
and this process was repeated 5 times.
Large unilamellar vesicles (LUVs) were obtained from the MLVs by
extrusion in a 10 ml stainless steel extruder (Lipex Biomembranes,
Vancouver, BC, Canada), inserted in a thermostated cell with a
re-circulating water bath, at 35 °C. The samples were passed several
times through polycarbonate ﬁlters (Nucleopore, Pleasanton, CA,
USA) of decreasing pore size (600, 200 and 100 nm; 5, 5 and 10
times, respectively), under inert (N2) atmosphere.
Size distribution of extruded vesicles was determined by qels anal-
ysis (Malvern Zeta Sizer 5000, Malvern Instruments, Malvern,
Worcestershire,UK) using a helium-neon laser (633 nm) as a source
of incident light, and operating at a scattering angle of 90° and at
37 °C. Mean particle size was thus determined as being of 106±4 nm
(average and standard deviation of 6 independent measurements). The
phospholipid concentration was determined by the phosphomolibdate
method [40].2.3. Differential scanning calorimetry
Differential scanning calorimetry (DSC) was performed in a
Micro-DSCIII microcalorimeter (SETARAM, Caluire, France) essentially
as described previously [41]. In brief, samples were run against HEPES
buffer in the reference cell, and blank experiments with HEPES buffer
in both cells were also performed for subsequent blank correction.
The solution or suspension volume used in each cell was of around
0.8 ml, and the masses of solution in sample and reference cells were
subsequently matched by weighing ±0.00005 g. Two successive
heating and cooling scans were performed for each sample, the heating
scan at a scanning rate of 0.5 °C/min and the cooling scan at 3 °C/min,
over the temperature range of 10–35 °C. The results provided here al-
ways refer to the second heating scan, as we have observed that
small differences can exist between ﬁrst and second scans, but not
thereafter. The sample mixtures were prepared immediately before
the DSC run, by adding the desired amount of peptide (LFcin17-30,
LFampin265–284 or LFchimera) stock solution (in HEPES buffer)
to the LUVs suspension of DMPC or DMPC/DMPG (3:1). Samples
with peptide-to-lipid molar ratios (P:L) from 1:197 to 1:29 were
used. All procedures regarding sample preparation and handling
(lag time at low temperature, time between mixtures, and start of
the experiment) were kept constant in all experiments, to ensure
that all samples had the same thermal history. The instrument was
electrically calibrated for temperature and the scan rate with the
SETARAM Calibration Unit. The Micro-DSCIII software was used for
blank subtraction (run with buffer solution on both cells (sample
and reference)). Tm and the ΔtransH were calculated by integration
of the heat capacity versus temperature curve (Cp versus Temperature).
A linear baseline was used to calculate the integral areas under the
curves [41].
Table 1
Properties of synthetic lactoferrin peptides.
Peptide LFcin17-30 LFampin265-284 LFchimeraa
Sequence FKCRRWQWRMKKLG DLIWKLLSKAQEKFGKNKSR FKCRRWQWRMKKLG–K DLIWKLLSKAQEKFGKNKSR
Chargeb +6 +4 +12
Freeze fracture microscopyc
LC50d 1.5 1.2 0.5
a The carboxyl group of the linking lysine (C-terminal) is in carboxamide form.
b Calculated overall charge at pH=7.0.
c From previously published results [37,38]. Insert (a) is the control. The scale is embedded in each ﬁgure.
d From previously published results [37,38]; LC50 is the peptide lethal concentration that causes 50% of C. albicans death determined in a 5 mM NaCl containing phosphate buffer.
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Circular dichroism (CD) experiments were carried out in a Jasco
720 spectropolarimeter (Japan Spectroscopy Co., Tokyo) equipped
with a rectangular cell, path length of 1 mm. Scans were performed
between 175 and 250 nm, bandwidth 1.0 nm, and resolution of
100 mdeg. The measurements were performed in 2 mM HEPES,
100 mM NaCl, pH 7.4. Spectra of pure liposome preparations were
performed in the same solvent media at the concentrations used in li-
posome/peptide mixture. These were used as blank experiments to
be subtracted from the liposome/peptide spectra. The peptide con-
centration in buffer was 36 μM. Liposome concentrations were:
6 mM for DMPC and 3 mM for DMPC/DMPG (3:1), in both cases
with a P:L ratio of 1:167. The peptide solution and liposome suspen-
sion were mixed just prior to each measurement and incubated at
35 °C for 30 min and measurements were performed thereafter
at the same temperature. Each spectrum was the average of nine ac-
cumulations. After blank correction, the observed ellipticity was
converted to a mean residue molar ellipticity (θ) (deg·cm2·dmol−1),
based on the total amount of peptide in the mixture.
2.5. X-ray diffraction studies
Peptide solution in the same buffer used for preparing the lipo-
somes was added to the liposome suspension at different P:L molar
ratios, and the mixtures were incubated for 30 min at 35 °C. The sam-
ples were then centrifuged at 13 000 rpm in a microcentrifuge at
least for 15 min, and transferred thereafter into glass capillaries
(Spezialglas Markröhrchen 1.5 mm capillaries, Glass Technik &
Konstruktion — Müller & Müller OHG, Germany). In the transfer
care was taken to always have a signiﬁcant amount of supernatant
in the capillaries, to guarantee that all samples were studied at high
water contents. The capillaries were sealed by ﬂame, and stored at
4 °C, at least 3 days before use.
Small angle X-ray diffraction (SAXD) and wide angle X-ray diffrac-
tion (WAXD) experiments were performed at the synchrotron soft con-
densed matter beamline A2 in HASYLAB at Deutsches Elektronen
Synchrotron (DESY), Hamburg, Germany, using a monochromatic radi-
ation ofλ=0.15 nmwavelength. Diffractogramswere taken at selected
temperatures, where the sample was equilibrated for 5 min before ex-
posure to radiation, or by performing up and down temperature scans
at a scan rate 1 °C/min, where diffractograms were recorded for 10 s
every minute. The heating and cooling of the sample were regulated
by a thermocouple connected to the temperature controller JUMOIMAGO 500 (JUMO GmbH & Co. KG, Fulda, Germany). The evacuated
double-focusing camera was equipped with a linear position sensitive
detector for WAXD and a 2D MarCCD detector or a linear position sen-
sitive detector for SAXD. The raw data were normalized against the in-
cident beam intensity. The SAXD patterns were calibrated using Ag
behenate [42] or rat tail collagen [43] and the WAXD patterns by
tripalmitin or polyethylene terephthalate [44,45]. Each diffraction
peak was ﬁtted by Lorentzians above a linear background by use of
the Peakﬁt or Origin software programs, in order to derive the lattice
parameters. For cubic phases, the lattice parameter was determined as
the slope of the dependence of s(Å−1) vs. √(h2+k2+ l2), passing
through the origin (0,0), where h, k, l are Miller indices. The uncertainty
assigned to the lattice parameters is half of the interval of maximum
width that can be obtained through calculation of minimum and maxi-
mum values for lattice parameters from the slope above together with
its statistical standard error, as obtained from the regression. For lamel-
lar phases, the obtained uncertainty never exceeds ±0.1 Å, and thus
from hereafter we will not quote the uncertainty for the lattice param-
eter in lamellar phases. The reported uncertainties for cubic phase lat-
tice parameters are calculated as above and presented together with
the lattice parameter value throughout the text.
3. Results
3.1. Differential scanning calorimetry
DSC experiments show the inﬂuence of both lipid charge and
peptide-to-lipid molar ratio (P:L) on the thermotropic behavior of
the peptide/lipid systems. The endotherms obtained for each peptide,
LFcin17-30, LFampin265-284 and LFchimera, with the model mem-
branes of DMPC and DMPC/DMPG (3:1), are shown in Figs. 1 and 2,
respectively.
The thermodynamic description is based on the parameters
characterizing the gel-to-liquid crystalline phase transition of the
liposomes, namely transition temperature (Tm) and the correspond-
ing enthalpy change (ΔH). By comparing the calorimetric proﬁles
obtained for the pure liposomes and the liposome/peptide mixtures
at the various P:L ratios allow us to derive the inﬂuence of the pep-
tides on this thermotropic transition. The obtained thermodynamic
parameters are listed in Tables 2 and 3, where values for the pure
lipid systems are also shown. In order to overcome the slight differ-
ences that may occur for different lipid samples, measurements of
the same peptide/lipid system were always performed with liposome
suspension from the same preparation batch.
Fig. 1. DSC curves for DMPCandDMPC/peptidemixtures of varying composition. The lipid
concentration was 3.0±0.3 mM in all experiments. (a) LFcin17-30; (b) LFampin265-284
and (c) LFchimera. Pure lipid (solid black); P:L=1:196 (solid gray); P:L=1:129 (solid
light gray); P:L=1:96 (dash black); P:L=1:46 (dash gray); P:L=1:29 (dash light gray).
Maximal P:L molar ratio used was 1:46 for LFchimera.
Fig. 2. DSC curves for DMPC/DMPG (3:1) and DMPC/DMPG (3:1)/peptide mixtures
of varying composition. The lipid concentration was 3.0±0.3 mM in all experiments.
(a) LFcin17-30; (b) LFampin265-284 and (c) LFchimera. Pure lipid (solid black); P:L=
1:196 (solid gray); P:L=1:129 (solid light gray); P:L=1:96 (dash black); P:L=1:46
(dash gray); P:L=1:29 (dash light gray). Maximal P:L molar ratio used was 1:46 for
LFchimera.
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ized by a temperature of 24.5 °C and an enthalpy change that varies be-
tween 19 and 27 kJ·mol−1 (Table 2) for different sample preparations.
The ΔHtrans value observed for the sample used together with
LFchimera is signiﬁcantly higher than the other two (stated uncertainty
between samples ±3 kJ·mol−1), but the same sample was used for all
mixtures with this peptide, and the results are consistent within
sample. The observed thermodynamic parameters are in very good
agreement with literature values [41,46,47]. The calorimetric proﬁle
for the pure lipid system is a symmetric and cooperative peak. As re-
garding the peptide/lipid mixtures, we can see that LFcin17-30 and
LFampin265-284 do not alter the gel-to-liquid crystalline transition, asthe curves are superimposable for all tested P:L ratios and the parame-
ters Tm and ΔHtrans are the same, within the stated uncertainty (Fig. 1a
and b, and Table 2). As for LFchimera, it is clear that this peptide inter-
acts with the zwitterionic lipid system for all P:L ratios, and as a result
we observe a progressive decrease of Tm as the peptide content in the
mixture increases, reﬂecting a better interactionwith the liquid crystal-
line phase, and the appearance of a shoulder at the high temperature
side for the highest P:L ratios (Fig. 1c and Table 2), which is indicative
of domain segregation in the membrane [41]. The ΔHtrans values
decrease with increasing peptide content, indicating a progressive
Table 2
Thermodynamic parameters Tm and ΔHtrans for the gel to liquid crystalline phase transition of DMPC liposomes for different P:L ratios.
Tm
a (°C) ΔH transb (kJ mol−1)
(P:L) LFcin17-30 LFampin265-284 LFchimera LFcin17-30 LFampin265-284 LFchimerac
0 24.4 24.5 24.4 22 19 27
1:196 24.4 24.5 23.7 21 21 26
1:129 24.4 24.5 23.6 22 21 23
1:96 24.4 24.5 23.5 20 19 23
1:46 24.3 24.5 23.3 20 18 23
1:29 24.3 24.4 – 21 18 –
a Tm estimated uncertainty is ±0.1 °C (same liposomes preparation, used for the full P:L series) and ±0.3 °C (within samples).
b ΔHtrans estimated uncertainty is ±0.5 kJ mol−1 (same liposomes preparation, used for the full P:L series) and ±3 kJ mol−1 (within samples).
c The value for pure lipid is signiﬁcantly higher than for the other peptides, but is consistent within the same preparation (series) for this peptide.
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deeper insertion of the peptide in the hydrocarbon moiety.
As regarding the mixed system DMPC/DMPG (3:1), we can see
that an interaction exists for the three peptides, with strength that in-
creases in the order LFcin17-30, LFampin265-284 and LFchimera
(Fig. 2). This is reﬂected in a very small change in the thermodynamic
parameters for LFcin17-30 that is higher for LFampin265–284, and
much more signiﬁcant for LFchimera. In all cases we observe a de-
crease in Tm and ΔHtrans (Table 3). For LFcin17-30, although the de-
crease in both parameters is within the quoted uncertainty, the
observed trend is clearly downwards (Fig. 2a). For LFampin265-284
the differences are already outside the error limits at the highest P:L
ratios, and overall the trend in both parameters is towards lower
values. It should be stressed that for this peptide a signiﬁcant change
in shape occurs already at P:L ratio 1:46, as a very distorted curve
with signiﬁcantly higher width is observed, showing a large reduction
in the cooperativity of the transition. This indicates the onset of a sig-
niﬁcant structural change in the membrane at higher P:L ratios
(Fig. 2b).
For LFchimera the decrease in both parameters is signiﬁcant for all
P:L ratios, and although overall the shape of the calorimetric proﬁle is
somewhat similar to the one observed for DMPC, it is clear that the ef-
fect is much stronger (Fig. 2c). Again we see a trend for Tm and ΔHtrans
to decrease as peptide content in the mixtures increases. This is rea-
sonable, as on one hand the system is still predominantly zwitterionic
(DMPC is 75% of the lipid content of the membrane), and on the other
the electrostatic favorable contribution in the case of the partially
negatively charged system DMPC/DMPG (3:1) is expected to increase
the interaction, as seen in the results. Further, the proﬁle is sig-
niﬁcantly different from the ones observed for the constituent pep-
tides. We observed the same differential pattern in DSC studies of
the three peptides with DMPG liposomes, where LFchimera had a
completely disruptive behavior already at low P:L ratios, at odds
with the other two peptides, that only presented a signiﬁcant interac-
tion as the P:L ratio increases [16]. This was also seen by Haney et al.
in a DSC study with DPPG liposomes [18]. Again these results are in
line with the effect that these peptides show on C. albicans, as it will
be discussed further.Table 3
Thermodynamic parameters Tm and ΔHtrans for the gel to liquid crystalline phase transition
Tm
a (°C)
(P:L) LFcin17-30 LFampin265-284 LFchimera
0 25.0 25.0 24.8
1:196 25.0 24.9 24.7
1:129 25.0 24.9 24.5
1:96 25.0 24.8 23.7
1:46 24.8 24.4 23.2
1:29 24.6 23.9 –
a Tm estimated uncertainty is ±0.1 °C (same liposomes preparation, used for the full P:L
b ΔHtrans estimated uncertainty is ±0.5 kJ mol−1 (same liposomes preparation, used forFinally in order to try to shed some light in the observed lipid/peptide
cubic organization for the mixture DMPC/DMPG (3:1) and LFampin265-
284 at high peptide contents [36] we did perform some further DSC ex-
periments at higher P:L ratios for this system, and the obtained results
can be seen in Fig. 3. A clear peak splitting is observed, as anticipated in
the highest ratio of previous collection of results. Overall the transitions
occur between 20 and 30 °C, and when we did the deconvolution of
the overall DSC curves, two peaks were obtained, one at lower and the
other at higher temperature as compared to the pure lipid mixture.
At 1:12 the ﬁrst transition is about one degree higher than the ones
observed for 1:8 and 1:3, whereas the higher temperature transition
occurs at about the same temperature (within estimated uncertainty)
irrespective of P:L ratio.
3.2. Circular dichroism
The secondary structures of LFcin17-30, LFampin265-284 and
LFchimera were examined by CD in HEPES buffer and in the presence
of the liposome systems. CD spectra of the peptides at a concentration
of 36 μM in the aqueous buffer (2 mM HEPES, 100 mM NaCl, pH=
7.4) are shown in Fig. 4, together with the CD spectra obtained in
the presence of DMPC and DMPC/DMPG (3:1) liposomes. Measure-
ments at different peptide concentrations in aqueous buffer showed
that the peptide structures are not signiﬁcantly affected by peptide
concentration within the concentration range of 15 to 50 μM (results
not shown). Therefore, only one concentration is plotted for each
peptide in buffer. As for peptide/liposome mixtures, we have tested
several combinations, and observed that all provide the same second-
ary structure information. Therefore, we only plot the ones that pro-
vided the best quality spectra.
All peptides show a predominantly random coil structure in buffer.
In the presence of DMPC the structure remains practically the same
for LFampin265-284, whereas LFcin17-30 changes slightly the minima
to higher wavelengths and more negative ellipticity values between
210 and 230 nm, indicating a more signiﬁcant contribution of
β-structure to the overall CD signal (Fig. 4a and b). In the case of
LFchimera, we have a mixture of structures, where the minimum
around 200 nmmoves to about 217 nm, characteristic of the presenceof DMPC/DMPG (3:1) liposomes for different P:L ratios.
ΔH transb (kJ mol−1)
LFcin17-30 LFampin265-284 LFchimera
23 21 26
22 21 26
22 19 24
22 19 21
22 20 20
21 18 –
series) and ±0.3 °C (within samples).
the full P:L series) and ±3 kJ mol−1 (within samples).
Fig. 3. DSC curves for DMPC/DMPG (3:1) and DMPC/DMPG (3:1)/LFampin 265–284
mixtures at high P:L ratios. The lipid concentration was 6.0±0.3 mM in all experi-
ments. Pure lipid (solid black); P:L=1:12 (heavy solid black); P:L=1:8 (heavy solid
gray); P:L=1:3 (heavy solid light gray). The dashed (low temperature peak) and dot-
ted (high temperature peak) lines represent the deconvoluted curves for each P:L ratio.
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and LFampin265-284 alone do hardly interact with DMPC liposomes,
as revealed from DSC and CD, when bound together in LFchimera they
contribute to themixture of structures observed by CD for this peptide's
interaction with zwitterionic lipids.
In the presence of DMPC/DMPG (3:1), both LFampin265-284 and
LFchimera show the predominance of α-helix structure, with
well-deﬁned minima around 208 and 222 nm (Fig. 4b and c). Never-
theless the α-helix structure is better deﬁned in the case of
LFampin265-284. Finally LFcin17-30 shows CD spectra in this lipid
mixture that clearly reﬂects a mixture of α-helix and β-structure
(Fig. 4a). We should stress that in a previous paper we showed that
this peptide presents the structure of a β-turn in the presence of
purely negatively charged membranes of DMPG [16], and it is thus
reasonable that this structure already appears in the DMPC/DMPG
(3:1) lipid mixture, although to a smaller extent.
Overall, it is clear that the structure of the peptides changes in the
presence of membranes, and that the structure adopted depends on
the peptide and the lipid mixture.Fig. 4. CD spectra of (a) LFcin17-30, (b) LFampin265-284 and (c) LFchimera at 35 °C in:
buffer (peptide concentration 36 μM) (solid black); DMPC 6 mM (dash gray); and
DMPC/DMPG (3:1) 3 mM (dotted light gray). P:L ratio in peptide/LUV mixtures was
1:167.3.3. X-ray diffraction
Curiously, SAXD experiments revealed that each of the three stud-
ied peptides induces different structural changes in DMPC/DMPG
(3:1) membrane. The structural changes are temperature dependent,
and we present typical diffraction patterns at selected temperatures
with the aim to shed more light into the mechanism of peptide–
membrane interaction.
The SAXD and WAXD results obtained for LFcin17-30 and DMPC/
DMPG (3:1) at selected temperatures, for a P:L ratio 1:8 (mol/mol)
can be found in Fig. 5. Despite the high peptide to lipid molar ratio
in the sample, SAXD did not indicate the occurrence of membrane
disruption. As described in the Materials and methods section, prior
to interaction with the peptide the DMPC/DMPG (3:1) mixture
forms a dispersion of unilamellar (or oligolamellar) vesicles. Such dis-
persion does not have a long range order and SAX diffraction shows a
broad peak with intensity at the level of background (not shown). In
the gel phase, the phospholipid acyl chains are fully extended, packed
hexagonally and oriented more or less perpendicularly to the surface
of the bilayer, a structural feature documented by a peak in WAX dif-
fraction. For our pure DMPC/DMPG (3:1) mixture the temperature of
gel to liquid crystalline phase transition was found to be Tm=25 °C
by our DSC experiments (Table 3). The diffractogram obtained for
the mixture LFcin17-30 and DMPC/DMPG (3:1) taken at 10 °Ccorresponds well with the description above and shows no evidence
of interaction of the AMP with the DMPC/DMPG (3:1) membrane.
However, heating the system above the phase transition temperature
of the mixture, we observe a lamellar phase with a repeat distance d
slightly decreasing with increasing temperature — d=61.7 and
58.5 Å at 35 and 50 °C, respectively. The WAXD pattern, on the
other hand, exhibits wide diffuse scattering in the range ~0.18–
0.35 Å−1, characteristic for phospholipid liquid-like carbon chains
(Fig. 5). This indicates that the peptide has a better interaction with
the membrane in liquid crystalline resulting in structural changes
due to charge screening of both DMPC/DMPG membrane and
LFcin17-30. Cooling down the mixture, we identiﬁed two distinct
Fig. 5. SAXD (a) and WAXD (b) patterns for a peptide/lipid mixture of LFcin17-30 and DMPC/DMPG (3:1) for P:L=1:8 (mol/mol), at selected temperatures. The lipid concentration
was 12 mM.
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repeat distances dA=70.9 Å and dB=65.7 Å at 10 °C, an indication
that the cooling process leads to a non-homogeneous distribution of
the components in the system.
The other two peptides of the lactoferrin family show a more dis-
ruptive behavior against the DMPC/DPMG (3:1) membrane. Our
previously published X-ray diffraction study on the system with
LFampin265-284 and DMPC/DMPG (3:1) revealed the membrane dis-
integration through a micellar cubic phase of space group Pm3n [36].
By performing SAXD measurements at increasing temperatures we
observed that the cubic phase Pm3n occurs in a temperature range
where the pure DMPC/DMPG (3:1) mixture was still in the gel state.
Fig. 6 shows SAX diffractograms of mixtures of LFampin265-284
with DMPC/DMPG (3:1) at two P:L molar ratios (1:8 and 1:5) and se-
lected temperatures. At both P:L ratios and ~20 °C we observe a cubicFig. 6. SAX diffractograms for mixtures of LFampin265-284 with DMPC/DMPG (3:1) at
different temperatures and P:L molar ratios: (a) and (b): P:L=1:8; (c) and (d): P:L=
1:5. Intensities are plotted in logarithmic scale.phase of Pm3n space group (Fig. 6a, c). The lattice parameters depend
on P:L ratio, as the value obtained for a P:L ratio 1:5 was a=129.0±
0.1 Å, whereas for 1:8 we obtained a=119.4±0.1 Å, determined as
described in the Materials and methods section. The unit cell dimen-
sion of Pm3n cubic phase was also found to be dependent on temper-
ature, with the cell dimension slightly decreasing as the temperature
increased. The Pm3n phase is usually observed at high water content
and is supposed to consist of discrete micelles of amphiphiles ar-
ranged on a cubic lattice and separated by a continuous ﬁlm of water.
The phase transition accompanying the disappearance of the cubic
phase involves massive structural changes in the mixture, which in
SAX is reﬂected in a broad, not well resolved peak [36]. At higher tem-
peratures, we detected a lamellar Lα phase. The onset of the Lα phase
was found to depend on P:L molar ratio — for P:L=1:8 it was ob-
served at ~29 °C, whereas for P:L=1:5 the Lα phase was not detected
until ~60 °C. Bellow this temperature, diffractograms show 2–3 peaks
above a broad background as (Fig. 6), probably due to scattering
on partly ordered intermediated structures in the process of cubic
phase disappearance.
LFchimera was identiﬁed as the peptide with much stronger dis-
ruptive effect on the model membrane, as revealed by the DSC results
(Section 3.1, Fig. 2c and Table 3).
We examined its effect on the DMPC/DMPG (3:1) membrane at
several P:L molar ratios. At low molar ratio (P:L=1:38) the peptide
does not disrupt the membrane, but in the temperature range of
15–40 °C we observe a lamellar phase with periodicities 64.2 and
56.3 Å at 20 and 40 °C, respectively (not shown). This shows
that although the peptide initially interacts with unilamellar or
oligolamellar vesicles at low P:L ratio it has the ability to build a
multilamellar structure. At the same temperatures, we found
dDMPC=66.5 and 62.0 Å, where dDMPC is the repeat distance of
DMPC bilayer stacking. The observed lower spacing (~6 Å) at 40 °C
indicates that either the peptide mediates a closer approach between
two opposite charged bilayers due to membrane/AMP charge com-
pensation or the thickness of the membrane itself is reduced after
AMP intercalation. As we increase P:L ratio, SAX diffractograms al-
ready detected changes in the lamellar organization, but at tempera-
tures below Tm and for P:L=1:30 we only observe a not well resolved
phase of higher symmetry (not shown), that becomes better deﬁned
Fig 7. SAX diffractograms of a heating scan between 15 and 40 °C for LFchimera and
DMPC/DMPG (3:1) at a P:L ratio 1:21.
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compatibility with the ﬂuid phase, as expected. Increasing the
LFchimera content to molar ratio P:L=1:21, the membrane was
disrupted and SAXD clearly conﬁrmed the presence of non-lamellar
phase(s) (Figs. 7 and 8). In Fig. 7 we show diffractograms of a heating
scan between 15 and 40 °C for this peptide with DMPC/DMPG (3:1)
at this later P:L ratio, where the peaks corresponding to a phase or
phases of higher symmetry are clearly seen.
Two representative diffractograms at 24 and 30 °C with respective
peak assignment are presented in Fig. 8. At low temperature, the
deconvolution of the diffraction pattern revealed the coexistence ofFig. 8. SAXD patterns for a peptide/lipid mixture of LFchimera and DMPC/DMPG (3:1) for
P:L=1:21 (mol/mol), at selected temperatures, 30 and 24 °C. Insert: a plot of s (Å−1) vs.
√(h2+k2+ l2) for all observed reﬂections at 24 °C.two cubic phases with reﬂections compatible with Pn3m and Im3m
space groups. The lattice parameters aPn3m=107.9±0.3 Å and
aIm3m=155.6±0.9 Å at 24 °C were determined as described in the
Material andmethods section, with R2=0.9999 and 0.9997, respective-
ly. The ratio of the unit cell parameters for the two cubic phases is aIm3m/
aPn3m ~1.4. On increasing temperature above ~25 °C both cubic phases
vanish and we observe two diffuse peaks with intensities decreasing
with temperature, and ﬁnally merging in the background (Figs. 7
and 8). Concurrently a lamellar phase is detected, with periodicity
d~56.5–54.9 Å in the range of 27–40 °C, thus decreasing as the temper-
ature increases.
4. Discussion
The determination of the structure of AMPs upon interaction with
membranes, together with the characterization of the changes ob-
served in the membrane structure as a result of this interaction, can
help to unravel the antimicrobial peptide's mechanism of action. In
the present study we address these two aspects through DSC, CD
and SAXD studies on model membranes, and compare themwith pre-
vious results of their effects on C. albicans (Table 1) [37,38]. The struc-
tural characterization derived from SAXD using model membranes
and from freeze-fracture with C. albicans allows a comparison of re-
sults derived from two widely different approaches, namely with
model and pathogen membranes.
The designed lactoferrin chimera and its constituent peptides
presented high candidacidal activity, as can be seen by the low values
of LC50 previously obtained [37,38] and provided in Table 1. Freeze-
fracture electron microscopy of the yeast showed that the peptides in-
duce different levels of membrane damage [37,38]. All peptides clearly
affected the membrane morphology of C. albicans, albeit differently
(Table 1). LFcin17-30 had theweakest effect on themembrane, altering
signiﬁcantly the distribution of the intra-membranous particles (IMP)
as compared to control, into IMP-free and IMP-dense areas, suggesting
possible IMP aggregation and/or lipid segregation (Table 1, b).
LFampin265–284 had a much stronger effect, indicating substantial
weakening of the cytoplasmic membrane, as evidenced by the appear-
ance of disruptions into vesicle-like structures (Table 1, c). Finally
LFchimera severely destroyed the membrane (Table 1, d).
Our DSC results showed that LFcin17-30 and LFampin265-284 do
not interact with the model membranes formed from zwitterionic
DMPC, whereas LFchimera does. Measurements performed with
DPPC liposomes and LFampin265-284 [48] as well as with similar
peptides, LFcin17-41 [49], LFcin17-31 [21] and LFampin268-284
[17] also show that the thermotropic proﬁle of the liposomes is not
affected by the presence of the peptides, up to a P:L ratio of 1:10.
All these results indicate that LFcin and LFampin peptides do not sig-
niﬁcantly alter the structural organization of bilayers of zwitterionic
lipids. It is interesting to note that LFchimera is the result of a special
link between LFcin17-30 and LFampin265-284 through an additional
lysine [16], and it shows signiﬁcant interaction with DMPC liposomes,
at odds with the constituent peptides. This synergism has been ob-
served for this peptide [16,18,37,50,51], and probably reﬂects its
very high charge (+12), that along with its amphipatic structure
leads to the partition to zwitterionic membranes. In line with the crit-
ical importance of charge in AMP/membrane interaction, a strong
correlation was recently found between the net positive charge of
peptides and their capacity to induce anionic lipid clustering, which
was found to be independent of their secondary structure [52]. Over-
all, the obtained results of the interaction of these peptides with zwit-
terionic membranes are in agreement with the non-hemolytic
behavior of LFcin17-30 and LFampin265-284, and the mild hemolytic
character of LFchimera [51,53,54].
All three peptides change their secondary structure upon interaction
with the membranes, as long as the membrane has signiﬁcant negative
charge (25% in our case), as shown by the CD results. Only in the case of
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membranes is observed, in line with the DSC results. Again this effect
might follow from a high charge and amphipaticity, with a mixture of
secondary structures that would maximize the electrostatic and hydro-
phobic interactions.
In the present work we observed the predominance of α-helix
structure upon interaction with DMPC/DMPG membranes for
LFampin265-284 and LFchimera. The presence of signiﬁcant amounts
of α-helix was also found for LFampin268-284 [17] and LFampin265-
284 [18,48] in the presence of SDSmicelles. Strøm et al. [55] have stud-
ied LFcin17-31, and they obtained a percentage of helicity of only 4% for
this peptide in contactwith SDS, indicating that in the presence of purely
negative micelles this peptide does hardly adopts a helical structure.
Haney et al. [18] have studied these three peptides, LFcin17-30,
LFampin265-284 and LFchimera by a variety of techniques, but their
CD results are also obtained in the presence of SDS micelles. Again,
they found that for LFcin17-30 the intensity of the negative peaks char-
acteristic of α-helix structure is fairly weak, whereas for LFampin265-
284 and LFchimera strong negative minima are present. These results
are in linewith the ones reported here for DMPC/DMPG (3:1) liposomes,
as well as with our previous results in the presence of DMPG [16].
The biological importance of cubic phases was addressed in the
seminal work of Luzatti and collaborators [32]. In recent years, Lohner
et al. addressed this issue by X-ray scattering in the context of AMPs
[12], and the presence of cubic phases upon AMP interaction is now
documented both with simple model membranes [19,36,56] as well
as with lipid extracts from pathogenic agents [26,27]. Further, their
importance has been stressed in recent reviews [1,23,28]. The induc-
tion of cubic phases by AMPs, mostly by lowering the lamellar to
non-lamellar phase boundary of lipid membranes, could indicate
that the peptides act by promoting an extensive bilayer curvature,
leading eventually to either the formation of pores, mainly of the to-
roidal type [28] or even to membrane disruption (micellization). The
formation of non-lamellar phases could also alter lipid domains in the
cellular membrane that are important for many biological processes
such endocytosis, or even the activity of membrane proteins that
most of the time depend on these domains, culminating into impair-
ment of the membrane function [33,34]. Most reported work so far
points to the induction of cubic phases, mostly of Pn3m and Im3m
symmetry, as we have found for LFchimera. In the present report it
was very interesting to ﬁnd that three peptides from the same family,
lactoferrin, have quite different effects on membranes of the same
composition. LFcin17-30 only induces segregation of the lipid moiety,
and leads to the formation of two lamellar phases in the gel phase, on
cooling, with repeat distances dA=70.9 Å and dB=65.7 Å at 10 °C. At
this temperature, neutral DMPC itself forms a gel lamellar phase with
the repeat distance of ~60.1 Å. This value is comparable with the pe-
riodicity of LB phase dB=65.7 Å indicating thus the domain with less
AMP. Lowering the temperature beyond Tm may affect differently the
mobility of individual membrane's components, which together with
the tendency for effective charge compensation results in a segrega-
tion of the membrane components. For systems polyelectrolyte–cat-
ionic membrane it was suggested that the presence of negatively
charged DNA between bilayers can induce a partial lateral segregation
of cationic surfactants to minimize the electrostatic energy of the
whole system, i.e., lateral “demixing” in the plane of the bilayer can
occur [57]. It has been proven experimentally that the polyelectrolyte-
bound population is enriched with oppositely charged lipid, while the
polyelectrolyte-free lipid population is correspondingly depleted
[58,59]. These observations correlate very well with the membrane
lipid segregation observed by freeze-fracture, and consequent protein
reorganization.
LFcin17-30 was found to be the peptide among the three studied
here with lowest membrane activity against C. albicans. It is indeed
remarkable that our SAX results indicate that for LFcin17-30, only a
segregation effect on the lipid mixture takes place, as revealed bythe appearance of two lamellar phases upon cooling, and the peptide
does not induce a cubic phase. This peptide's mild effect on the mem-
brane also agrees with previous reports of internal targets for LFcin
peptides [8–11], as well as with the slower kinetics observed against
Leishmania [50]. All these results lead us to propose that peptides that
only induce a mild membrane effect, like LFcin17-30, as observed by
SAXD (segregation) are likely to have internal targets as part of
their mode of action, as long as they are known to be active.
LFampin265-284 induces amicellar cubic phase of Pm3n type on the
model membranes of DMPC/DMPG, compatible with a detergent-like
action that would cause plasma membrane solubilization [36]. The
DSC results obtained for DMPC/DMPG (3:1) and LFampin265-284 at
high peptide contents (Fig. 3) allowed us to shed some light in the ob-
served lipid/peptide cubic organization for the mixture. Overall we
can see that a transition is still observed by DSC in a temperature
range where we already observe the presence of a cubic phase by
SAX. As it is known that the transition to cubic phase is a low energy
one, thus not easily detectable by DSC [60], the peaks observed must
be related to a transition between gel and liquid crystalline phases.
This transition is compatible with the peak we observe in WAX at
20 °C (not shown) indicative of the presence of gel phase. Further, it
can account for what we previously hypothesized [36], i.e., that not all
lipids are involved in the cubic phase and that the volume fraction of
non-lamellar phase depends on temperature and P:L ratio. Thus the re-
sults frombothmethods taken together show that the cubic phasemust
coexist with a lamellar phase, whose presence is reﬂected in SAX
diffractograms in the high background observed for both 1:5 and 1:8
P:L mixtures. Further, by DSC we see that above 30 °C the mixture is
completely in liquid crystalline state, which is compatible with the ob-
served peaks of an organized lamellar phase whose onset we see by
SAX at 29 °C [36] for the 1:8mixture. For themixturewith high peptide
content (1:5) the lamellar phase only appears at high temperature,
probably because the volume fraction involved in the cubic phase is
higher at this peptide content.
As mentioned before in the results' section, two peaks are clearly
seen in DSC, thus the mixture is not homogeneous. The ﬁrst appears
at a temperature lower than Tm of the pure lipid mixture, leading to
the onset of gel to liquid crystalline transition at ~22.6 °C. This de-
creased stability should facilitate the transition to a cubic arrange-
ment, and in fact we could see by SAXD that for the mixture 1:8 the
onset of cubic phase appearance could be observed already at
~22 °C. The DSC tracing also shows a very broad transition (between
~20 and 32 °C), in a temperature range that coincides with the
presence of cubic phase. Thus from ~20 °C there is a fraction of the
peptide/lipid membrane that starts to have a transition to liquid crys-
talline state and subsequently can undergo a transition to cubic phase
in this temperature range, whereas the remaining fraction is still in
the gel phase until ~26 °C. This last fraction shows a very broad,
non-cooperative transition that could be responsible for the observed
high background in the diffractograms in this temperature range. At
temperatures above the disappearance of the cubic phase a massive
system reorganization takes place, as pointed out before [36]. The ob-
servation of Lα at high temperatures can seem surprising, as micellar
phase Pm3n is commonly known to change either to a micellar solu-
tion or to a hexagonal phase. It must be stressed that we do not sug-
gest that the origin of the Lα phase at high temperature is a transition
from the cubic Pm3n phase. As the temperature is raised, the cubic
phase vanishes and a redistribution of charged AMP induces massive
structural changes. Further, as we suggested earlier [36] and our DSC
results here conﬁrm, part of the lipid mixture is not involved in the
cubic phase. We found a repeat distance d=65.9 Å of Lα phase at
50 °C (P:L=1:8), and DMPC multilamellar vesicles show at this tem-
perature a repeat distance of 60.7 Å. The higher spacing observed as
compared to pure DMPC can be accounted for either to the presence
of the peptide between the lipid bilayers or as due to a residual charge
imbalance in the system.
1338 T. Silva et al. / Biochimica et Biophysica Acta 1828 (2013) 1329–1339It is worth noting that the micellization that we could retrieve by
SAXD, aside from being the ﬁrst reported micellar cubic phase in the
context of antimicrobial/peptide membrane interactions, is a result
that parallels the ﬁndings by freeze-fracture for LFampin265-284
when in contactwith C. albicans, showing again a remarkable agreement
between the results with model and actual pathogens' membranes.
SAXD results for LFchimera show the presence of cubic phase, and
for the P:L ratio 1:21 the coexistence of two cubic phases (Pn3m and
Im3m) was clearly resolved. The ratio obtained of the unit cell param-
eters for the two cubic phases was aIm3m/aPn3m ~1.4, showing a signif-
icant deviation from the ideal Bonnet relation 1.28, for coexisting
cubic phases related to the minimal surfaces for a system in thermo-
dynamic equilibrium [61,62]. For AMPs/model membranes, epitaxial
relationships between coexisting cubic phases and hexagonal or
lamellar phases were reported previously [19,23,26,27,63]. The tran-
sitions from liquid crystalline lamellar to cubic phase as well as with-
in different cubic phases occur in a narrow range, and coexistence of
phases has been reported, as well as hysteresis. Therefore the system
might not have been able to reach thermodynamic equilibrium, and
that could justify the deviation of the ratio of lattice parameters
from the ideal Bonnet relation. Further, the Bonnet transformation
is derived from a mathematical treatment of coexisting inﬁnite
minimal surfaces (IMS), and relates the primitive and diamond (and
gyroid) surfaces via intermediate self-interacting minimal surfaces,
and real systems can deviate from this theoretical prediction, either
because they do not conform to it or because the system is not at
equilibrium [63]. As the temperature increases above the range of
cubic phase stability the lipid network is disrupted. Some released
lipid/AMP fragments can initially keep some symmetry in their orga-
nization, which in SAXD is observed as two diffuse peaks. With
heating, their volume fraction in the sample decreases as documented
by the observed decrease in the intensity of the diffuse peaks, while
simultaneously we observe the increase in the intensity of peaks re-
lated to a lamellar phase. The released lipid or lipid/AMP fragments
are reorganized into the lamellar phase to decrease the free energy
of the whole system. The retrieved periodicity of the lamellar phase
(d~54.9 Å at 40 °C) is smaller than for DMPC membrane at the
same temperature (dDMPC~62.0 Å), and closer to the periodicity
(d~56.3 Å at 40 °C) derived from our system at low P:L molar ratio
where DMPC/DMPG membrane was not disrupted (P:L=1:38). At
molar ratio P:L=1:30 SAXD detected the membrane disruption by
LFchimera (see Results section). Thus our experiments indicate the
value ~1:34(±4) as a critical for the DMPC/DMPG (3:1) membrane
disruption by LFchimera.
Finally we would like to point out that the formation of two cubic
phases, of symmetry Pn3m and Im3m, would lead to total membrane
disruption, in a way that parallels what was observed by freeze-
fracture. It should be noted that Bolscher et al. [37] refer the presence
of some vesicular structures as observed in freeze-fracture experi-
ments also in the case of LFchimera, together with a massive mem-
brane disruption. This peptide is very complex, both due to its
extremely high positive charge as well as to its unusual link of con-
stituent peptides through a lysine side chain. In our SAXD experi-
ments with the simple model system of DMPC/DMPG (3:1) we
could only assign the presence of two cubic phases, Pn3m and
Im3m. Nevertheless, the possibility of other structures to be formed
upon interaction with the more complex membrane of C. albicans
cannot be discarded.
Thus, overall we could ﬁnd a remarkable match between the effect
of these peptides on C. albicans membrane as observed by freeze-
fracture and the structural features they revealed in a simple model
membrane system particularly suited to mimic C. albicans (known
to have a signiﬁcant PC content). This has several important conse-
quences: i) it indicates that structural studies involving simple
model membranes can provide very important information as regard-
ing different modes of action of AMPs; and ii) the conclusions that canbe drawn are indeed much more sound when accompanied by mea-
surements involving real pathogens.
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Fig. 1. DSC curves for DMPC and DMPC/peptide mixtures of varying
composition. The lipid concentration was 3.0 ± 0.3 mM in all experi-
ments. (a) LFcin17–30; (b) LFampin265–284; (c) LFchimera. Pure lipid
(solid black); P:L = 1:196 (solid red); P:L = 1:129 (solid green); P:
L = 1:96 (dash blue); P:L = 1:46 (dash pink); P:L = 1:29 (dash
yellow). Maximal P:L molar ratio used was 1:46 for LFchimera.
Fig. 2. DSC curves for DMPC/DMPG (3:1) and DMPC/DMPG (3:1)/
peptide mixtures of varying composition. The lipid concentration was
3.0 ± 0.3 mM in all experiments. (a) LFcin17–30; (b) LFampin265–
284; (c) LFchimera. Pure lipid (solid black); P:L = 1:196 (solid red);
P:L = 1:129 (solid green); P:L = 1:96 (dash blue); P:L = 1:46 (dash
pink); P:L = 1:29 (dash yellow). Maximal P:L molar ratio used was
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http://dx.doi.org/10.1016/j.bbamem.2013.03.018LFampin 265–284 mixtures at high P:L ratios. The lipid concentration
was 6.0 ± 0.3 mM in all experiments. Pure lipid (solid blue); P:L =
1:12 (solid red); P:L = 1:8 (solid green); P:L = 1:3 (solid magenta).
The dashed (low temperature peak) and dotted (high temperature
peak) lines represent the deconvoluted curves for each P:L ratio.
Fig. 4. CD spectra of (a) LFcin17–30, (b) LFampin265–284 and
(c) LFchimera at 35 °C in: buffer (peptide concentration 36 μM)
(black); DMPC 6 mM (red); and DMPC/DMPG (3:1) 3 mM (green).
P:L ratio in peptide/LUV mixtures was 1:167.
Fig. 5. SAXD (a) and WAXD (b) patterns for a peptide/lipid mix-
ture of LFcin17–30 and DMPC/DMPG (3:1) for P:L = 1:8 (mol/mol),
at selected temperatures. In blue the diffractograms from the heating,
and in black from the cooling scans. The lipid concentration was
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Mycobacterium avium causes respiratory disease in susceptible individuals, as well as disseminated infections in immunocom-
promised hosts, being an important cause of morbidity andmortality among these populations. Current therapies consist of a
combination of antibiotics taken for at least 6 months, with nomore than 60% overall clinical success. Furthermore, mycobacte-
rial antibiotic resistance is increasing worldwide, urging the need to develop novel classes of antimicrobial drugs. One potential
and interesting alternative strategy is the use of antimicrobial peptides (AMP). These are present in almost all living organisms
as part of their immune system, acting as a first barrier against invading pathogens. In this context, we investigated the effect of
several lactoferrin-derived AMP againstM. avium. Short peptide sequences from both human and bovine lactoferricins, namely,
hLFcin1-11 and LFcin17-30, as well as variants obtained by specific amino acid substitutions, were evaluated. All tested peptides
significantly inhibited the axenic growth ofM. avium, the bovine peptides being more active than the human. Arginine residues
were found to be crucial for the display of antimycobacterial activity, whereas the all-D-amino-acid analogue of the bovine se-
quence displayed the highest mycobactericidal activity. These findings reveal the promising potential of lactoferricins against
mycobacteria, thus opening the way for further research on their development and use as a new weapon against mycobacterial
infections.
The genus Mycobacterium includes several species capable ofcausing disease in humans and other animals. Mycobacterium
tuberculosis is one of the most deadly human pathogens, killing 1
million to 2 million people every year (1), while Mycobacterium
avium and Mycobacterium intracellulare are frequent opportunis-
tic pathogens of immunosuppressed individuals and people with
chronic respiratory distress (2, 3). Equipped with a complex lipid-
rich cell envelope and adapted to proliferate inside the host’s mac-
rophages, mycobacteria tend to cause persistent infections, which
are difficult to cure, requiring long treatment regimens that rely
on the combination of several drugs. The increasing emergence of
drug-resistant strains of mycobacteria makes the treatment of
these diseases even more challenging (1).
The vast array of antimicrobial peptides (AMP) produced by
virtually all living organisms as natural barriers against infection is
a new and promising source of potential antimicrobial weapons.
Although they have little sequence homology, the vast majority of
AMP contain a high proportion of hydrophobic and cationic
amino acids, and when in contact with bacterial membranes, they
adopt amphipathic structures (4). The fact that AMP are active
against a wide variety of microorganisms, combined with the ob-
servation that both the L and D enantiomers are active, supports
the notion that the target of these peptides is a general structure
conserved across different bacterial species, such as the cytoplas-
mic membrane (5, 6). Thus, it is thought that electrostatic attrac-
tion is responsible for the initial approach between the cationic
peptide and the negatively charged phospholipids usually present
at the pathogen’s surface (4). Downstream events that lead to bac-
terial killing are not yet fully understood (4, 6). Acting in such a
fundamental and conserved biological target as the bacterial
membrane, AMP are believed to be less prone to the development
of secondary microbial resistance than other types of antibiotics
(4, 7). Therefore, a deeper understanding of the mechanisms of
action of AMP, along with the establishment of structure-activity
relationships, is an essential step toward the identification and
development of more active molecules with improved therapeutic
characteristics and possibly higher specificity toward pathogens of
interest.
Lactoferricins are naturally occurring peptides, formed by the
cleavage of the highly cationic N1 terminal domain of the iron-
binding protein lactoferrin. Bovine lactoferricin is composed by
25 amino acids, corresponding to residues 17 to 41 in the native
protein (5, 8), and has broad-spectrum antimicrobial activity (5,
9–15). A shorter version of bovine lactoferricin containing amino
acids 17 to 30 (LFcin17-30) was found to have even higher anti-
microbial activity (16). A human peptide with the first 11 amino
acids from human lactoferrin (hLFcin1-11) was also demon-
strated to be active against a great variety of bacteria, including
antibiotic-resistant strains, and fungi, especially Candida albicans
(17–21), and was already used in different preclinical and clinical
trials, where its overall safety was proved (20, 22).
In the present work, we investigated the activity against M.
avium of hLFcin1-11 and LFcin17-30, as well as peptides obtained
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from these by specific amino acid substitutions, to test the im-
portance of various factors on the potency of AMP against that
pathogen.
MATERIALS AND METHODS
Peptides. Human lactoferricins (hLFcin1-11 and hLFcin1-11 all K) (Ta-
ble 1) were prepared as C-terminal amides by standard Fmoc/tBu [1-(9H-
fluoren-9-yl)-methoxycarbonyl)/tert-butyl chemistry] solid-phase pep-
tide synthesis on a Liberty1 microwave (MW) peptide synthesizer (CEM
Corporation, Mathews, NC, USA) (23). Briefly, Fmoc-Rink-amide resin
(NovaBiochem, Switzerland) was preswelled for 15 min in N,N-dimeth-
ylformamide (DMF) (VWR International, Portugal) and then transferred
into the MW reaction vessel. The initial Fmoc deprotection step was car-
ried out using 20% piperidine in DMF containing 0.1 M 1-hydroxyben-
zotriazole (HOBt) (Sigma-Aldrich, Germany) in two MW irradiation
pulses: 30 s at 24 W plus 3 min at 28 W, with the temperature in both cases
being no higher than 75°C. The Fmoc-protected C-terminal amino acid
(Bachem, Switzerland) was then coupled to the resin, using 5 molar equiv-
alents (eq) of the Fmoc-protected amino acid in DMF (0.2 M), 5 eq of 0.5
M N,N,N=,N=-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluo-
rophosphate/HOBt in DMF, and 10 eq of 2 M N-ethyl-N,N-diisopropyl-
amine (DIPEA) (Sigma-Aldrich, Germany) in N-methylpyrrolidone
(NMP) (VWR International, Portugal); the coupling step was carried out
for 5 min at 35-W MW irradiation, with a maximum temperature reach-
ing 75°C. The remaining amino acids were sequentially coupled in the
C¡ N direction by means of similar deprotection and coupling cycles,
except for incorporation of the following: (i) Fmoc-Arg(Pbf)-OH, whose
coupling was done in two steps, 25 min with no MW irradiation (room
temperature), followed by 5 min of coupling at 25 W, and (ii) Fmoc-
Cys(Trt)-OH and Fmoc-Trp(Boc)-OH, both also coupled in two steps,
first 2 min of coupling without MW irradiation (room temperature) and
then 4 min of coupling at 25 W, with the maximum temperature reaching
50°C. Following completion of sequence assembly, the peptides were re-
leased from the resin with the concomitant removal of side chain protect-
ing groups, by a 3-h acidolysis at room temperature using a trifluoroacetic
acid (TFA) (VWR International, Portugal)-based cocktail containing tri-
isopropylsilane (TIS) (Sigma-Aldrich, Germany) and water as scavengers
(TFA-TIS-H2O, 95:2.5:2.5 [vol/vol/vol]). Crude products were purified
by reverse-phase (RP) liquid chromatography on a Vydac C18 column
(238TPB1520; Vydac, Hesperia, CA, USA) to a purity of at least 95%, as
confirmed by high-performance liquid chromatography (HPLC) analysis
on a Hitachi-Merck LaChrom Elite system equipped with a quaternary
pump, a thermostated (Peltier effect)-automated sampler, and a diode-
array detector (DAD). Pure peptides were quantified by UV absorption
spectroscopy (Helios Gama, Spectronic Unicam), and their molecular
weights were confirmed to be as expected by electrospray ionization/
ion trap mass spectroscopy (ESI/IT MS) (LCQ-DecaXP LC-MS sys-
tem; ThermoFinnigan).
Bovine lactoferricins (LFcin17-30, D-LFcin17-30, LFcin17-30 all R,
and LFcin17-30 all K) (Table 1) were synthesized by solid-phase peptide
synthesis using Fmoc-protected amino acids (Orpegen Pharma GmbH,
Heidelberg, Germany) in a Syro II synthesizer (Biotage, Uppsala, Sweden)
as described previously (24). Peptides were purified to a purity of at least
95% by semipreparative RP-HPLC (Jasco Corporation Tokyo, Japan) on
a Vydac C18 column (218MS510; Vydac, Hesperia, CA, USA), and the
authenticity of the peptides was confirmed by matrix-assisted laser de-
sorption ionization–time of flight (MALDI-TOF) mass spectrometry on a
Microflex LRF mass spectrometer equipped with an additional gridless
reflectron (Bruker Daltonik, Bremen, Germany) as described previously
(25).
All purified peptides were freeze-dried, after which peptide stock so-
lutions were prepared in phosphate-buffered saline (PBS) (pH 7.4) and
stored at20°C until use.
Bacteria. The strains of Mycobacterium avium used in this study were
clinical isolates. Strain 2447 smooth transparent variant (SmT) was pro-
vided by F. Portaels (Institute of Tropical Medicine, Antwerp, Belgium);
strains 2-151, either SmT or SmD (smooth-domed), was provided by J.
Belisle (Colorado State University, Fort Collins, CO, USA).
Mycobacteria were grown to mid-log phase in Middlebrook 7H9 me-
dium (Difco, Sparks, MD) containing 0.05% of Tween 80 (Sigma, St.
Louis, MO) and 10% of ADC supplement (albumin-dextrose-catalase) at
37°C. Bacteria were harvested by centrifugation, washed twice with saline
containing 0.05% Tween 80, resuspended in the same solution, and briefly
sonicated in order to disrupt bacterial clumps. The suspension was stored
in aliquots at 80°C until use. Just before use, an aliquot was quickly
thawed and diluted to the appropriate concentration.
Effect of antimicrobial peptides on the viability of M. avium in ax-
enic cultures. M. avium was grown in Middlebrook 7H9 medium to ex-
ponential phase (bacterial growth was monitored by measuring the opti-
cal density at 600 nm). Bacteria were seeded at 106 CFU per well into
96-well flat bottom plates and incubated with the peptides in a final vol-
ume of 200 l. Each condition was tested in triplicate. The plates were
incubated at 37°C in a humid atmosphere. After 1, 2, 4, or 7 days of
incubation, bacterial viability was measured by a CFU assay. A bacterial
suspension from each well was serially diluted in water containing 0.05%
Tween 80. The dilutions were plated in Middlebrook 7H10 agar medium
(Difco, Sparks, MD) and supplemented with OADC (oleic acid-albumin-
dextrose-catalase), and the colonies were counted after 7 days at 37°C. The
TABLE 1 Antimicrobial activities of lactoferricin peptides against Mycobacterium avium
Peptide Amino acid sequence Mol wta Chargeb
Activity (M) (mean SD) against M. avium strainc
2447 SmT 2-151 SmT 2-151 SmD
IC50 IC90 IC50 IC90 IC50 IC90
hLFcin1-11 GRRRRSVQWCA 1,374 5 15.8 4.5 34.6 22.4 11.0 4.1 65.8 19.3 15.2 2.9 37.9 15.9
hLFcin1-11 all K GKKKKSVQWCA 1,262 5 39.1 6.9d
LFcin17-30 FKCRRWQWRMKKLG 1,923 6 14.2 1.5 18.9 4.0 8.0 1.5 22.8 9.1 12.4 0.3 21.5 4.0
D-LFcin17-30 FKCRRWQWRMKKLG 1,923 6 10.7 0.9e 14.4 1.9
LFcin17-30 all K FKCKKWQWKMKKLG 1,839 6 18.0 2.1e,f,g 34.4 8.2e,f
LFcin17-30 all R FRCRRWQWRMRRLG 2,007 6 10.8 1.6e 19.3 4.8
a Molecular weight.
b Calculated overall charge at pH 7.0.
c Each value represents the average for at least three independent experiments, with the corresponding SD indicated. IC50 is the peptide concentration that inhibits 50% of
mycobacterial viability at 7 days of incubation. IC90 is the peptide concentration that inhibits 90% of mycobacterial viability at 7 days of incubation.
d P 0.0001 (compared to results for the parental peptide, hLFcin1-11).
e P 0.05 (compared to results for the parental peptide, LFcin17-30).
f P 0.05 (compared to results for LFcin17-30 all R, by cross-comparison within the bovine peptides).
g P 0.0001 (compared to results for hLFcin1-11 all K, by cross-comparison within all peptides).
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difference, in terms of log10 CFU/ml, between the first and the last days of
incubation was designated “log increase.”
IC50 and IC90 (peptide concentration that inhibits 50% or 90% of
mycobacterial growth after 7 days of incubation) values were obtained by
fitting CFU data through a four-parameter dose-response sigmoidal curve
using the GraphPad Prism software program (GraphPad Software Inc., La
Jolla, CA). The reported final values correspond to the average of at least
three independent experiments, with the corresponding standard devia-
tion (SD) indicated.
Statistical analysis was performed with GraphPad Prism software us-
ing one-way analysis of variance (ANOVA) with adjustment for multiple
comparisons in two ways: (i) comparing each value to a control (the
corresponding parental peptide) and (ii) performing cross-comparisons
among all peptides (within each family). The statistical significance, ad-
justed P value, and confidence intervals were obtained through the Bon-
ferroni method for a chosen 95% significance.
SEM.M. avium 2447 SmT was grown in Middlebrook 7H9 medium to
exponential phase. Approximately 106 CFU of bacteria were incubated
with the peptides (25 M) for 2 days at 37°C. After incubation, cytospin
centrifugation (1,000 rpm, 2 min) (Cytospin 4; Thermo Scientific) was
used to concentrate the bacteria in glass coverslips previously coated with
APES (3-aminopropyltriethoxysilane) to promote bacterial adherence.
Bacteria were fixed with 2.5% glutaraldehyde solution in 0.1 M sodium
cacodylate buffer (supplemented with 5 mM MgCl2 and 5 mM CaCl2;
pH  7.2) for 2 h, followed by postfixation with 1% osmium tetroxide
(OsO4) in 0.1 M sodium cacodylate buffer (1 h). Bacteria were then de-
hydrated by successive incubations with increasing concentrations of eth-
anol (10 to 100%), dried in a critical point dryer (CPD7501; Polaron), and
sputter coated with a gold/palladium thin film (50 s with a 15-mA current)
using SPI Module sputter coater equipment. The scanning electron mi-
croscopy (SEM) exam was performed using a high-resolution (Schottky)
environmental scanning electron microscope with X-ray microanalysis
and electron backscattered diffraction analysis: Quanta 400 FEG ESEM/
EDAX Genesis X4M.
TEM. A suspension of M. avium 2447 SmT in exponential growth
phase was incubated with the peptides (25 M) for 2 days at 37°C. Bacte-
ria were fixed with a 4% formaldehyde and 1.25% glutaraldehyde solution
in 0.1 M sodium cacodylate buffer (supplemented with 5 mM MgCl2 and
5 mM CaCl2; pH 7.2) overnight at 4°C (first 3 h at room temperature),
followed by postfixation with 1% osmium tetroxide (OsO4) in 0.1 M
sodium cacodylate buffer (1 h) and 1% uranyl acetate in water (30 min),
gradually dehydrated in ethanol (25 to 100%), included with propylene
oxide, and embedded in Epon resin (26, 27). Ultrathin sections were
stained with lead citrate and uranyl citrate for 15 min each, and the sam-
ples were observed and photographed in a Jeol JEM-1400 transmission
electron microscope (TEM).
RESULTS
Antimycobacterial activity of lactoferricin peptides. Human
and bovine lactoferricin peptides (hLFcin1-11 and LFcin17-30)
were evaluated for their antimicrobial activities against three dif-
ferent strains of M. avium (2-151 SmT, 2447 SmT, and 2-151
SmD) (28). Both peptides were active against the three strains in
axenic cultures, with an IC50 of 15 M (Table 1). The bovine
peptide tended to be more active than the human one, exhibiting
lower IC90 values for all M. avium strains. The activities of each
peptide were similar between the M. avium strains (Table 1).
Arginine residues were reported to be critical for the antimi-
crobial activity of lactoferricins (5, 8, 29). hLFcin1-11 has four
arginine residues, and LFcin17-30 has three (Table 1). In order to
investigate whether these residues were important for the display
of antimycobacterial activity, we synthesized and tested lactoferri-
cin analogues in which arginine residues were replaced by lysine
(all-K variants). Lysine was chosen because it has the same charge
as arginine, and hence any differences in activity would not be
attributable to the alteration of overall positive charge. Since bo-
vine LFcin17-30 has three lysine residues, we also tested a variant
of this peptide in which all lysines were replaced by arginines
(all-R variant).
When tested against M. avium 2447 SmT in axenic culture, the
all-K variants of each peptide were significantly less active than the
corresponding original peptide (Table 1) (P 0.0001 for IC50 for
human peptides; P 0.0329 for IC50 and P 0.0074 for IC90 for
bovine peptides). Conversely, the all-R variant of LFcin17-30 was
slightly more active than the original peptide (Table 1) (for IC50,
P 0.0377). Of note, even in the all-K variants, the bovine peptide
exhibited a stronger antimicrobial activity than the human pep-
tide (P 0.0001) (Table 1).
Given that one of the limitations of therapeutic applications of
peptides is their sensitivity to proteolysis, we thought it would be
interesting to know whether replacement of all native amino acids
in LFcin17-30 by their D enantiomers (less prone to degradation)
would preserve the peptide’s activity against M. avium. Remark-
ably, the all-D LFcin17-30 sequence (D-LFcin17-30) was found to
be significantly more active than the corresponding native peptide
(Table 1) (for IC50, P 0.0455).
We observed in all cases an abrupt decrease in mycobacterial
viability at peptide concentrations around 12.5 M, which trans-
lated into very close values for IC50 and IC90 (Table 1). This sug-
gested that a critical concentration threshold may exist for the
peptides to exert their activity. To test this hypothesis, we assessed
the effect of the human and bovine parental peptides, hLFcin1-11
and LFcin17-30, on M. avium 2447 SmT using narrower concen-
tration intervals in the 12.5 to 25 M range. As shown in Fig. 1,
this experiment confirmed the existence of a threshold concentra-
tion and further showed that the dose-effect correlation is differ-
ent for the two peptides. For hLFcin1-11, there is a gradual de-
crease in the viability of M. avium as the peptide concentration
increases, whereas for LFcin17-30, there is a critical inhibitory
concentration above which the increase in the peptide concentra-
tion has no further effect on mycobacterial viability.
To assess in detail the time dependence of the action of lacto-
ferricin peptides against M. avium 2447 SmT, the antimicrobial
activity was determined by CFU at the end of 1, 2, and 4 days of
FIG 1 Direct effect of human and bovine lactoferricin onM. avium viability at
7 days of incubation. M. avium 2447 SmT was incubated with hLFcin1-11 or
LFcin17-30 at 0, 6.25, 12.5, 15, 17.5, 20, 22.5, 25, 50, and 100 M concentra-
tions. M. avium viability was determined by measuring CFU after 7 days of
incubation. Statistical analysis was performed using one-way ANOVA (Bon-
ferroni test): , P  0.001. The results of one experiment out of three are
shown.
Mycobactericidal Activity of Lactoferricin Peptides
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incubation. No significant effects were seen up to 1 day. All peptides
showed significant inhibitory activity after 2 days of incubation at
12.5 M (Fig. 2) and 25 M (not shown). For the most active pep-
tides (hLFcin1-11, LFcin17-30, D-LFcin17-30, and LFcin17-30 all R),
mycobacterial death was observed at 4 days (Fig. 2).
Similar to what was observed at 7 days of incubation, at shorter
times the bovine peptides tended to be more active than the hu-
man ones, and the peptides with arginines (human or bovine)
were more active than those with lysines.
Surface and ultrastructural alterations inM. avium induced
by lactoferricins. To gain a better understanding of the mecha-
nisms of antimicrobial action of lactoferricin peptides against M.
avium, we performed scanning electron microscopy (SEM) and
transmission electron microscopy (TEM) to identify surface and
ultrastructural alterations in the bacteria upon peptide treatment.
After 2 days of incubation with lactoferricins at 25M, SEM anal-
ysis of M. avium 2447 SmT revealed overall shape deformations
(Fig. 3, left panel, arrow), increased roughness of the bacterial
surface, and the accumulation of biological material outside the
cells (Fig. 3, left panel, arrowhead), this last suggesting leakage of
intracellular content. Ultrastructural alterations were also seen us-
ing TEM, namely, condensation of cytoplasmic dense material,
such as proteins (Fig. 3, right panel, empty arrow), once again with
the suggestion of leakage of intracellular material, indicated by
accumulation of material extracellularly (Fig. 3; right panel, ar-
rowhead), as well as translucent cytoplasm and a high number of
“ghost” cells (Fig. 3, right panel, asterisk). In agreement with the
previous results for activity, the bovine peptides induced more
severe structural alterations in the bacteria than the human ones,
especially D-LFcin17-30 and LFcin17-30 all R (Fig. 3).
DISCUSSION
Considering the potential of AMP as new alternative therapies to
fight infectious diseases and the urgent need to develop more ef-
ficient therapies for infections caused by mycobacteria, we tested
several lactoferricin peptides against Mycobacterium avium. Aside
from the antimicrobial activity, toxicity is a fundamental param-
eter in possible future use. hLFcin1-11 has already been used in
different preclinical and clinical trials, where its overall safety was
proved (20, 22), and LFcin17-30 has been shown to be nontoxic
for erythrocytes and rat hepatocytes up to a 50 M concentration
(30). In the present work, we found that both the human and
bovine lactoferricins (hLFcin1-11 and LFcin17-30, respectively)
were active against M. avium strains of different virulences, the
bovine peptide being more active than the human one.
AMP vary widely in many aspects, such as length, sequence,
structure, and source, but they share important common traits,
such as a positive charge, presumed to be fundamental for inter-
action with the negatively charged surface of pathogen cells (4, 6),
and amphipathicity, which enables better interaction with the hy-
drophobic part of the microbial membrane, leading to its disrup-
tion (31, 32). Arginine residues were previously suggested to be
important for the antimicrobial activity of lactoferricins (5, 8, 29)
and also to potentiate the internalization of peptides (33–35).
Therefore, we studied lactoferricin variants with arginines re-
placed by lysines and vice versa. As shown in Table 1 and Fig. 2, all
peptides, human and bovine, with all arginines replaced by lysines
were less active against M. avium, whereas when lysines were re-
placed by arginines, the peptides were more active. This shows
that arginine residues are crucial for the antimicrobial activity of
these peptides against M. avium. The contribution of arginine for
activity is probably not charge related, since it bears the same
charge as lysine (1). The higher activities of peptides with argi-
nine residues could be the result of the presence of the bulky gua-
nidinium group on the side chain, enabling a better interaction
with the membranes, since multiple hydrogen bonds can in this
case be formed with the lipid headgroups around, whereas lysines
can interact with only one (5, 8, 33, 35, 36). Arginine can also
establish stronger cation- interactions, which occur mainly be-
tween aromatic residues (e.g., tryptophan) and residues with pos-
itively charged side chains (e.g., arginines and lysines), that could
allow the peptides to penetrate deeper into the membrane (8, 33,
35, 36). Moreover, arginines can form hydrogen bonds while es-
tablishing cation- interactions, with tryptophan, for instance,
whereas lysines cannot (8, 33, 35, 36). All these factors combined
may have contributed to a more efficient activity against myco-
bacteria (5, 8, 29, 33, 36).
Due to the large diversity of AMP and of their properties, there
is most probably no universal mechanism for their action. In this
work, we have contributed to the elucidation of the mechanism of
action of lactoferricins againstM. avium. Our observation that the
D enantiomer of LFcin17-30 is more active than the L form sug-
gests that antimycobacterial activity is not dependent on chiral
centers, such as specific protein receptors, which is in agreement
with previous observations made for lactoferricin and other AMP,
such as magainin, cecropin, melittin, and protegrin, against other
pathogens (5, 6, 37–39). One of the major drawbacks of the use of
AMP in the clinic is their susceptibility to proteases and other
plasma components, resulting in low metabolic stability and bio-
availability (40). One way to overcome this problem is to use D
peptides, which are more resistant to protease activity (32, 41).
This seems to be the case for LFcin17-30, which exhibited a higher
activity against M. avium with all D-amino acids, indicating that
FIG 2 Direct effect of lactoferricins on M. avium viability at 1, 2, and 4 days of incubation. M. avium 2447 SmT was incubated with hLFcin1-11, hLFcin1-11 all
K, LFcin17-30, D-LFcin17-30, LFcin17-30 all K, or LFcin17-30 all R at 0 and 12.5M.M. avium viability was determined by measuring CFU after 1, 2, and 4 days
of incubation. The results of one experiment out of three are shown.
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this can be used advantageously in comparison to the L enan-
tiomer.
The concentration-effect curves obtained for the antimicrobial
activities of lactoferricins did not show a gradual decrease. Around
12.5 M, there was a sharp drop in mycobacterial viability, more
pronounced in the case of the bovine peptide, reflected in very
close values for IC50 and IC90. This observation is in line with some
models of AMP activity that predict the existence of a threshold
concentration for their antimicrobial activity (4).
M. avium is a slow-growing mycobacterium, and thus we used
7 days of culture to determine lactoferricin activity. However, pre-
vious reports showed that LFcin17-30 is able to exert antimicro-
bial activity against other pathogens in about 1 h (24, 42–44). In
order to evaluate the kinetics of the activity of lactoferricins
against M. avium, we performed several assays with shorter cul-
ture times. We did not observe any significant decrease in the
number of viable mycobacterial cells in less than 2 days of incu-
bation, with peptide concentrations up to 25 M (data not
shown). This “delay” in activity against M. avium compared to
that against other pathogens can be explained by the particular
characteristics of the mycobacterial cell wall, as well as an intrinsic
low rate of proliferation. Mycobacterium species are characterized
by a complex hydrophobic envelope of extremely low fluidity and
high impermeability, which contributes to the capacity of the
pathogen to survive inside the host and resist chemotherapy (45,
46). Furthermore, the possibility of an internal target for the action of
these peptides against M. avium cannot be discarded. In fact, there
are numerous evidences in the literature pointing to the probable
existence of an internal target for lactoferricins (5, 47–49).
Finally, electron microscopy studies showed that all lactoferri-
cin peptides tested induced significant changes both in the surface
and in the ultrastructural organization of the mycobacterial cells.
In agreement with the bacterial viability assays, D-LFcin17-30 and
the all-R variant showed the most drastic effects on the mycobac-
terial morphostructure. However, these studies did not allow us to
obtain definitive information on what is the target (or targets) of
the peptides. The observed accumulation of biological material
outside the cells, seen by both SEM and TEM, and the presence of
translucent cytoplasm and a high number of “ghost” cells (TEM)
indicate leakage and are compatible with cell membrane permea-
bilization. Clearer evidences that the peptides act by permeabili-
zation, such as the appearance of vesicular budding and disap-
pearance of the cell wall or membrane, were not observed. A
mechanism of action that includes crossing over the bacterial sur-
face and acting on internal targets has been proposed for bovine
lactoferricins. The higher activity of lactoferricins containing ar-
ginines also supports this hypothesis, since this amino acid is often
correlated with peptides that exert their activity on internal targets
(33–35), as opposed to lysines, which are usually described as cru-
FIG 3 Surface and ultrastructural alterations in M. avium induced by lacto-
ferricins at 2 days of incubation. M. avium 2447 SmT was incubated with
hLFcin1-11, hLFcin1-11 all K, LFcin17-30, D-LFcin17-30, LFcin17-30 all K, or
LFcin17-30 all R at 25M for 2 days. Cells were observed and photographed in
a scanning electron microscope (left panels) and in a transmission electron
microscope (right panels). Representative pictures are shown. Bar 1m (left
panels) or 0.5m (right panels). Symbols: arrow, shape deformations; arrow-
head, increased roughness and accumulation of intracellular material outside;
empty arrow, condensation of cytoplasmic material; asterisk, translucent cy-
toplasm and ghost cells.
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cial for membrane-lytic activities. In recent studies, we have
shown that LFcin17-30 has a mild effect on model membranes,
acting by lipid segregation instead of leading to full membrane
disruption, as observed for other membrane-active peptides (50).
Further, Haukland et al. (47) showed that lactoferricin is found in
the cytoplasm of Staphylococcus aureus and Escherichia coli, and
Ulvatne et al. (49) showed that it inhibits the macromolecular
synthesis (DNA, RNA, and protein synthesis) of E. coli and Bacil-
lus subtilis. The alterations seen suggest that the mechanism of
action of the studied lactoferricins against mycobacteria is not
confined to the cell wall or membrane but probably also includes
action on internal targets, leading to impairment of several intra-
cellular processes, such as DNA replication, DNA, RNA, and pro-
tein synthesis, protein folding, etc., which eventually culminates
in cell death.
In summary, key molecular features of lactoferricin-based
peptides for the display of antimycobacterial activity were identi-
fied, contributing to the understanding of their mechanism of
action against mycobacteria. Hence, this work demonstrates that
lactoferricin-related AMP are promising molecules for develop-
ment of clinically useful weapons to treat infections caused by
mycobacteria.
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Abstract  
The incidence of infections caused by nontuberculous mycobacteria (NTM) is increasing 
worldwide. Within this group, bacteria from the Mycobacterium avium complex (MAC) are 
the main cause of disease, especially disseminated disease in immunocompromised 
hosts (e.g. HIV-infected patients). Treatment of NTM is currently long, toxic, costly and 
usually extrapolated from the tuberculosis experience. Moreover, antibiotic resistance 
development is increasing, pressing the need for new antimicrobial alternatives. 
Antimicrobial peptides (AMP) are ubiquitous in nature and are active components of the 
host antimicrobial defence mechanisms.  
We have previously reported that a shorter version of bovine lactoferricin along with 
variants obtained by specific amino acid substitutions were active against Mycobacterium 
avium growing in broth culture. In the present work, those same peptides were tested 
against M. avium growing inside its host cells, macrophages. We found that only the D 
enantiomer of lactoferricin was active alone against mycobacteria, but all peptides were 
active when combined with the conventional antibiotic ethambutol. We then sought to 
understand the mechanisms behind mycobacterial death. For that, the distribution and 
sub-cellular localization of lactoferricins inside M. avium-infected macrophages were 
evaluated, as well as the peptides ability to modulate the macrophage’s antimicrobial 
mechanisms. We found that lactoferricins do not localize to M. avium-harbouring 
phagosomes and while they significantly induce the production of IL-6 and TNF by 
infected macrophages, this production does not explain the AMP anti-mycobacterial action.  
Further studies are needed to clarify lactoferricin’s mode of action. 
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Introduction 
Nontuberculous mycobacteria (NTM) include more than 150 species and are important 
causes of morbidity and mortality. NTM are ubiquitous in the environment, being present 
in soil and water. The incidence of NTM infections, predominantly caused by species of 
the Mycobacterium avium complex (MAC), is increasing worldwide, surpassing in some 
regions the number of infections caused by Mycobacterium tuberculosis (Cassidy et al. 
2009, Brode et al. 2014). Disseminated infections by NTM occur mainly in patients with a 
compromised immune system, such as HIV-infected patients, patients with cancer, organ 
or stem cell transplants, among others. Pulmonary disease can also occur, most 
frequently affecting patients with underlying lung disease such as chronic obstructive 
pulmonary disease or older women and also appearing as nosocomial infections after 
surgery (revised in (Weiss and Glassroth 2012, Orme and Ordway 2014, Henkle and 
Winthrop 2015)). Mycobacteria are equipped with a unique and complex highly 
impermeable cell wall, and as facultative intracellular pathogens are able to proliferate 
inside host cells, such as macrophages, resisting chemotherapy and causing persistent 
infections that are difficult to eradicate (Flannagan et al. 2009, Guenin-Mace et al. 2009). 
Treatment regimens are based on a combination of several drugs taken from months to 
years, and in general have limited efficacies (Brown-Elliott et al. 2012, Philley and Griffith 
2015). Furthermore, mycobacterial antibiotic resistance is increasing worldwide, urging 
the need to develop novel classes of antimicrobial drugs (Falzon et al. 2015). 
Antimicrobial peptides (AMP) are a large number of antimicrobial molecules widespread in 
nature as part of the host defence mechanisms, constituting potential new antimicrobial 
therapies (Yeung et al. 2011). Although their mode of action is still under debate, they are 
thought to act in a multiple hit strategy, which probably contributes to their high efficacy 
and large spectrum of activity. AMP can act directly on the pathogens, either by disrupting 
the membrane due to pore formation and/or micellization, or by acting on internal targets 
(Nguyen et al. 2011). They can also act by immunomodulation, being involved in several 
processes such as, modulation of pro- and anti-inflammatory responses, chemoattraction, 
cellular differentiation, angiogenesis and wound healing, enhanced bacterial clearance, 
autophagy and apoptosis, among others (Mansour et al. 2014). The nature of the 
peptide’s target, the cytoplasmic membrane, a conserved and essential structure across 
different species, together with the fact that both L and D enantiomers are active 
(indicating a non-receptor mediated activity) (Haug et al. 2007), suggest that these 
compounds are less prone to the development of microbial resistance than conventional 
antibiotics.  
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Lactoferricin peptide is obtained by pepsin digestion of the highly cationic N1 terminal 
domain of the iron-binding protein lactoferrin (Bellamy et al. 1992b, Kuwata et al. 1998). 
The bovine lactoferricin is constituted by 25 amino acids (17 to 41 in the native protein) 
(Bellamy et al. 1992a), and has broad-spectrum of activity (reviewed in (Gifford et al. 
2005)). A shorter version, with amino acids 17 to 30 (LFcin17-30), was found to be even 
more active (Groenink et al. 1999). In the previous chapter we have shown that arginine 
residues are crucial for the antimicrobial activity of LFcin17-30 against M. avium growing 
in broth culture, and that the D enantiomer (D-LFcin17-30) was even more active than the 
L form (chapter 7). In the present work, LFcin17-30 and its variants were tested against M. 
avium growing inside mouse macrophages, alone or in combination with the conventional 
antibiotic ethambutol, and found that the D-LFcin17-30 was the most active peptide. We 
further tried to establish the mechanism by which this peptide exerts its activity against 
intracellular M. avium.  
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Material and Methods 
Peptides 
Bovine lactoferricins (LFcin17-30, D-LFcin17-30, LFcin17-30 all K and LFcin17-30 all R) 
(Table 1) were synthesized by solid phase peptide synthesis using 9-fluorenyl-
methoxycarbonyl (Fmoc) chemistry with a Syro II synthesizer (Biotage, Uppsala, Sweden) 
as described previously (Bolscher et al. 2011). Peptide synthesis grade solvents were 
obtained from Actu-All Chemicals (Oss, The Netherlands), the preloaded NovaSyn TGA 
resins from Novabiochem (Merck Schuchardt, Hohenbrunn, Germany) and the N-α-Fmoc-
amino acids from Orpegen Pharma (Heidelberg, Germany) and Iris Biotech (Marktredwitz, 
Germany). LFcin17-30 and D-LFcin17-30, were labelled in synthesis with 5(6)-
carboxytetramethylrhodamine (TAMRA; Novabiochem) by coupling TAMRA to the ε-
aminogroup of a C-terminally additional lysine residue using Fmoc-Lys(ivDde)-OH, 
resulting in a labelling stoichiometry of 1:1, without any free TAMRA remaining. Briefly, the 
peptide was synthesized as described above on Fmoc-Lys(ivDde)-OH coupled to 
NovaSyn TGR resin (Novabiochem) with the N-terminal amino acid protected by N-α-t.-
Boc. Subsequently, the ivDde-protecting group at the C-terminal Lys was released by 
hydrazinolysis (2% hydrazine hydrate in 1-methyl-2-pyrrolidone, NMP) followed by 
overnight incubation with 1.5 eq. TAMRA in (NMP) containing 1.5 eq. 1-
hydroxybenzotriazole (HObt), 1.7 eq. 2-1[H-benzotriazole-1-yl]-1,1,3,3-
tetramethylaminium tatrafluoroborate (TBTU) and 70 μL N,N-diisopropylethylamine 
(DIPEA) in a final volume of 2ml. Next, the peptide containing resin was washed twice 
with NMP and twice with 20% piperidine, followed by three times washing with 
consecutively NMP, isopropyl alcohol (IPA) and dichloromethane (DCM). Subsequently, 
the peptide was detached from the resin and deprotected as described previously 
(Bolscher et al. 2011). 
Peptides were purified to a purity of at least 95% by semipreparative RP-HPLC (Jasco 
Corporation Tokyo, Japan) on a Vydac C18-column (218MS510; Vydac, Hesperia, CA, 
USA) and the authenticity of the peptides was confirmed by MALDI-TOF mass 
spectrometry on a Microflex LRF mass spectrometer equipped with an additional gridless 
reflectron (Bruker Daltonik, Bremen, Germany) as described previously (Bolscher et al. 
2011). 
All purified peptides were freeze-dried. Peptide stock solutions were prepared in 
Phosphate Buffered Saline (PBS, pH = 7.4), with 10 % DMSO in the case of the labelled 
peptides, and stored at -20 °C until use. 
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Bacteria 
In this work two strains of Mycobacterium avium were used: i) M. avium strain 2447 
smooth transparent variant (SmT), originally isolated by Dr. F. Portaels (Institute of 
Tropical Medicine, Antwerp, Belgium) from an AIDS patient, and ii) M. avium 104:pMV306 
(hsp60/gfp) expressing green fluorescent protein (M. avium-GFP) (Parker and Bermudez 
1997) for confocal microscopy experiments.  
Mycobacteria were grown to mid-log phase in Middlebrook 7H9 medium (Difco, Sparks, 
MD) containing 0.05% of Tween 80 (Sigma, St. Louis, MO) and 10% of albumin-dextrose-
catalase supplement (ADC) at 37 °C. Bacteria were harvested by centrifugation, washed 
twice with saline containing 0.05% Tween 80, re-suspended in the same solution and 
briefly sonicated in order to disrupt bacterial clumps. The suspension was stored in 
aliquots at -80 °C until use. Just before macrophage infection, an aliquot was quickly 
thawed and diluted to the appropriate concentration. 
 
Bone Marrow derived Macrophages (BMM)  
Macrophages were derived from the bone marrow of male BALB/c, C57BL/6 and 
C57BL/6.TNF-alpha deficient mice (Tnf-/-) bred at the IBMC animal facility. TNF-alpha 
deficient breeder mice were originally purchased from B&K Universal (East Yorkshire, 
United Kingdom). 
Each femur and tibia was flushed with Hank’s Balanced Salt Solution (HBSS, Gibco, 
Paisley, U.K.). The resulting cell suspension was centrifuged and re-suspended in 
Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco, Paisley, U.K.) supplemented with 10 
mM glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 10% Fetal Bovine Serum (FBS, 
Gibco, USA) and 10% of L929 cell conditioned medium (LCCM) as a source of 
Macrophage Colony Stimulating Factor (M-CSF). Cells were cultured overnight at 37 °C in 
a 7% CO2 atmosphere to remove fibroblasts. Non-adherent cells were collected with cold 
HBSS medium, washed and seeded at the concentration of 4x105 cells/mL and incubated 
at 37 °C in a 7% CO2 atmosphere. Four days after seeding, 10% of LCCM was added to 
the culture medium and on the 7th day, the medium was renewed. Cells were used at day 
10 of culture, when fully differentiated into macrophages. 
 
Macrophage infection and quantification of bacterial growth 
BMM were cultured in 24-wells culture plates. At day 10 of culture, 106 Colony Forming 
Units (CFU) of M. avium 2447 SmT in DMEM were added to each well and cells were 
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incubated for 4 h at 37 °C in a 7% CO2 atmosphere. After incubation, cells were washed 
several times with warm HBSS to remove non-internalized bacteria, and re-incubated with 
new medium, DMEM with 10% FBS and 10% LCCM, with or without 40 µM of peptide, 
alone or in combination with the antibiotic ethambutol (7.2 µM of ethambutol 
dihydrochloride, Sigma, St. Louis, MO, USA). Each condition was tested in triplicates. 
After 5 days in culture, the intracellular growth of M. avium 2447 SmT was evaluated by 
colony forming units (CFU). Macrophages were lysed, using 0.1% saponin. The bacterial 
suspensions were serially diluted in water containing 0.05% Tween 80 and plated in 
Middlebrook 7H10 agar medium (Difco, Sparks, MD) supplemented with oleic acid-
albumin-dextrose-catalase (OADC). The number of colonies was counted after 7 days at 
37 °C. The results were expressed as percentage of growth of mycobacteria in each well 
relative to the growth of mycobacteria in the non-treated infected wells (control), in each 
experiment. The reported final values correspond to the average of at least three 
independent experiments with the corresponding standard deviation. Statistics were 
performed with GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA) using 
two-way ANOVA with Sidak’s multiple comparisons test.  
 
Measurement of macrophage viability 
Viability of BALB/c BMM cultured in 96-wells culture plates, was determined by resazurin 
reduction. After 24 h of infection and peptide treatment (see above), supernatant was 
removed and cells were incubated with new medium (DMEM/ 10% FBS/ 10% LCCM) 
containing 125 µM resazurin (Sigma, St. Louis, MO, USA), for 24 h at 37 °C in a 7% CO2 
atmosphere. The fluorescence of resorufin, resulting from the conversion from resazurin 
by viable cells, was measured at λex = 560 nm and λem = 590 nm. The results are 
expressed as the percentage of viable cells relative to the corresponding non-peptide-
treated infected cells. 
 
Confocal Microscopy  
BALB/c BMM were cultured in µ-Slide 8 well plates (ibidi GmbH, Germany). At the 10th 
day of culture, macrophages were infected, as described above, with either GFP-
expressing M. avium or M. avium 2447 SmT. After infection, LFcin17-30-TAMRA or 
D-LFcin17-30-TAMRA were added (10 µM, final concentration) to the cell culture medium. 
Simultaneously, ethambutol (7.2 µM, final concentration), was added to some infected 
wells with GFP-expressing M. avium. Fluorescein-conjugated dextran (10,000 MW) (22.5 
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µM, final concentration) (Molecular Probes, Invitrogen) or MitoTracker® Green FM (200 
nM, final concentration) (Molecular Probes, Invitrogen), were added to M. avium 2447 
SmT-infected macrophages for endosomal or mitochondrial labelling, respectively. 
Fluorescein-conjugated dextran was added along with the peptides, immediately after 
infection and incubated for 2 h, whereas MitoTracker® Green FM was incubated for 30 
min prior visualization. 
Macrophages were observed and photographed live, using a Laser Scanning Confocal 
Microscope Leica TCS SP5II (Laser Microsystems, Germany) with the 63x oil objective. 
Immediately before visualization, cells were washed with cold PBS and kept in RPMI 
medium without phenol red (Life Technologies, Paisley, U.K.). 
 
Cytokine production 
Cytokine production was evaluated in the supernatant of macrophage cultures, 24 h after 
infection and peptide treatment. The levels of six different cytokines (IL-12p70, TNF-alpha, 
INF-γ, CCL2, IL-10 and IL-6) were determined using the BD™ Cytometric Bead Array 
(CBA) Mouse Inflammation Kit (BD Biosciences, San Jose, CA, USA) following the 
manufacturer’s instructions. Briefly, standards and samples were incubated for 2 h, with a 
mixture of capture beads for each cytokine, and with a mixture of phycoerythrin (PE)-
conjugated antibodies as detection reagent. Afterwards, the wells were washed, the 
supernatant discarded, and the beads were re-suspended with Wash buffer. The 
standards and samples were then acquired in a BD FACSCantoTM II cytometer (BD, 
Biosciences, San Jose, CA, USA), and the results analysed using the FCAP ArrayTM 
software (BD, Biosciences, San Jose, CA, USA). The results represent the average of 
three independent experiments, and are presented as the fold increase relative to the 
uninfected control in each experiment. Statistical analysis was performed with GraphPad 
Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA) using one-way ANOVA with 
Tukey’s multiple comparisons test. 
 
HPLC 
Peptides (LFcin17-30 and D-LFcin17-30) were incubated with DMEM, supplemented as 
stated above, at 37 °C for 4 days. At the end of 0, 0.5, 2, 4, 8, 24, 48, 72 and 96 h an 
aliquot was taken from each mixture and analysed through high performance liquid 
chromatography (HPLC). The HPLC (Hitachi Elite Autosampler L-2200, Pump L-2130, 
Diode Array Detector L-2455 and Column OvenL-2300) was performed with a C18 
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reverse phase column with 150 mm (Merck). Each analysis, with an injection volume of 40 
µL, was done in 30 min with 0-100% of acetonitrile (with H2O+0.05% TFA as solvent A) at 
a flow rate of 1 mL/min and the detection was at 220 nm.  
The chromatograms were analysed with EZChrom EliteTM software and the peaks 
integrated in order to extract the area. The results were then presented as the percentage 
of the remaining peptide in relation to the amount of peptide present in time zero. 
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Results 
1- Lactoferricin peptides are not toxic to primary mouse macrophages up to 
40 µM. 
In the previous chapter (chapter 7) we showed that bovine lactoferricin, LFcin17-30, its 
variants with all arginines substituted by lysines and vice-versa (LFcin17-30 all K and 
LFcin17-30 all R, respectively), and the variant with all amino acids in the D-form (D-
LFcin17-30), killed M. avium in axenic cultures. In this chapter, we decided to investigate 
whether those peptides were able to kill mycobacteria when they are growing inside 
macrophages, their natural host cell. Before testing the peptides for their antimicrobial 
activity, we evaluated their potential toxicity towards bone marrow derived macrophages 
(BMM). In figure 1, we show that the peptides did not exert a significant toxic effect on 
macrophages up to 80 µM with the exceptions of the D-form (D-LFcin17-30) and the 
variant with all arginines (LFcin17-30 all R), which had a significant toxic effect at 80 but 
not at 40 µM. 
 
2- Lactoferricin peptides inhibit M. avium growth inside macrophages and 
synergize with ethambutol 
Given that the peptides were not toxic to macrophages up to 40 µM, we next evaluated 
their effect on M. avium growing inside these cells. Since one of the possible applications 
of AMP is the co-administration with conventional antibiotics, we included ethambutol in 
this assay. Ethambutol is known to have a low effect on mycobacteria growing inside 
macrophages (Deshpande et al. 2010), making it a good model to assess the possible 
synergistic effect of AMP.  
Bone marrow derived macrophages were obtained from BALB/c mice and infected with M. 
avium 2447 SmT and the non-internalized bacteria were washed-out. The different 
peptides were added at 40 µM, and ethambutol was added at 7.2 µM. After 5 days in 
culture, the number of intracellular bacteria per culture well was quantified in a CFU assay. 
The results obtained are shown in figure 2. 
Among the peptides tested, only D-LFcin17-30 significantly inhibited the intramacrophagic 
growth of M. avium (52% reduction, P<0.0001). The other peptides and ethambutol alone 
did not caused inhibition of M. avium growth. Interestingly, when given to the 
macrophages in combination with ethambutol, all peptides had a significant inhibitory 
effect. Even in combination with ethambutol, D-LFcin17-30 was still the most active 
peptide (73% reduction in M. avium growth relative to the control; P<0.0001). 
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Since D-LFcin17-30 was the only peptide with significant antimycobacterial activity inside 
macrophages, we decided to proceed with this peptide together with its L-form, LFcin17-
30, to investigate their mechanisms of antibacterial activity inside macrophages. 
 
3- D-LFcin17-30 is more resistant to degradation by medium components 
than LFcin17-30. 
In order to understand the reason why D-LFcin17-30 had a stronger effect on the 
intramacrophagic growth of M. avium than LFcin17-30, and considering that peptide 
degradation is one of the factors that can impact on efficacy, we evaluated the kinetics of 
degradation of both peptides in the presence of the cell culture medium used in the 
infection assays. As expected, the peptide composed of amino acids in the D-form was 
significantly more resistant to degradation, persisting in the medium at a higher 
concentration up to 96 h of incubation, with no more than 30% of degradation, whereas 
50% of degradation happens for the L-form of the peptide, before 24 h of incubation, 
being completely degraded after 96 h (figure 3). 
 
4- Lactoferricins do not co-localize with M. avium inside macrophages. 
In order to understand possible mechanisms by which lactoferricins inhibited the 
intramacrophagic growth of M. avium, we started by characterizing the intracellular 
distribution of the peptides inside M. avium-infected macrophages. For that, we used 
peptides labelled with TAMRA (a rhodamine derivative) on the C-terminal together with a 
strain of M. avium expressing GFP; and fluorescein-labelled markers of endosomes and 
of mitochondria. Representative images of the assays with LFcin17-30 are shown in figure 
4 and those with D-LFcin17-30 are shown in figure 5. 
The two peptides exhibited a similar distribution inside macrophages and neither 
LFcin17-30 nor D-LFcin17-30 co-localized with M. avium. Figures 4A and 5A depict 
representative pictures of BALB/c BMM 2 hours after infection with M. avium-GFP and 
lactoferricin treatment. The exclusion of the peptides from mycobacteria-containing 
vesicles was not altered by the treatment with ethambutol (figures 4B and 5B), by the 
incubation time (20 min up to 24 h) (data not shown), or the time of peptide addition, either 
immediately after infection (figures 4 and 5) or 4 to 5 days after infection (data not shown). 
Since the intracellular distribution of both peptides had a vesicular appearance, we 
studied their co-localization with the endocytic pathway. For that, M. avium-infected 
macrophages were co-incubated with peptides and dextran for 2 h, and we found that 
 138 
 
both peptides extensively co-localized with endosomes and lysosomes (figures 4C and 
5C), suggesting they are internalized by this pathway. Importantly, neither LFcin17-30 nor 
D-LFcin17-30 significantly localized with mitochondria, which indicates that they do not 
exert a toxic effect in this organelle (figures 4D and 5D). 
 
5- Lactoferricins increase macrophage production of pro-inflammatory 
cytokines 
Since lactoferricins decreased M. avium viability inside macrophages without a direct 
interaction with the bacteria (figures 4 and 5), we asked whether they had a modulatory 
effect on macrophage function. 
For that, we used macrophage supernatants to measure the levels of several cytokines 24 
hours after infection with M. avium and treatment with the peptides. In figure 6, we can 
see that the treatment with lactoferricins significantly increased the production of TNF-
alpha and IL-6 by BMM infected with M. avium, with no significant differences between the 
two peptides. IL-10, CCL2, IL-12p40 and IFN-gamma were not significantly induced either 
by M. avium infection or by peptide treatments (data not shown). 
 
6- The antimicrobial effects of lactoferricins inside macrophages are NOT 
dependent on the production of TNF-alpha and/or IL-6 by macrophages. 
Since both peptides increased the production of TNF-alpha by M. avium infected 
macrophages and macrophage activation by TNF-alpha can lead to intracellular killing of 
mycobacteria (Appelberg and Orme 1993, Appelberg et al. 1994), we asked whether this 
cytokine was necessary for the antibacterial effect of the peptides. We took BMM from 
Tnf-/- mice and from congenic C57BL/6 wild-type mice, infected them with M. avium 2447 
SmT, treated with LFcin17-30 or D-LFcin17-30 and measured M. avium growth after 5 
days. Our results, presented in figure 7, showed that, similarly to what was observed 
before in BALB/c macrophages (figure 2), only D-LFcin17-30 significantly inhibited the 
growth of M. avium inside its host cell (figure 7). More interestingly, the effect of 
D-LFcin17-30 on M. avium intracellular growth was similar on C57BL/6 or Tnf-/- BMM, 
leading us to conclude that TNF-alpha is not necessary for the antibacterial effect of this 
peptide. By measuring cytokine levels in macrophage supernatants, as described above, 
we confirmed that Tnf-/- BMM were not producing TNF-alpha and also found that these 
macrophages did not have a significant production of IL-6, showing that the effect of the 
peptide is also IL-6-independent (data not shown).  
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Discussion 
In this chapter we show that the D enantiomer of lactoferricin strongly inhibits M. avium 
growth inside infected-macrophages, and lactoferricin variants cooperate with the 
antibiotic ethambutol to inhibit intracellular M. avium growth. Although the exact 
mechanism of action was not elucidated, we gathered evidences indicating that the 
peptides act by increasing antimicrobial effects of the macrophage. 
Following the work on the direct antimicrobial activity of a set of lactoferricin peptides 
against Mycobacterium avium (chapter 7), we proceed to test those peptides on M. avium-
infected macrophages. Although LFcin17-30, its variants with arginines substituted by 
lysines and vice-versa (LFcin17-30 all K and LFcin17-30 all R), and the D enantiomer (D-
LFcin17-30) were all active against M. avium in axenic cultures, only D-LFcin17-30 
induced a significant decrease in the mycobacterial growth inside macrophages.  
The combination of antimicrobial peptides with conventional antibiotics is of great potential 
interest as it could reduce the dosages of each compound, diminish the probability of 
resistance, and also reduce the treatment time. The advantageous combination of 
ethambutol and iron chelators in the control of M. avium growth inside macrophages has 
recently been reported (Moniz et al. 2015). Ethambutol acts by impairing the biosynthesis 
of the cell wall, increasing cell permeability and potentiating the action of other drugs 
(Hoffner et al. 1990, Rastogi et al. 1990, Brown-Elliott et al. 2012). In the clinic, 
ethambutol is used in combination with other antimycobacterial drugs not only as a 
strategy to prevent the appearance of resistant strains, but also due to its high toxicity 
when given alone in high doses (Brown-Elliott et al. 2012, Egelund et al. 2015). In the 
present work, the administration of ethambutol with lactoferricins resulted in a significant 
inhibition of M. avium growth. This improvement in the antimycobacterial activity of both 
compounds is probably related with increased cell permeability induced by either 
ethambutol or by the peptides, allowing for the compounds to enter the cell more easily, 
potentiating their activity. However, D-LFcin17-30 was still the most active peptide even 
when combined with ethambutol, which in this case did not bring a significant 
improvement to the peptide’s effect. For this reason, we proceed to investigate the 
mechanism by which the D enantiomer of LFcin17-30 exerts its antimycobacterial activity.  
Due to their peptidic nature, AMP are highly susceptible to proteases and other plasma 
components. This feature is one of the obstacles to AMP application in the clinic, as it 
results in low stability and bioavailability, limiting AMP application to topical agents (Seo et 
al. 2012). One strategy employed to overcome this problem is the use of non-natural D 
enantiomers of amino acids, since in principle, they are more resistant to proteolytic 
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activity (Deslouches et al. 2013). In the case of the peptides studied in this work, 
D-LFcin17-30 was capable of resisting degradation, persisting in cell culture medium at a 
higher concentration over time than LFcin17-30, a probably crucial factor for the higher 
antimycobacterial activity. Wakabayashi et al. in 1999 reported a similar effect for a D 
enantiomer of a lactoferricin derivative (LFcin20-29) (Wakabayashi et al. 1999). The fact 
that the D enantiomer is more active than the L one, also reveals that the observed 
antimicrobial effect is probably not related to chiral receptors, since they would not 
recognized D-amino acids. As reported in the previous chapter, these peptides exhibit a 
direct inhibitory effect against M. avium in broth culture (chapter 7), being able to interact 
directly with the mycobacteria. Thus, we hypothesized that the inhibition of the 
mycobacterial growth could be the result of a direct effect on the mycobacteria, such as a 
disruption of the cell membrane, or the activity on an intracellular target in M. avium. In 
order to clarify this aspect, the distribution and sub-cellular localization inside M. avium 
infected macrophages of LFcin17-30 and D-LFcin17-30 was assessed. Contrarily to what 
was expected, our localization studies showed that none of the peptides co-localized with 
M. avium when growing inside macrophages. This result was not altered by the presence 
of ethambutol, the incubation time or the time-point of peptide addition after infection. 
These peptides seem to follow an endocytic pathway, co-localizing with fluorescein-
conjugated dextran, never reaching the mycobacteria-harbouring phagosomes. Thus, we 
sought other possible effects of D-LFcin17-30 on the M. avium-infected macrophages that 
could be leading to a better clearance of the mycobacteria.  
The administration of LFcin17-30 and D-LFcin17-30 was accompanied by an increase in 
the levels of TNF-alpha and IL-6 produced by M. avium-infected macrophages. TNF-alpha 
is involved in macrophage activation, being able to induce intracellular killing of 
mycobacteria (Bermudez and Young 1988, Appelberg and Orme 1993, Appelberg et al. 
1994). Also, TNF-deficient mice infected with M. avium do not resist the infection (Florido 
and Appelberg 2007). IL-6 is a cytokine involved in the modulation of inflammation and the 
acute phase response. It is also able to induce the development of IL-17-producing T cells 
that are involved in the host response to mycobacterial infections (Torrado and Cooper 
2010). Although both peptides increased the levels of TNF-alpha and IL-6, these are not 
essential for the antimicrobial effect of D-LFcin17-30, since their absence did not interfere 
with the peptide’s effect. We did not find evidences supporting a role of nitrites in the 
antimicrobial effect of D-LFcin17-30 (data not shown). Furthermore, several works 
reported that oxygen and nitrogen reactive species are not required for the 
antimycobacterial mechanisms of M. avium-infected macrophages (Gomes et al. 1999, 
Gomes and Appelberg 2002).  
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Lactoferricin has been reported to have multiple roles on the host immune response. 
Besides its direct antimicrobial activity towards several pathogens, lactoferricin can 
selectively kill cancer cells (Yoo et al. 1997, Mader et al. 2005, Furlong et al. 2006, Mader 
et al. 2007, Furlong et al. 2010, Pan et al. 2013) and can inhibit septic shock by binding to 
endotoxins (Yamauchi et al. 1993). Recently, it was described that apoptosis and 
autophagy are involved in lactoferricin-induced death of cancer cells (Pan et al. 2013). 
Autophagy is a host cell effector mechanism used as a quality control for the removal of 
protein aggregates and damaged organelles. Under stress conditions (e.g. infection), the 
cell can activate autophagy for survival (Deretic and Levine 2009, Mansilla Pareja and 
Colombo 2013). In the case of mycobacterial infections, vitamin D3 induces not only the 
production of antimicrobial peptides such as cathelicidin, but also induces autophagy, both 
playing a role in the control of the pathogen growth within the macrophage (Gutierrez et al. 
2004, Yuk et al. 2009, Selvaraj et al. 2015). Therefore one of the mechanism by which 
D-LFcin17-30 inhibits the growth of M. avium inside macrophages could be the induction 
of autophagy, which will be investigated in future studies.  
M. avium, similarly to other pathogenic mycobacteria, is capable of living and proliferating 
inside macrophages by inhibiting the formation of a phagolysosome, which would 
constitute a harsh environment for the bacteria growth (Appelberg 2006b). One possible 
way to interfere with the pathogen growth would be to interfere with this process, 
favouring the maturation of the compartment where the mycobacteria are living and thus 
restricting the access to nutrients or exposing the mycobacteria to toxic compounds 
(Appelberg 2006a, Appelberg 2006b, Gomes et al. 2008). In future experiments, we will 
investigate whether D-LFcin17-30 acts through this pathway. 
In summary, in this work we showed that a D enantiomer of lactoferricin is active against 
M. avium growing inside mouse macrophages, by a mechanism that is independent of 
direct contact with the bacteria. The exact mechanism behind the peptide’s activity is still 
not clear, but is probably related with modulation of the macrophage’s capacity to kill M. 
avium.  
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Tables 
Table 1 – Properties of synthetic lactoferrin peptides.  
Peptide Amino Acid sequence MW Charge a 
LFcin17-30 FKCRRWQWRMKKLG 1923 +6 
D-LFcin17-30 FKCRRWQWRMKKLG 1923 +6 
LFcin17-30 all K FKCKKWQWKMKKLG 1839 +6 
LFcin17-30 all R FRCRRWQWRMRRLG 2007 +6 
a Calculated overall charge at pH= 7.0 
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Figures 
 
Figure 1 – Effect of lactoferricin peptides on macrophage viability. BALB/c mouse 
BMM were infected with M. avium 2447 SmT and incubated with LFcin17-30 (circles), 
D-LFcin17-30 (squares), LFcin17-30 all K (triangles) and LFcin17-30 all R (diamonds), for 
24 h. At the end of this period, 10% resazurin 125 µM was added and 24 h later 
fluorescence was measured at 560/590 nm to evaluate cell viability. The graph shows the 
average + standard deviation of two independent experiments, presented as the 
percentage of viable cells relative to the corresponding non-peptide-treated infected cells. 
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Figure 2 – Inhibition of the growth of M. avium inside BALB/c BMM by lactoferricin 
peptides alone or in combination with ethambutol. M. avium 2447 SmT growing inside 
BALB/c BMM were treated with 40 µM of LFcin17-30, D-LFcin17-30, LFcin17-30 all K or 
LFcin17-30 all R, alone (non-patterned bar) or in combination with 7.2 µM of ethambutol 
(patterned bar). After 5 days of incubation, bacteria were quantified by a CFU assay. The 
results represent the average + standard deviation of at least four independent 
experiments, and are expressed as the percentage of growth of mycobacteria in each well 
relative to the growth of mycobacteria in the non-treated infected wells (control), in each 
experiment. Statistics were performed using two-way ANOVA with Sidak’s multiple 
comparisons test. * P < 0.05; ** P < 0.01; *** P < 0.001. 
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Figure 3 – Stability of lactoferricin peptides in culture medium. LFcin17-30 (grey 
circles) and D-LFcin17-30 (black squares), at 40 µM of final concentration, were incubated 
with DMEM/10%FBS/10% LCCM at 37 °C. After 0, 0.5, 2, 4, 8, 24, 48, 72 and 96 h of 
incubation an aliquot was taken and immediately analysed by RP-HPLC with a gradient 
from 100% solution A (0.05% TFA in water) to 100% solution B (acetonitrile). The results 
are presented as the percentage of the remaining peptide in relation to the amount of 
peptide present in time zero. 
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Figure 4 – Intracellular distribution and localization of LFcin17-30 in M. avium 
infected macrophages. Live cell imaging of BALB/c BMM infected with M. avium-GFP (A, 
B) or M. avium 2447 SmT (no fluorescent label, C, D) for 2 h, and treated with 10 µM 
LFcin17-30-TAMRA for 2 h. A) BMM infected with M. avium expressing GFP; B) BMM 
infected with M. avium expressing GFP and treated with 7.2 µM ethambutol for 2 h; C) 
BMM infected with M. avium 2447 SmT and incubated with 22.5 µM fluorescein-
conjugated dextran for 2 h; D) BMM infected with M. avium 2447 SmT and incubated with 
200 nM MitoTracker Green for 30 minutes. Macrophages were visualized and 
photographed in a Laser Scanning Confocal Microscope Leica TCS SP5II with 63x oil 
objective. One representative cell, of one representative experiment out of three, is shown 
for each condition. Bar scale: 5 µm. 
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Figure 5 – Intracellular distribution and localization of D-LFcin17-30 in M. avium 
infected macrophages. Live cell imaging of BALB/c BMM infected with M. avium-GFP (A, 
B) or M. avium 2447 SmT (no fluorescent label, C, D) for 2 h, and treated with 10 µM 
D-LFcin17-30-TAMRA for 2 h. A) BMM infected with M. avium expressing GFP; B) BMM 
infected with M. avium expressing GFP and treated with 7.2 µM ethambutol for 2 h; C) 
BMM infected with M. avium 2447 SmT and incubated with 22.5 µM fluorescein-
conjugated dextran for 2 h; D) BMM infected with M. avium 2447 SmT and incubated with 
200 nM MitoTracker Green for 30 minutes. Macrophages were visualized and 
photographed in a Laser Scanning Confocal Microscope Leica TCS SP5II with 63x oil 
objective. One representative cell, of one representative experiment out of three, is shown 
for each condition. Bar scale: 5 µm. 
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Figure 6 – Cytokine production by M. avium infected macrophages treated with 
lactoferricin peptides. 24 h after infection and treatment with LFcin17-30 (grey) or 
D-LFcin17-30 (black), the levels of TNF-alpha (A) and IL-6 (B) were determined in the 
supernatant of BALB/c BMM, using the BD™ Cytometric Bead Array (CBA) Mouse 
Inflammation Kit. The samples were acquired in a BD FACSCantoTM II cytometer, and 
analysed using the FCAP ArrayTM software. The graphs represent the average + standard 
deviation of three independent experiments, presented as the fold increase relative to 
uninfected control macrophages. Statistical analysis was performed using one-way 
ANOVA with Tukey’s multiple comparisons test. * P < 0.05; ** P < 0.01; *** P < 0.001. 
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Figure 7 – Effect of lactoferricin peptides on C57BL/6 and Tnf-/- BMM infected with M. 
avium. M. avium 2447 SmT growing inside C57BL/6 and Tnf-/- BMM were treated with 40 
µM of LFcin17-30 (grey) or D-LFcin17-30 (black). After 5 days of incubation, bacteria were 
quantified by a CFU assay. The graph represents the average of two independent 
experiments, expressed as the percentage of growth of mycobacteria in each well relative 
to the growth of mycobacteria in the non-treated infected wells (control), in each 
experiment. Statistics were performed using two-way ANOVA with Tukey’s multiple 
comparisons test. ** P < 0.01; *** P < 0.001. 
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CHAPTER 9. Final Remarks and Future Perspectives 
Taking into account the potential advantageous use of antimicrobial peptides as new 
therapeutic alternatives, the purpose of this work was to enlighten the mechanisms of 
action by which two families of AMP exert their activity, as well as to assess their potential 
as antimycobacterial therapeutics. As discussed throughout this thesis, AMP are 
characterized by the possibility of acting on multiple fronts by a variety of mechanisms, 
being sometimes called “dirty-drugs”. The importance of antimicrobial peptides as 
potential alternatives to conventional antibiotics relies on the fact that these AMP 
represent a new antimicrobial paradigm. The antibiotics currently used in the clinic have a 
single defined target, most often a protein, which is common to all compounds within the 
same family. Thus, it is relatively easy for bacteria to develop resistance to the antibiotics 
by making a simple change in this target. At odds, the advantage of AMP relies on factors 
such as:  
i) it would require an overall organization of the entire membrane for bacteria to modify the 
peptide’s target – the cytoplasmic membrane. This would affect all its constituents such as 
proteins, receptors, transport systems, among others, which is difficult to achieve without 
a significant loss of fitness; 
ii) even if this was possible, as has already been reported for some peptides and 
pathogens (Maria-Neto et al. 2015), AMP have the possibility of acting on other targets 
such as proteins, nucleic acids and intracellular membranes and processes, not to 
mention their role in the immune system and in the modulation of host defence 
mechanisms;  
iii) finally, AMP have evolved in almost all living organisms for many thousands of years. 
The fact that they keep their activity may indicate the low probability of resistance 
development by pathogens. 
Despite these arguments, resistance development still raises many questions and 
concerns. What will happen if we increase the exposure of bacteria and other pathogens, 
to AMP; will they develop resistance then? What are the implications for our health, if 
resistance to our own immune system develops? And even if resistance would not be a 
problem, what are the risks of increasing the amounts of these immune system 
compounds in our bodies? 
The results presented in this thesis reflect the heterogeneity of AMP pathways, as we 
report different mechanisms of action not only between peptides of two distinct families, 
but even for peptides within the same family. This clearly indicates that the way AMP acts 
 160 
 
depends significantly on the peptide nature but also on the lipid composition of the target 
membrane. 
Cecropin A-melittin hybrid ((CA(1-7)M(2-9) or CAM) was an extremely interesting 
peptide, due to its high capacity to interact with lipid membranes, in an interaction that can 
be observed by the naked eye, as they induce extensive precipitation and condensation of 
the membranes. Based on the results reported here (chapter 5), we propose that the 
peptide acts through the carpet model, leading eventually to membrane disruption and 
consequent cell death.  
For most natural peptides, several problems are faced when their application in clinic is 
attempted. A large number of peptides exhibit cytotoxicity against eukaryotic membranes, 
and/or are highly degradable within our digestive system. Another very important issue is 
the high costs associated with peptide synthesis that has precluded extensive use of 
peptide of proven antimicrobial action. Thus, rational design is a strategy that must be 
used for peptide’s improvement. The cecropin A-melittin hybrids are one of the first 
examples of rational design in the AMP field resorting to sequence hybridization (Boman 
et al. 1989). With this synthesis approach one can combine and optimize the individual 
characteristics of different peptides into one molecule, which was the case of cecropin A-
melittin hybrid peptides that have higher antimicrobial activity than cecropin A alone, with 
reduced haemolytic activity as compared to melittin (Boman et al. 1989, Andreu et al. 
1992). These were very promising agents that were extensively studied by us and many 
others (Andreu et al. 1992, Piers and Hancock 1994, Merrifield et al. 1995, Mancheño et 
al. 1996, Giacometti et al. 2004, Abrunhosa et al. 2005, Sato and Feix 2006, Saugar et al. 
2006, Pistolesi et al. 2007, Bastos et al. 2008, Ferre et al. 2009, Milani et al. 2009, 
Teixeira et al. 2010, Salomone et al. 2012, Schlamadinger et al. 2012). Nevertheless, it 
has been reported that the peptide can have significant cytotoxicity (Fernandez-Reyes et 
al. 2010). Accordingly, biophysical studies revealed that CAM is capable of strongly 
interact with zwitterionic PC membranes, used to mimic the eukaryotic membranes 
(Abrunhosa et al. 2005, Bastos et al. 2008). Moreover, we have previously tested this 
peptide against M. avium, and although it was effective against the mycobacteria growing 
in broth culture, it exerted a significant toxic effect against macrophages (unpublished 
data). Nevertheless, other in vivo studies show that CAM is effective against the tested 
infection without significant toxicity (Alberola et al. 2004). Several strategies have been 
employed to try to overcome this problem, for instance by acylation of the N-terminal with 
fatty acids (Chicharro et al. 2001) or by lysine N-trimethylation (Fernandez-Reyes et al. 
2010, Teixeira et al. 2010, Diaz et al. 2011). Overall no high improvement over the 
parental peptide was obtained. Another strategy could be the targeted delivery of the 
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peptide to the local of infection by encapsulating it into liposomes or other stable and non-
toxic vehicles (Urban et al. 2012). It is therefore worthwhile to study this peptide and its 
variants with model membranes, to contribute to a deeper understanding of its mechanism 
of action. We would finally stress that as CAM is highly active against several pathogens, 
it will be of great interest to introduce it into the clinic, probably as a topical agent, or for 
localized infections. In order to achieve that goal, research must proceed to understand 
the action of this peptide and therefore, optimize this molecule and its characteristics.  
In the case of lactoferrin peptides, we studied the mechanism of action of LFcin17-30 and 
LFampin265-284 (Groenink et al. 1999, van der Kraan et al. 2005a, van der Kraan et al. 
2006), and also a hybrid peptide obtained from their connection through a lysine linker 
(LFchimera) (Bolscher et al. 2009a, Bolscher et al. 2012). These three peptides were 
previously tested against M. avium, but only LFcin17-30 showed promising activity 
(unpublished data). Therefore that was the peptide chosen to proceed the studies of this 
thesis to further investigate its antimycobacterial potential. 
As regarding the interaction of these peptides with model membranes, we found that the 
three peptides act by three different mechanisms, in remarkable agreement with the 
results obtained on its action on C. albicans (chapter 6).  
LFchimera, a hybrid peptide between LFcin17-30 and LFampin265-284, was the most 
potent peptide both against C. albicans and model membranes (chapter 6). Contrarily to 
CA(1-7)M(2-9), LFchimera is not a linear peptide constructed via a simple peptide bond. 
LFcin17-30 and LFampin265-284 are spatially close in the native protein lactoferrin, and 
are located in the N-terminal domain, which is thought to be one of the reasons 
responsible for many of the beneficial properties of LF. Thus, LFchimera was constructed 
in order to mimic the spatial topology of its constituent peptides in LF, coupling the C-
terminals of LFcin17-30 and LFampin265-284 to an additional lysine, leaving the two N-
terminals as free ends (Bolscher et al. 2009a, Bolscher et al. 2012, Haney et al. 2012b). In 
our studies with LFchimera, this peptide had the most disruptive behaviour destroying C. 
albicans membrane (Bolscher et al. 2012) probably through the formation of bicontinuous 
cubic phases (chapter 6). This strong activity of LFchimera has been reported against 
several different pathogens, being more active than its counterparts LFcin17-30 and 
LFampin265-284, even when these two were added simultaneously (Bolscher et al. 2009b, 
Leon-Sicairos et al. 2009, Flores-Villasenor et al. 2010, Lopez-Soto et al. 2010, Bolscher 
et al. 2012, Flores-Villasenor et al. 2012a, Silva et al. 2012, Kanthawong et al. 2014, 
Leon-Sicairos et al. 2014). This peptide is capable of inducing not only membrane 
permeabilization but also severe damages in the surface of the pathogens, supporting a 
mechanism of action that involves membrane disruption (Leon-Sicairos et al. 2009, 
 162 
 
Flores-Villasenor et al. 2010, Bolscher et al. 2012, Silva et al. 2012, Kanthawong et al. 
2014, Leon-Sicairos et al. 2014). Studies based on structural features of LFchimera have 
shown that although LFcin17-30 and LFampin265-284 are coupled in a special way that 
could bring the two peptides to closer spatial proximity, they do not interact with each 
other in LFchimera (Haney et al. 2012b). This suggests that the enhanced antimicrobial 
features of LFchimera are not related to a combined structural component between 
LFcin17-30 and LFampin265-284. Further, the leishmanicidal activity of this peptide was 
not hampered when its constituent peptides were joined by a simple peptide bond, or 
even when formed by dimers of LFcin17-30 or LFampin265-284 (Silva et al. 2012). Even 
so, their coupling is relevant, as the simultaneous addition of LFcin17-30 and 
LFampin265-284 results in a lower antimicrobial activity than that shown by LFchimera, 
showing possibly a synergistic effect between the mechanisms of action of the two 
individual peptides. Finally, another reason behind LFchimera strong activity is most 
probably its high positive charge as compared to the other two peptides (+12 for 
LFchimera, +4 for LFampin265-284 and +6 for LFcin17-30), enhancing electrostatic 
interactions with the negative phospholipids at the membranes’ surface. Overall it seems 
that LFchimera acts primarily by disrupting the pathogen’s membrane, probably through 
the formation of cubic phases. Nevertheless, since an intracellular target has been 
suggested for LFcin17-30, we cannot discard this possibility also for LFchimera.  
LFchimera has a high potential as new therapeutics against several infections. In fact, 
Flores-Villasenor et al. have recently found that LFchimera can protect mice against a 
lethal infection with enterohemorrhagic E. coli (Flores-Villasenor et al. 2012a, Flores-
Villasenor et al. 2012b). Therefore, it is of high interest to continue to investigate the 
mechanism of action of LFchimera and the structural features that are required for its 
activity. For that, further studies could be performed with model membranes of different 
lipid compositions and also with LFchimera variants, in order to understand what are the 
structural characteristics responsible for the peptide’s activity and how it can be improved 
in terms of activity: Further synthesis costs are also a major concern that could lead 
tentatively to related AMPs with shorter amino acid sequences. The final goal will always 
be to assess its antimicrobial properties in in vivo models of infection for future clinical 
development. 
LFampin265-284, found in the N-terminal domain of lactoferrin (van der Kraan et al. 2004, 
van der Kraan et al. 2005a, van der Kraan et al. 2006), interacts with fungal model 
membranes inducing the formation of a micellar cubic phase (Pm3n) (chapter 6) (Bastos 
et al. 2011). This was not only the first report describing such phase in the context of 
antimicrobial peptides and membrane interaction, but it is also in agreement with the 
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results obtained on C. albicans, where weakening of the membrane was observed by the 
appearance of vesicular-like structures (van der Kraan et al. 2005b). The formation of a 
micellar cubic phase clearly indicates that the mechanism of action of LFampin265-284 
relies on membrane disruption. This is supported by other reports where membrane 
permeabilization and significant damage of the cell surface induced by LFampin was 
observed (van der Kraan et al. 2005b, Flores-Villasenor et al. 2010, Silva et al. 2012, 
Leon-Sicairos et al. 2014). The interaction of this peptide with membranes is tightly 
connected with its unique structural characteristics (Haney et al. 2012a). LFampin265-284 
contains a positive and flexible C-terminal region that is separated from the helical 
structured N-terminal region. When approaching a membrane, the C-terminal will 
establish electrostatic interactions with the head groups of the negatively charged 
phospholipids, inducing the folding of the N-terminal domain into a α-helix. The helix will 
then penetrate into the membrane leading to its disruption, probably as we did propose 
through the formation of a micellar cubic phase, culminating in cell death (Haney et al. 
2007, Adao et al. 2011, Bastos et al. 2011, Haney et al. 2012a). We can then hypothesize 
that within LFchimera this part of the molecule can be the main responsible for the 
membrane perturbation effects. This peptide has not been extensively explored in terms 
of antimicrobial activity. However, there are evidence that this peptide does not exert 
toxicity towards eukaryotic cells (van der Kraan et al. 2005a, Haney et al. 2009, Adao et al. 
2011, Haney et al. 2012a), and thus, it can possibly be used as antimicrobial if its activity 
is properly studied and its features improved. 
LFcin17-30 had the lowest membrane effect among the three lactoferrin peptides tested. 
On C. albicans membrane, LFcin17-30 induced an alteration on the distribution of intra-
membranous particles (van der Kraan et al. 2005b) consistent with lipid segregation as 
seen by SAXD on model membranes (chapter 6). These findings support previous reports 
indicating that despite having a clear inhibitory effect against several pathogens, this 
peptide has mild membranolytic activity. In fact, different lactoferricin derivatives were 
found incapable of inducing significant leakage from model membranes and their 
antimicrobial activities were shown not to correlate with the levels of membrane interaction 
(Ulvatne et al. 2001, Nguyen et al. 2005, Jing et al. 2006). Moreover, LFcin17-30 exhibited 
a slow kinetics of membrane permeabilization in Leishmania and C. albicans, and induced 
small structural damages on the pathogens surface, as compared to more membrane-
active peptides such as LFchimera (Bolscher et al. 2012, Silva et al. 2012, Leon-Sicairos 
et al. 2014). LFcin has also been found to translocate into the cytoplasm of 
Staphylococcus aureus and Escherichia coli (Haukland et al. 2001), and to inhibit the 
macromolecular synthesis (DNA, RNA, and protein synthesis) of E. coli and Bacillus 
 164 
 
subtilis (Ulvatne et al. 2004). Finally, LFcin led to apoptosis in cancer cell lines by 
attacking the mitochondrial membrane (Mader et al. 2007). These observations suggest 
that the mechanism of action of LFcin is not confined to the cell surface but most probably 
includes action on internal targets, leading to impairment of several intracellular processes, 
which eventually culminate in cell death. Independently of how LFcin17-30 acts, it still has 
to interact with the membrane, cross it and reach its final target(s). The observed lipid 
segregation can be the means that allows LFcin17-30 internalization. Our work with 
LFcin17-30 and Mycobacterium avium can further support this mechanism of membrane 
perturbation to allow peptide internalization, to act eventually on intracellular targets 
(chapter 7 and 8).  
When we tested LFcin17-30 variants against M. avium growing in broth culture, the 
replacement of all arginines by lysines (LFcin17-30 all K) significantly decreased the 
antimycobacterial activity, especially when compared to the variant with all arginines 
(LFcin17-30 all R) (chapter 7). Arginine residues have been found to be important for the 
antimicrobial activity of several AMP, including lactoferricin (Kang et al. 1996, Gifford et al. 
2005, Chan et al. 2006), and there are also evidences that this amino acid plays a role in 
AMP internalization and is important for intracellular mechanisms of action (Mitchell et al. 
2000, Rothbard et al. 2004, Hansen et al. 2008). Although these peptides induce 
significant changes in the surface and morphology of the cell, no clear evidences of 
permeabilization were observed (chapter 7), suggesting the existence of an intracellular 
target. The D enantiomer of LFcin17-30 was more active than the L peptide, probably due 
to its ability to resist proteolytic degradation (chapter 7). This also suggests that the 
mechanism of action of LFcin17-30 does not require the interaction with chiral receptors, 
since they would not recognize non-natural D amino acids. All the information gathered 
supports also the idea of a mechanism of action that involves membrane interaction to 
gain access to the intracellular environment, where the peptide will exert its main activity.  
Moving to a more complex in vitro system, we proceeded to test LFcin17-30 and its 
variants against M. avium growing inside macrophages (chapter 8). Surprisingly, only 
D-LFcin17-30 induced a significant inhibition of the mycobacterial growth inside 
macrophages, and the combination with a conventional antibiotic ethambutol, did not 
result in a significant improvement over D-LFcin17-30 activity (chapter 8). As speculated 
above, the enhanced activity of D-LFcin17-30 is probably related to the ability to resist 
degradation. In chapter 7, we have determined that all lactoferricin peptides exhibited a 
direct antimycobacterial activity, probably by acting on internal targets, so the question 
now was – how is D-LFcin17-30 killing M. avium inside macrophages? The distribution 
and sub-cellular localization of lactoferricins inside M. avium-infected macrophages 
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showed no differences between LFcin17-30 and D-LFcin17-30. Strikingly, we showed that 
they do not co-localize with M. avium, following instead an endocytic pathway, never 
reaching the M. avium-harbouring phagosomes (chapter 8). Therefore, the only possible 
conclusion is that D-LFcin17-30 is modulating the macrophage antimicrobial mechanisms 
in order to promote M. avium killing. In fact, TNF-alpha and IL-6 were significantly 
enhanced in the supernatant of M. avium-infected macrophages treated with either 
LFcin17-30 or D-LFcin17-30, but this revealed to be irrelevant for the peptide’s activity 
(chapter 8). Therefore, at this point we still do not know the reason behind D-LFcin17-30 
activity against M. avium growing inside macrophages. Given recent suggestions that 
lactoferricin may be involved in the induction of autophagy and apoptosis (Pan et al. 2013) 
and that autophagy and antimicrobial peptides can contribute to the control of 
mycobacterial infections (Gutierrez et al. 2004, Yuk et al. 2009, Selvaraj et al. 2015) we 
intend to investigate the hypothesis that D-LFcin17-30 is inhibiting the growth of M. avium 
inside infected macrophages by inducing autophagy. A possible related mechanism is the 
interference with the maturation of mycobacteria-harbouring phagosomes with 
consequent restriction of the access to nutrients and/or exposure of mycobacteria to toxic 
environments (Appelberg 2006a, Appelberg 2006b, Gomes et al. 2008). These two 
possible mechanisms will be evaluated in the future in order to achieve a better 
understanding of the peptide’s mechanism of action. 
The studies presented here involving lactoferricin, and especially D-LFcin17-30, have 
shown the high potential of these peptides in the fight against mycobacterial infections. 
The mechanism by which this peptide exert its activity is probably not tightly connected to 
a specific protein and/or receptor. More, we speculate, based on our results so far, that 
this mechanism must involve a modulation of the macrophage capacity to fight the 
infection. Thus, the development of resistance appears to be very difficult for this 
particular peptide, increasing the interest on its applicability against relevant infections 
such as those caused by mycobacteria. Once the mechanism of action on M. avium-
infected macrophages will be enlightened the obvious road will be to proceed to in vivo 
studies for the control of disseminated M. avium infection. If the obtained results will be 
promising, the next step will be to assess the antimycobacterial potential of D-LFcin17-30 
on more relevant pathogens such as M. tuberculosis, although the efficacy on one species 
does not guarantee an efficiency on other. Since D-LFcin17-30 is highly resistant to 
proteolytic activity without harbouring significant toxicity towards host cells, parental 
administration of this peptide should be possible. In view of the results of our work, we 
believe it could potentially be used in the treatment of disseminated mycobacterial 
infections, or even the pulmonary infections caused not only by M. tuberculosis but also 
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by M. avium and other mycobacteria. If it will be shown that D-LFcin17-30 cannot be 
administered in this way, and should follow the road of other peptide agents as topical 
drugs, it can still be applied to mycobacterial infections, for instance for the treatment of 
ulcers caused by M. ulcerans.  
Although further studies are needed in order to evaluate the effects of these peptides in 
vivo, data obtained in this thesis present new views on mechanism of action of 
antimicrobial peptides, both on model membranes and with pathogenic agents, that can 
be essential for the development of a new antimicrobial peptide able to control 
mycobacterial infections.  
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